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“Grab a calculator and fix yourself 
Space is only noise if you can see” 
Nicolas Jaar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“And she turned around and took me by the hand 
And said I've lost control again 
And how I'll never know just why or understand 
She said I've lost control again 
And she screamed out kicking on her side 
And said I've lost control again 
And seized up on the floor, I thought she'd die 
She said I've lost control 
She's lost control again 
She's lost control” 
 
Ian Curtis was lead-singer and lyricist of the band Joy Division. He suffered from the 
comorbidity of epilepsy and depression. Age 23, he committed suicide on 18 May 1980. 
The figure on the cover of this thesis is based on the cover of Joy Division’s album 
“Unknown pleasures” which contains the song “She’s lost control”.  
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OUTLINE OF THE THESIS AND RESEARCH AIMS 
The GENERAL INTRODUCTION provides a concise overview of relevant literature and 
describes the key concepts about epilepsy, the comorbidity with depression, emotion 
regulation, vagus nerve stimulation (VNS) and event-related potentials (ERPs) that are 
studied in the four empirical chapters. 
The aim of this doctoral thesis was to investigate the following research questions using 
event-related potentials in patients with refractory epilepsy: 
1. Is the P3 a biomarker for the therapeutic response to VNS in epilepsy?  
The first study discussed in CHAPTER 1 is part of a translational research line of our 
research group LCEN3 about the role of the locus coeruleus noradrenergic (LC-NE) 
system in the mechanism of action of VNS. In animal models for epilepsy, our laboratory 
has found a strong positive correlation between the seizure-suppressing effect of VNS 
and the NE levels in the brain. In this study we evaluated the effect of VNS on NE 
signaling in the human brain through a non-invasive marker of LC-NE activity, i.e., the 
P3 component of the ERP. The aim of this study was to evaluate whether VNS-induced 
modulation of the P3 component could be used as a non-invasive biomarker for the 
efficacy of VNS in patients with epilepsy.  
2.  Is refractory epilepsy associated with dysfunction of emotion regulation?  
Patients with refractory epilepsy have a high prevalence of comorbid mood disorders. The 
second and third study aimed to evaluate whether refractory epilepsy is associated with 
dysfunction of emotion regulation. In the second study, discussed in CHAPTER 2, ERPs 
were used in order to investigate whether a possible dysfunction arises during early 
(attention) and/or late (regulation) stages of emotional stimuli processing. The aim of the 
third study, discussed in CHAPTER 3, was to investigate whether the ERP response to 
negatively valenced stimuli in patients with refractory epilepsy is sensitive to reappraisal, 
a cognitive emotion regulation strategy that can decrease negative affect. 
3. Is visual processing in the amygdala modulated by attention and emotion in 
patients with refractory epilepsy? 
How emotion and attention influence processing of visual stimuli in the amygdala 
remains a matter of intense debate in the literature. We hypothesized that attentional 
and emotional factors operate independently and in parallel on the sensory processing in 
the amygdala in order to increase the saliency and selection of behaviorally relevant 
information. To test this hypothesis local field potentials were recorded in the amygdala 
of ten patients with refractory epilepsy implanted with intracranial depth electrodes. In 
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this study we aimed to evaluate whether sensory processing of both attended and 
unattended emotional visual stimuli can be inferred from local field potentials recorded 
directly in amygdala and whether amygdala ERPs are modulated by attentional control 
and emotional factors. These results are discussed in CHAPTER 4. 
The empirical chapters are followed by a GENERAL DISCUSSION in which the three 
central research questions are discussed in light of the new insights revealed by our 
studies and future research challenges and opportunities are marked out. 
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GENERAL INTRODUCTION 
1 Introduction on epilepsy 
1.1 Epidemiology, classification and diagnosis  
The word “epilepsy” originates from the Greek verb “επιλαμβανειν” (epilambanein) 
meaning “to seize, possess or afflict”, which is a consequence of the ancient belief that a 
patient having seizures was being possessed by gods, demons or evil spirits [Magiorkinis 
et al., 2010]. Nowadays, epilepsy is defined by the International League Against Epilepsy 
(ILAE) as a disease of the brain characterized by an enduring predisposition to generate 
epileptic seizures, and by the neurobiological, cognitive, psychological, and social 
consequences of this condition [Fisher et al., 2005; Fisher et al., 2014]. An epileptic 
seizure is defined as a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity of the brain [Fisher et al., 2005]. Because the 
conceptual definition of epilepsy can be difficult to apply in everyday clinical practice, the 
ILAE has now proposed a practical definition for epilepsy which requires that any of the 
following conditions are met: (i) at least two unprovoked (or reflex) seizures occurring 
more than 24 hours apart, (ii) one unprovoked (or reflex) seizure and a probability of 
further seizures similar to the general recurrence risk after two unprovoked seizures (at 
least 60 %) occurring over the next 10 years, and (iii) diagnosis of an epilepsy syndrome 
[Fisher et al., 2014].  
Worldwide, the lifetime prevalence of epilepsy is estimated to be about 65 million people 
[Ngugi et al., 2010; Thurman et al., 2011]. In high-income countries, the annual 
incidence of epilepsy is 46 per 100,000, whereas the prevalence approaches 7 per 1000 
people a year [Hirtz et al., 2007]. Higher incidence rates occur in low-income counties, 
rural areas and among infants and elderly people [Hirtz et al., 2007; Ngugi et al., 2010]. 
Epileptic seizures are classified into two subtypes according to the networks in which they 
originate: focal epileptic seizures originate within networks limited to one hemisphere, 
while generalized epileptic seizures arise within and rapidly engage, bilaterally distributed 
networks [Berg et al., 2010]. Generalized seizures can be further classified in absence, 
myoclonic, atonic, clonic, tonic and tonic-clonic seizures. Focal seizures used to be 
classified in simple or complex seizures on the basis of presumed changes in the level of 
consciousness [Bancaud et al., 1981]. However, the ILAE recommend abandoning these 
imprecise terms and instead describe focal seizures according to their clinical 
manifestations using the Glossary of Ictal Semiology (e.g., aura, focal motor, autonomic 
events, retained/altered responsiveness or awareness) [Blume et al., 2001; Berg et al., 
2010]. 
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Epilepsy is not a singular disease entity but encompasses a variety of disorders with 
different clinical manifestations reflecting underlying brain dysfunction that can result 
from many different causes [Fisher et al., 2005]. The etiology or underlying causes of 
epilepsies can be classified into three categories: genetic, structural-metabolic or 
unknown [Berg et al., 2010]. Genetic epilepsy designates that the epilepsy is, as best as 
understood, the direct result of known or presumed genetic defects in which seizures are 
the core symptom of the disorder and in which the causative or susceptibility genes are 
inherited (with Mendelian, mitochondrial, or complex patterns of inheritance) or result 
from de-novo mutations that might or might not be further inherited. In structural-
metabolic epilepsy there is a distinct other structural or metabolic condition or disease 
(including traumatic brain injury, stroke, brain tumors, encephalitis, meningitis, 
malformations of cortical development) that has been demonstrated to be associated 
with substantially increase risk of developing epilepsy in appropriately designed studies. 
Epilepsy of unknown cause designates that the nature of the underlying cause is as yet 
unknown [Berg et al., 2010; Moshe et al., 2015].  
The diagnosis of epilepsy is usually based on anamnesis of the clinical description of the 
seizure, family and personal medical history of the patient, neurological and cognitive 
status, electrocardiogram (ECG) to rule out cardiac abnormalities and the 
electroencephalogram (EEG) [Moshe et al., 2015]. The EEG in patients with epilepsy is 
characterized by the occurrence of epileptiform activity, i.e., spikes, polyspikes, sharp 
waves, and spike-wave discharges, that can be recorded during (ictal) and in between 
(interictal) seizures (Figure 1) [Duncan et al., 2006; Osorio et al., 2011]. Recording of 
habitual seizures during a video-EEG monitoring is the gold standard for confirmation of 
the diagnosis of epilepsy and classification of seizure type [Cascino, 2002]. A brain 
magnetic resonance imaging (MRI) to detect structural epileptogenic lesions is generally 
needed, except for patients presenting with typical syndromes such as juvenile absence 
epilepsy or juvenile myoclonic epilepsy [Moshe et al., 2015]. 
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Figure 1. Electroencephalogram (EEG) in epilepsy. (A) Focal interictal epileptic 
discharges in bilateral temporal lobes with independent sharp and slow wave complexes 
over right (*) and left (**) anterior temporal regions. (B) Ictal EEG showing focal 
rhythmic seizure pattern localized to right temporal region. Figure adapted from [Osorio 
et al., 2011]. 
  
1.2 Treatment of epilepsy 
Antiepileptic drugs (AEDs) are the first line treatment of epilepsy and approximately  
70 % of patients achieve seizure freedom with appropriately used medication therapy 
[Moshe et al., 2015]. AEDs can induce a variety of adverse effects, including effects on 
metabolism, bone and connective tissue, the endocrine system and the central nervous 
system with changes in mood, cognition and behavior [Aldenkamp et al., 2003; Reijs et 
al., 2004]. The probability of becoming seizure free with drugs decreases proportionally 
with the number of AEDs unsuccessfully tried [Schiller and Najjar, 2008]. On the basis of 
this observation, the ILAE defined drug resistant or refractory epilepsy as a failure of 
adequate trials of two tolerated, appropriately chosen and used antiepileptic drug 
schedules (whether as monotherapies or in combination) to achieve sustained seizure 
freedom [Kwan et al., 2010]. 
In patients with drug refractory epilepsy, resective surgery is the first treatment of 
choice. During the presurgical evaluation the results of different techniques, including 
video-EEG monitoring, structural and functional magnetic resonance imaging (MRI and 
fMRI), EEG source imaging (ESI), neuropsychological evaluation, interictal positron 
emission tomography (PET), ictal single photon emission computed tomography (SPECT) 
and magnetoencephalography (MEG), are combined in order to delineate the 
epileptogenic zone [Rosenow and Luders, 2001; Van Mierlo et al., 2014]. The 
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epileptogenic zone is the region that is necessary and sufficient to be totally removed or 
disconnected to achieve complete seizure-freedom [Rosenow and Luders, 2001]. Patients 
with non-localizing ictal scalp EEG, absence of a structural epileptogenic lesion on MRI, 
discongruent results between these techniques or potential overlap with eloquent cortex 
can require an invasive video-EEG monitoring with intracranial electrodes to identify the 
epileptogenic zone [Carrette et al., 2010]. About half of the patients undergoing surgical 
treatment will become long-term seizure-free [de Tisi et al., 2011].  
Patients for whom resective surgery is not an option or in whom resection fails to control 
seizures alternative treatment options are available including neurostimulation of the 
peripheral nerve system with vagus nerve stimulation (VNS) [Vonck et al., 2009] or 
central nerve system with deep brain stimulation (DBS) [Sprengers et al., 2014]. Both 
types of neurostimulation involve direct application of electrical currents to the nervous 
system by means of implanted electrodes connected to a pulse generator. 
Neurostimulation represents an increasingly attractive treatment option that directly 
targets a specific neural region or network thereby avoiding the typical side effects 
associated with medications [Fisher and Velasco, 2014]. Various brain structures have 
been targeted with DBS including the anterior thalamic nucleus, the centromedian 
thalamic nucleus, the cerebellar cortex and the hippocampus [Sprengers et al., 2014]. 
Closed-loop or responsive neurostimulation systems are able to detect epileptiform EEG 
activity in real time and deliver in turn direct electrical stimulation to ictal onset zone in 
response [Morrell, 2011; Vonck and Boon, 2015]. Double-blind randomized controlled 
trials reported treatment effects of DBS similar or slightly superior to VNS [Sprengers et 
al., 2014]: the percentage seizure frequency reduction from baseline were higher for 
DBS of the anterior nucleus of the thalamus (40.4 % stimulated vs. 14.5 % control) 
[Fisher et al., 2010] and closed-loop ictal onset zone stimulation (37.9 % vs. 17.3 %) 
[Morrell, 2011] than two large randomized controlled trials of VNS (24.5 % vs. 6.1 % 
[George et al., 1995] and 27.9 % vs. 15.2 % [Handforth et al., 1998]). Both DBS and 
VNS trials showed further improvements in seizure reduction over a period of years 
during the non-blinded phases, with maximal effect seen typically 1 to 2 years after 
implantation [Fisher and Velasco, 2014]. The efficacy of neurostimulation therapies could 
be enhanced by improvement of our understanding of the mechanisms of action 
involved, which are currently incompletely understood. Further investigation of these 
mechanisms and identification of functional biomarkers, could help to identify the best 
candidates for specific types of neurostimulation and predict their responses to treatment 
[Vonck and Boon, 2015]. 
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2 Comorbidity of epilepsy and depression 
2.1  Epidemiology 
Depression represents the most frequent comorbid psychiatric disorder in epilepsy. 
Epidemiological data on depression in epilepsy vary depending on diagnostic criteria, 
applied measures, surveyed populations, and time frames [Hoppe and Elger, 2011]. 
Large community-based studies of epilepsy patients report lifetime prevalence rates of 
major depression of about 20 %, but higher rates ranging from 30 to 65 % have been 
reported in specific populations, such as patients with refractory epilepsy or patients with 
focal seizures of temporal and frontal lobe origin [Grabowska-Grzyb et al., 2006; Kanner 
and Schachter, 2010]. These rates are much higher than the lifetime prevalence rates of 
major depressive disorder reported in the general population (12 to 16.6 %) [Alonso et 
al., 2004; Kessler et al., 2005]. In addition, more than 70 % of mood disorders in 
epilepsy are atypical and fail to meet any of the diagnostic criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, fifth edition (DSM-5) [Kanner and Schachter, 
2010; Blumer et al., 2004]. Several studies suggest the existence of an epilepsy specific 
depressive disorder that has an unique manifestation which is poorly reflected by the 
criteria of conventional classification systems or taxonomies such as the DSM-5. This 
atypical mood disorder mostly resembles a dysthymic disorder, but with waxing and 
waning affective symptoms, and is therefore called “interictal dysphoric disorder” 
[Blumer et al., 2004] or “dysthymic-like disorder of epilepsy” [Kanner and Schachter, 
2010]. In patients with epilepsy, presence of negative affect has a major impact on the 
quality of life, even more than seizure frequency and severity [Boylan et al., 2004; 
Johnson et al., 2004], and increases the risk of suicide up to tenfold [Jones et al., 2003]. 
Hence, a better understanding of the specific nature and pathogenic mechanisms 
underlying the comorbidity of mood disorders in epilepsy may have far-reaching 
diagnostic, therapeutic and preventive implications. 
2.2  Bidirectional relation 
Comorbid mood disorders in patients with epilepsy have often been considered to be a 
consequence or complication of the chronic seizure disorder. However, an intriguing 
bidirectional relationship between epilepsy and depression has recently been 
demonstrated [Kanner, 2011; Hesdorffer et al., 2012; Mula, 2012]: not only are patients 
with epilepsy at greater risk of developing a depressive disorder, conversely, patients 
with primary depressive disorders are also at greater risk of developing epilepsy 
[Hesdorffer et al., 2000; Hesdorffer et al., 2012; Adelow et al., 2012]. This suggests that 
the pathogenic mechanisms may be strongly intertwined and the structural and 
functional alterations from one disease are likely to trigger the other [Kondziella et al., 
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2007; Kanner et al., 2012]. Epilepsy and depression are both heterogeneous diseases 
that are likely multifactorial, in which genetic vulnerability, developmental insults, 
traumas and environmental stressors can have important and synergistic contributions 
[Mayberg et al., 2005; Kanner and Schachter, 2010]. Research on the pathophysiological 
link between depression and epilepsy has generally focused on common neuroendocrine 
and neurotransmitter abnormalities. These studies have consistently reported a 
hyperactive hypothalamic–pituitary–adrenal axis and disturbances in serotonergic, 
noradrenergic, GABAergic and glutamatergic neurotransmitter systems, all of which may 
be interrelated (for reviews, see [Jobe, 2003; Pineda et al., 2010; Kanner, 2011]).  
The role of decreased functioning of the monoamines serotonin and noradrenaline in 
depression is well recognized and the primary goal of antidepressant drugs is to enhance 
the noradrenergic and/or serotonergic neurotransmission [Elhwuegi, 2004]. It has been 
demonstrated that a decreased activity of the same monoaminergic neurotransmitters 
lowers the seizure threshold in several animal models of epilepsy [Jobe, 2003; Kanner 
and Schachter, 2010]. These observations are consistent with the possibility that 
monoaminergic abnormalities might be operant in the pathophysiology of both mood 
disorders and epilepsy. The occurrence of epileptic seizures in depressed patients is 
typically attributed by clinicians to the belief that antidepressant drugs can have 
proconvulsant effects. However, proconvulsant effects of antidepressants have only been 
associated with overdoses or high serum concentrations in patients with slow metabolism 
[Jobe, 2003; Kanner et al., 2012]. Doses within the therapeutic range of the 
antidepressant monoamine oxidase inhibitors and norepinephrine and serotonin reuptake 
inhibitors have long been known to produce anticonvulsant effects in animal models for 
epilepsy and in some human patients [Jobe, 2003; Jobe and Browning, 2005; Vermoesen 
et al., 2012]. Moreover, neurostimulation treatment with VNS enhances the 
concentration of noradrenaline and serotonin in the brain and is effective for both 
refractory epilepsy and mood disorders [Nahas, 2005; Ben-Menachem, 2002; 
Grimonprez et al., 2015]. 
In addition, converging evidence from neuropsychological, structural and functional 
neuroimaging studies has demonstrated that in both diseases abnormalities are not 
limited to a single brain region, but instead, there is widespread dysfunction in a broad 
corticolimbic network. The areas within this network that are most reproducibly found to 
be dysregulated include: (i) the temporal lobes, with hippocampus, amygdala, entorhinal 
and lateral neocortex, (ii) the frontal lobes, with anterior cingulate cortex (ACC), 
dorsolateral, ventrolateral and ventromedial prefrontal cortex (DLPFC, VLPFC and VMPFC, 
respectively), (iii) subcortical structures such as basal ganglia and thalamus, and (iv) the 
connecting pathways between them [Kondziella et al., 2007; Kanner and Schachter, 
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2010; Kanner et al., 2012]. Although the initial pathologic event from either depression 
or epilepsy can vary in its noxious effects, repeated (depressive or seizure) episodes may 
interact with the neurobiological processes that underpin the other disease to increase 
the extent of brain dysfunction and thereby the likelihood of developing the comorbidity. 
For example, in temporal lobe epilepsy, hyperexcitability and neuronal cell loss in the 
limbic system may evoke mood disturbances, whereas neurotransmitter disturbances and 
brain atrophy in depression may decrease the seizure threshold [Kondziella et al., 2007; 
Kanner and Schachter, 2010]. Several animal models of epilepsy, such as the genetically 
epilepsy-prone rat (GEPR) and the genetic absence epilepsy rats from Strasbourg 
(GAERS), show behaviors equivalent to depressive symptomatology [Jobe, 2003; 
Kanner, 2011]. The increased depressive-like behaviors in these animals were evident 
preceding and following epilepsy onset. These observations indicate that the depressive 
symptoms were not a consequence of seizures, but rather an expression of comorbid 
neural network dysfunction [Jobe, 2003; Kanner, 2011]. 
2.3  Dysfunction of the network for emotion regulation 
Emotions are valenced responses to external stimuli and internal mental representations 
[Ochsner and Gross, 2005]. Considered from an evolutionary perspective emotions 
facilitate adaptive behavior, promoting survival and reproductive success [Lang, 1995]. 
The term “emotion regulation” refers to the initiation of new, or the alteration of ongoing 
emotional responses through the action of regulatory processes that can control the 
physiological, behavioral, and experiential components of affective responses [Ochsner 
and Gross, 2005; Hartley and Phelps, 2010; Gross, 2013]. The ability to modify or 
control the nature of our emotional responses upon changes of environmental 
circumstances is a critical component of normal adaptive human behavior and is often 
impaired in psychiatric disorders [Ochsner and Gross, 2005; Hartley and Phelps, 2010]. 
Emotion regulation involves both early automatic forms of regulation, like controlling 
attention to emotional arousing stimuli, as well as higher forms of cognitive control, such 
as the conscious reappraisal of the emotional valence or meaning of stimuli [Ochsner and 
Gross, 2005; Gross, 2013]. Recently, a new model for mood disorders was proposed, in 
which depression is hallmarked by dysfunction of both forms of emotion regulation 
[Holtzheimer and Mayberg, 2011]. This model emphasizes that it is not the negative 
affect or down state that is abnormal. Instead, it is the tendency to enter the negative 
affect state and the inability to disengage from this state because of the impaired 
emotion regulation that defines mood disorders (Figure 2). Thus, basic and clinical 
research on depression should further investigate the neurobiological bases for normal 
and abnormal mood reaction and regulation resulting in inadequate affective responses, 
rather than focusing on the negative mood state itself [Holtzheimer and Mayberg, 2011].  
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Figure 2. Model of depression defined by emotion regulation dysfunction. 
This model emphasizes that the down state itself is not abnormal. Instead, it is the 
tendency to inappropriately (re-)enter the negative affect state and the inability to 
disengage from this down state because of the impaired emotion regulation that defines 
depression [Holtzheimer and Mayberg, 2011]. 
The neural correlates of the affective system are a group of cortical and subcortical 
structures that are intimately interconnected with each other in a corticolimbic network 
that enables a subject to generate and regulate emotional responses (Figure 3). Cortical 
structures of the affective system are the PFC, the ACC, the insular cortex, and the 
somatosensory cortical areas. Subcortical structures include the amygdala, 
hypothalamus, ventral striatum (with nucleus accumbens) and brainstem [Damasio et 
al., 2000; Price and Drevets, 2010]. The amygdala is an almond shaped group of nuclei 
in the anterior medial temporal lobe that has a central role in the processing and 
regulation of emotions [LeDoux, 2000; Phelps and LeDoux, 2005]. The amygdala sends 
output projections to the hypothalamus which mediates autonomic responses, to the 
ventral striatum that integrates emotional and motivational aspects of behavior and to 
the hippocampus reinforcing encoding and consolidation of emotional memories [Hartley 
and Phelps, 2010]. The amygdala sends bottom-up projections to the ACC, a region that 
integrates limbic feedback and relays it to the PFC regions that are involved in cognitive 
control. On the other hand the VLPFC and DLPFC exert top-down inhibitory control that 
down regulate activity in the amygdala, thereby reducing the influences of emotional 
stimuli on ongoing behavior [Ochsner and Gross, 2005; Price and Drevets, 2010; Disner 
et al., 2011].  
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Figure 3. Neurocircuitry of emotion regulation.  
Emotions are regulated in a broadly distributed network that involves both cortical 
structures, including the ventrolateral, dorsolateral and ventromedial prefrontal cortex 
(DLPFC, VLPFC and VMPFC, respectively) and anterior cingulate cortex (ACC), and 
subcortical structures, such as the amygdala, ventral striatum, hypothalamus and 
brainstem. The amygdala has a central function in the expression and regulation of 
emotions and sends output projections to the hypothalamus which mediates autonomic 
responses, to the ventral striatum that integrates emotional and motivational aspects of 
behavior and to the hippocampus reinforcing consolidation of emotional memories. The 
amygdala sends bottom-up projections to the ACC, a region that integrates limbic 
feedback and relays it to the PFC regions that are involved in cognitive control. On the 
other hand the VLPFC and DLPFC exert top-down inhibitory control that down regulate 
activity in the amygdala. Figure adapted from [Hartley and Phelps, 2010; Disner et al., 
2011]. 
 
There are two main neuropsychological theories regarding hemispheric specialization for 
emotion: (i) the right hemisphere hypothesis, which proposes that the right hemisphere 
is dominant for emotion processing regardless of valence; and (ii) the valence 
hypothesis, which states that the right hemisphere is specialized for negative emotions 
and withdrawal, whereas the left hemisphere is dominant for positive emotions and 
approach behavior [Borod, 1992; Davidson et al., 2000]. These hypotheses are mainly 
based on observations in patients with unilateral brain damage (e.g., due to stroke). 
Stroke patients with right brain damage are significantly impaired relative to patients 
with left brain damage and matched controls with regards to facial, prosodic (emotional 
intonation) and lexical recognition of both positive and negative valenced emotions, 
supporting the right hemisphere hypothesis [Borod et al., 1998]. On the other hand, the 
valence hypothesis is supported by the observation that patients who have brain damage 
to the left frontal lobe have significantly greater frequency and severity of depression 
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than patients with lesions in other locations, whereas patients with damage to the right 
frontal lobe have significantly higher incidence of undue cheerfulness and mania 
[Starkstein et al., 1989]. However, such hemispheric asymmetries are not always reliably 
observed in healthy individuals. Meta-analysis of functional neuroimaging studies of 
emotion found no support for the hypothesis of overall right-lateralization of emotional 
processing, but provided partial support for the valence hypothesis with lateralization of 
emotional activity in frontal cortex, in which there was a trend toward left lateralization 
of positive and approach activations in the frontal cortex and a bilateral distribution of 
negative and withdrawal activations [Wager et al., 2003; Murphy et al., 2003]. 
The previously described regions with structural and functional abnormalities in patients 
with epilepsy and depression show an extensive regional overlap with the corticolimbic 
circuit involved in emotional control. Both disorders may arise due to alterations in 
structural and functional connectivity in this emotion regulating circuit leading to 
imbalanced regulatory top-down and bottom-up effects. Genetic factors, environmental 
stressors and brain traumas can affect the integrity of this network with aberrant 
neuronal plasticity and connectivity that might cause a predisposition to develop both 
depression and epilepsy. It is assumed that impaired emotion control in mood disorders 
is based on dysfunction of the PFC and the amygdala as well as of the connections 
between these structures, resulting in impaired top-down control of the PFC over 
amygdala function [Anand et al., 2005; Sheline et al., 2009; Disner et al., 2011].  
3 Vagus nerve stimulation and the locus coeruleus noradrenergic system 
VNS is a well-tolerated adjunctive therapy for patients with medically or surgically 
refractory epilepsy [Boon et al., 2001; Ben-Menachem, 2002]. VNS consists of two spiral 
nerve electrodes that are wound around the left vagus nerve at the cervical level and 
connected to a programmable pulse generator that delivers chronic, intermittent 
electrical stimulation (Figure 4). Since the first human VNS implantation in 1989, more 
than 100,000 patients with epilepsy worldwide have been treated with VNS. Two double-
blind randomized controlled trials have shown a statistically significant decrease in 
seizure frequency by VNS [George et al., 1995; Handforth et al., 1998; Privitera et al., 
2002]. Several long-term follow-up studies have further established the efficacy and 
safety of VNS [Vonck et al., 1999; DeGiorgio et al., 2000; De Herdt et al., 2007; Elliott et 
al., 2011]. A meta-analysis of VNS efficacy has shown that seizure reduction ranges from 
0 to 100 % (mean 45 %), and varies considerably across patients [Englot et al., 2011]. 
In general, VNS reduces seizure frequency by at least 50 % in a third of patients, one-
third experience a seizure frequency reduction of 30-50 %, and the remaining third show 
little to no response [Boon et al., 2001].  
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Figure 4. Vagus nerve stimulation and locus coeruleus noradrenergic system. 
VNS consists of a programmable pulse generator, which is implanted subclavicularly and 
connected to two spiral electrodes. The electrodes are wound around the left vagus nerve 
at the cervical level and deliver chronic, intermittent electrical stimulation. The vagus 
nerve afferent fibers project to the nucleus tractus solitarius, which in turn projects both 
directly and indirectly to the locus coeruleus. The locus coeruleus is the main source of 
noradrenaline in the brain and has widespread noradrenergic projections to all cortical 
regions, as well as to thalamic nuclei, amygdala and hippocampus. Figure adapted from 
[George et al., 2000; Carter et al., 2014]. 
The exact mechanism by which VNS exerts its antiepileptic effect is not yet fully 
understood. Further elucidation of the mechanism of action is necessary for the 
identification of patients who will be the best candidates for VNS and a more rational 
selection of stimulation parameters. Over the last 20 years, there has been an increasing 
amount of evidence highlighting that electrical stimulation of the vagus nerve activates 
the locus coeruleus (LC) norepinephrine (NE) system and that this activation is critical for 
the antiepileptic effect of VNS [Fornai et al., 2011]. First, the vagus nerve afferent fibers 
project to the nucleus of the solitary tract (NTS), the NTS in turn projects both directly 
and indirectly to the LC [Van Bockstaele et al., 1999]. The LC is the main source of NE in 
the brain and has widespread noradrenergic projections to all cortical regions, as well as 
to thalamic nuclei, amygdala and hippocampus [Sara, 2009] (Figure 4). Acute electrical 
stimulation of the vagus nerve induces an increase in the discharge rate of LC 
noradrenergic neurons [Groves et al., 2005]. In addition, the basal firing rate in the LC is 
significantly increased after long-term treatment with VNS [Dorr and Debonnel, 2006]. In 
rats VNS induces an increase of NE concentration in the hippocampus [Roosevelt et al., 
2006; Raedt et al., 2011; Manta et al., 2013], the amygdala [Hassert et al., 2004] and 
the prefrontal cortex [Follesa et al., 2007; Manta et al., 2013]. A recent PET study 
showed that VNS treatment markedly reduced the binding potential of the alpha-2 
adrenoreceptor antagonist [11C]yohimbine in limbic, thalamic and cortical brain regions, 
suggesting increased noradrenaline release in these regions in response to VNS [Landau 
et al., 2015]. Moreover, lesions of the LC block the anticonvulsant effect of VNS [Krahl et 
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al., 1998]. A recent preclinical study carried out in our laboratory demonstrated a strong 
positive correlation between the VNS-induced increase in norepinephrine levels in the 
brain and the seizure-suppressing effects of VNS [Raedt et al., 2011]. Intrahippocampal 
application of an alpha-2 adrenoreceptor antagonist in a hippocampal seizure model 
blocked the anticonvulsant effect of VNS [Raedt et al., 2011]. Altogether, these results 
bolster the assumption that the degree of norepinephrine release in the brain can provide 
a useful biomarker for the therapeutic efficacy of VNS in patients with epilepsy. 
Besides refractory epilepsy, VNS is also a safe and effective therapy for patients with 
treatment-resistant depression [Nahas et al., 2005; Daban et al., 2008; Bajbouj et al., 
2010]. At the neurotransmitter level, reduced noradrenergic signaling has been proposed 
as one of the underlying mechanisms giving rise to both epilepsy and depression [Jobe, 
2003]. In line with this assumption several antidepressive medications, such as the 
selective-noradrenaline reuptake inhibitors (e.g., reboxetine), work by increasing the 
norepinephrine levels in the brain [Cardamone et al., 2013]. Recently, a preclinical study 
conducted in our laboratory showed that selective lesioning of the noradrenergic LC 
neurons reduced the antidepressant-like effect of VNS [Grimonprez et al., 2015]. These 
results lend support to the theory that the antidepressant effects of VNS can also be 
caused by activation of the neuromodulatory LC-NE system [Jobe, 2003]. 
4 Electrophysiology  
4.1 Electroencephalography 
Electroencephalography (EEG) is an electrophysiological technique that measures 
electrical field potentials produced by the brain. These brain potentials can be recorded 
by placing electrodes on the scalp or into the brain tissue directly (i.e., intracranially). 
Scalp potentials mainly arise from summated excitatory and inhibitory postsynaptic 
potentials on the apical dendrites of the cortical pyramidal neurons that are orientated 
perpendicular to the surface of the head [Osorio et al., 2011]. This implies that scalp EEG 
recordings are the most sensitive to pick up activity from the cortical gyri near the 
surface of the head [Kropotov, 2009]. Postsynaptic potentials occur during 
neurotransmission when the binding of neurotransmitters to receptors changes the flow 
of ions across the cell membrane of the dendrite [Luck, 2014]. The postsynaptic 
potentials need to occur simultaneously in a large number of parallel oriented neurons, at 
least 6 cm2 of cortex is considered necessary, for detection with scalp EEG [Osorio et al., 
2011]. The signals recorded with EEG represent voltage fluctuations over space and time. 
The main advantage of the EEG is its very high temporal resolution in the order of 
milliseconds. In addition, EEG provides a direct measure of electrical neuronal activity 
during ongoing neurotransmission [Luck, 2014]. This makes it a powerful non-invasive 
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technique for investigating the electrophysiological time-course of brain activity. 
4.2  Event-related potentials 
Event-related potentials (ERPs) are electrical brain potentials embedded in the EEG that 
are time-locked to specific sensory, motor or cognitive events. The EEG reflects a variety 
of simultaneously ongoing brain processes and the ERP response to a single stimulus or 
event of interest is usually not visible on the scalp EEG recording during a single trial. 
This is because in most cases ERP changes are very small (microvolts) in relation to the 
EEG waveform (tens of microvolts) in which they are embedded [Rugg and Coles, 1996]. 
In order to see the ERP response to a specific stimulus or event, tens or hundreds of 
trials must be conducted and then averaged together to extract the time-locked ERP from 
the background EEG. Brain activity and noise that is unrelated to the event will vary 
randomly across epochs and this background EEG will tend to average to zero, while the 
brain response specific and time-locked to the event of interest will be constant and 
therefore be captured in this average [Rugg and Coles, 1996; Luck, 2014]. Accordingly, 
ERPs can provide an electrophysiological window during specific cognitive tasks that 
allows continuous analysis of the ongoing neuronal processes from stimulus onset until 
the response with a fine-grained temporal resolution. ERP studies usually focus on 
specific ERP components, which are characteristic parts of the ERP brain wave associated 
with specific cognitive processes and modulated by specific neurotransmitter systems 
[Luck, 2014].  
ERP components have three main characteristics: (i) latency, which is the time in 
milliseconds between stimulus onset and when a component arises or reaches a 
maximum, (ii) amplitude, which is the height/strength of the component in microvolt, 
and (iii) topography, which is the distribution of the voltage over the scalp. The latency 
reflects the time-course of activation and can for example be used to investigate 
temporal differences in terms of neural processing between conditions. Amplitude 
differences suggest a quantitative instead of qualitative difference: conditions have 
engaged the same cognitive process, but to different degrees. Differences in topographic 
voltage maps imply that different anatomical sources or patterns of neural activity are 
associated with the two situations; however, the converse does not apply [Handy, 2005]. 
It should be noted that the high temporal resolution of the ERPs is accompanied by a 
relatively low spatial resolution and it is difficult to determine the neuroanatomical origins 
of a given ERP effect purely on the basis of the observed scalp distribution [Luck, 2014]. 
This is because of the inverse problem: any given voltage distribution at the scalp can be 
explained by an infinite number of intracranial source configurations [Rugg and Coles, 
1996; Kropotov, 2009]. Therefore, intracranial recordings in patients with depth 
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electrodes for diagnostic purposes offer a unique opportunity to merge temporal and 
spatial precision into one single recording and measure local field potentials or even 
single unit activity directly from neurons deep inside the brain [Engel et al., 2005; 
Murray et al., 2014]. Because of its invasive nature, intracranial recordings in humans 
have been restricted to clinical circumstances and are primarily performed in patients 
with refractory epilepsy, in whom it can be indispensable for delineation of the 
epileptogenic zone [Lachaux et al., 2003; Engel et al., 2005; Lachaux et al., 2012]. In 
many patients with refractory epilepsy the hypothesized epileptogenic zone is located 
within the medial temporal lobe, and in these patients depth electrodes can record local 
field potentials from the hippocampus and the amygdala. These intracranial recordings 
can be used to address basic questions about neural encoding of memory and affective 
processing [Engel et al., 2005; Murray et al., 2014]. 
4.2.1  The P3 is an index for the locus coeruleus noradrenergic system 
The P3 was first reported 50 years ago [Sutton et al. 1965] and is probably one of the 
most studied ERP components [Duncan et al., 2009; Luck, 2014]. The P3 is a broad 
positive component with centro-parietal scalp topography and with latency between 300 
to 900 ms post stimulus onset. The P3 is usually measured using oddball paradigms in 
which a random sequence of stimuli is presented, with low-probability target stimuli 
(“oddballs”) embedded in a train of high-probability nontarget stimuli (“standards”). The 
task is to classify the stimuli and to respond only to the low-probability target stimuli. 
After presentation of the infrequent target stimuli a large P3 can be measured at parietal 
midline electrodes [Polich, 2007; Duncan et al., 2009; Luck and Kappenman, 2012]. The 
P3 component has been consistently associated with attention and memory processes, 
and is thought to index the allocation of attentional resources during information 
processing and the updating of working memory as incoming stimuli are evaluated 
[Donchin and Coles, 1988; Polich, 2007]. Given the nature of the P3 and its link to 
attention and memory-related operations it has been suggested to be generated by brain 
mechanisms engaged to inhibit concomitant task-irrelevant brain activity [Polich, 2007]. 
Since infrequent, low probability stimuli can be biologically important, it is adaptive to 
inhibit unrelated brain activity to promote the processing efficiency of the salient events 
thereby yielding large P3 amplitudes. In this regard, the P3 and its underlying sub-
processes could reflect rapid neural inhibition of ongoing activity to enhance focal 
attention during stimulus detection. Reduction of irrelevant “neural chatter” would focus 
incoming stimulus information and sharpen memory encoding. Thus, the P3 may be an 
index of stimulus events important enough to inhibit extraneous brain activity [Polich, 
2007; Luck and Kappenman, 2012]. 
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The neural origins of the P3 component are imprecisely delineated, nevertheless there 
exists a broad consensus that the P3 has multiple neural generators [Soltani and Knight, 
2000; Nieuwenhuis et al., 2005; Polich, 2007]. Evidence for the generators of the P3 
component have been obtained from lesion studies, intracranial recordings in human 
patients and animals, source localization of scalp ERPs and fMRI. These studies have 
identified P3 generators in multiple cortical and subcortical regions, including frontal and 
parietal lobe regions, the temporo-parietal junction, the thalamus, and medial temporal 
lobe structures, such as the hippocampus and amygdala [Knight, 1989; Linden et al., 
1999; Soltani and Knight, 2000; Mulert et al., 2003]. Taken together, converging 
evidence has demonstrated that the P3 component is not generated in a single brain 
region but instead represents distributed neural activity in a corticolimbic networks 
engaged during stimulus evaluation and salience detection [Soltani and Knight, 2000]. 
The fact that P3 can be recorded simultaneously from multiple scalp regions and within 
intracranial brain structures indicates that it reflects the activity of a central integrated 
system with widespread connections and a large-scale impact throughout different 
cortical and subcortical networks [Nieuwenhuis et al., 2005; Duncan et al., 2009]. A 
central system which is known to have a crucial modulatory effect on the P3 is the LC 
[Nieuwenhuis et al., 2005; Polich, 2007]. LC neurons display tonic and phasic discharge 
activity patterns: tonic activity involves its spontaneous (baseline) firing rate, whereas 
phasic activity refers to rapid increases in firing rate in response to salient sensory 
stimuli [Berridge and Waterhouse, 2003]. Behavioral performance is optimal during 
states of intermediate tonic activity which result in a maximal phasic response to sensory 
stimuli [Aston-Jones and Cohen, 2005]. The important role of phasic LC activity in the 
generation and modulation of the P3 is supported by several lines of evidence from 
animal, lesion, behavioral and pharmacological studies. (i) The LC–NE contribution to P3 
generation is consistent with the LC-NE mediated engagement and allocation of 
attentional resources to optimize task performance [Polich, 2007; Corbetta et al., 2008; 
Sara, 2009; Nieuwenhuis et al., 2011]. In healthy human participants the largest P3 
amplitudes are observed during optimal behavioral performance in a manner consistent 
with the LC phasic response [Murphy et al., 2011]. (ii) The timing and topographic 
distribution of intracranial and scalp-recorded P3 activity are consistent with the 
anatomical and physiological activation of these areas by the LC–NE system 
[Nieuwenhuis et al., 2005; Polich, 2007]. (iii) Lesions of the LC cell bodies reduce the 
auditory P3 amplitude in monkeys, indicating that the LC nucleus and its ascending fibers 
are important in the generation and modulation of the P3 [Pineda et al., 1989].  
(iv) Monkey studies with the oddball paradigm have shown that the conditions for 
generating the P3 are highly similar to those for the LC phasic response: both are 
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preferentially elicited by attended, task-relevant, arousing, and salient stimuli that are 
important for goal-directed behavior [Nieuwenhuis et al., 2005; Aston-Jones and Cohen, 
2005; Corbetta et al., 2008]. (v) Clonidine, a noradrenergic alpha-2 autoreceptor 
agonist, which inhibits LC activity and decreases NE release, decreases the amplitude of 
the P3 component in monkeys and healthy human participants [Joseph and Sitaram, 
1989; Swick et al., 1994; Nieuwenhuis, 2005]. (vi) Simultaneous EEG-fMRI recordings 
during oddball tasks have found evidence of functional coupling between the brainstem 
LC-NE region and cortical attention networks thought to be involved in the generation of 
the P3 response [Walz et al., 2003]. Taken together, these findings support the notion 
that the P3 component of the scalp-recorded ERP can be used as an indirect index of the 
phasic activity of the neuromodulatory LC-NE system [Nieuwenhuis et al., 2005; Murphy 
et al., 2011]. 
4.2.2  The late positive potential is an index for emotion regulation 
The ERP method is used extensively in affective neuroscience to investigate the temporal 
dynamics of emotion regulation processes, whereby an emotional response unfolds over 
time as a function of both how attention is allocated to the emotion-eliciting stimulus and 
how the meaning of the emotional stimulus or situation is interpreted [Gross, 2013]. A 
key component observed in ERPs evoked by emotionally engaging stimuli is the late 
positive potential (LPP). The LPP is a robust visual ERP component reaching a maximum 
amplitude over centro-parietal scalp sites and with onset latency around 300 ms after 
stimuli onset that can last up to several seconds [Hajcak et al., 2010; Luck and 
Kappenman, 2012; Gross, 2013]. The amplitude of the LPP is modulated by emotional 
content, with enhanced positive amplitudes following presentation of both positive and 
negative arousing emotional stimuli compared to neutral stimuli [Cuthbert et al., 2000; 
Schupp et al., 2000]. It has been argued that the LPP indexes sustained attentional 
engagement to emotional content [Robinson et al., 2013] and can be used as an indirect 
electrophysiological marker of the (covert) processing of the emotional intensity of the 
visual stimuli [Schupp et al., 2000; Hajcak et al., 2010]. Based on animal models, it has 
been suggested that the LPP might reflect re-entrant projections from the amygdala to 
the visual system that enhance the sensory processing of emotional stimuli [Lang and 
Bradley, 2010]. Combined EEG-fMRI research indicated that the LPP reflects modulation 
of a broad network of interconnected cortical and subcortical areas, including lateral 
occipital, inferior temporal and parietal extrastriate visual areas, the prefrontal cortex, 
the anterior cingulate cortex and the amygdala [Sabatinelli et al., 2007; Liu et al., 2012; 
Sabatinelli et al., 2013]. In addition, it has been shown that the LPP is associated with 
increased bidirectional functional connectivity between prefrontal and parietal-occipital 
cortex [Moratti et al., 2011]. These results suggest that the LPP response to emotional 
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stimuli is a product of automatic facilitation of visual processing, as well as post-
perceptual processing under cognitive control. Thus, both bottom-up and top-down 
mechanisms account for the modulation of the parietal LPP response [Ferrari et al., 
2008; Moratti et al., 2011; Gross, 2013]. In this regard, it has consistently been shown 
in human ERP studies that the magnitude of the LPP is sensitive to cognitive emotion 
regulation strategies, including suppression, distraction or reappraisal of the emotional 
significance of stimuli [Hajcak and Nieuwenhuis, 2006; Moser et al., 2006; Foti and 
Hajcak, 2008; Dennis and Hajcak, 2009; MacNamara and Hajcak, 2009; Thiruchselvam 
et al. 2011; Moran et al., 2013; Schonfelder et al., 2014]. Moreover, patients with 
general anxiety disorder [Weinberg and Hajcak, 2010], major depressive disorder [Foti et 
al., 2010], obsessive compulsive disorder [Paul et al., 2015] and schizophrenia [Horan et 
al., 2012] show abnormal modulation of the LPP response, indicating impairment of 
emotion regulation in these psychiatric disorders. Taken together, the LPP has proven to 
be a sensitive, valid and effective neurophysiological marker for investigating normal 
emotion regulation processes in healthy individuals, but also abnormal emotion 
regulation in psychiatric patients [Hajcak et al., 2010; Gross, 2013; Moran et al., 2013]. 
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CHAPTER 1  
The P3 event-related potential is a biomarker for the 
efficacy of vagus nerve stimulation in patients with 
epilepsy 
Leen De Taeye, Kristl Vonck, Marlies van Bochove, Paul Boon, Dirk Van Roost, Lies 
Mollet, Alfred Meurs, Veerle De Herdt, Evelien Carrette, Ine Dauwe, Stefanie Gadeyne, 
Pieter van Mierlo, Tom Verguts, Robrecht Raedt 
 
ABSTRACT 
Currently, the mechanism of action of vagus nerve stimulation (VNS) is not fully 
understood, and it is unclear which factors determine a patient’s response to treatment. 
Recent preclinical experiments indicate that activation of the locus coeruleus 
noradrenergic system is critical for the antiepileptic effect of VNS. This study aims to 
evaluate the effect of VNS on noradrenergic signaling in the human brain through a non-
invasive marker of locus coeruleus noradrenergic activity: the P3 component of the 
event-related potential. We investigated whether VNS differentially modulates the P3 
component in VNS responders versus VNS non-responders. For this purpose, we 
recruited 20 patients with refractory epilepsy who had been treated with VNS for at least 
18 months. Patients were divided into 2 groups with regard to their reduction in mean 
monthly seizure frequency: 10 responders (>50 %) and 10 non-responders (≤50 %). 
Two stimulation conditions were compared: VNS OFF and VNS ON. In each condition, the 
P3 component was measured during an auditory oddball paradigm. VNS induced a 
significant increase of the P3 amplitude at the parietal midline electrode, in VNS 
responders only. In addition, logistic regression analysis showed that the increase of P3 
amplitude can be used as a non-invasive indicator for VNS responders. These results 
support the hypothesis that activation of the locus coeruleus noradrenergic system is 
associated with the antiepileptic effect of VNS. Modulation of the P3 amplitude should be 
further investigated as a non-invasive biomarker for the therapeutic efficacy of VNS in 
patients with refractory epilepsy. 
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INTRODUCTION 
Vagus nerve stimulation (VNS) is a well-tolerated adjunctive therapy for patients with 
medically or surgically refractory epilepsy [Boon et al., 2001; Ben-Menachem, 2002]. 
VNS consists of a programmable pulse generator, which is implanted subclavicularly and 
connected to 2 spiral electrodes. The electrodes are wound around the left vagus nerve 
at the cervical level, and deliver chronic, intermittent electrical stimulation. Since the first 
human VNS implantation in 1989, more than 100,000 patients with epilepsy worldwide 
have been treated with VNS. Two randomized, double-blind clinical trials have shown a 
statistically significant decrease in seizure frequency by VNS [George et al., 1995; 
Handforth et al., 1998; Privitera et al., 2002]. Several long-term follow-up studies have 
further established the efficacy and safety of VNS [Vonck et al., 1999; DeGiorgio et al., 
2000; De Herdt et al., 2007; Elliott, 2011]. A meta-analysis of VNS efficacy has shown 
that seizure reduction ranges from 0 to 100 % (mean 45 %), and varies considerably 
across patients [Englot et al., 2011]. In general, VNS reduces seizure frequency by at 
least 50 % in a third of patients; one-third experience a seizure frequency reduction of 
30–50 %; and the remaining third show little to no response [Boon et al., 2001]. 
Therefore, at this moment, 1 of 3 patients undergoing the invasive and costly VNS 
surgical procedure does not experience any benefit from it. 
The exact mechanism by which VNS exerts its antiepileptic effect is not yet fully 
understood. Therefore, prior to implantation of the VNS device, we are currently unable 
to predict which patients will be responders or non-responders. Further elucidation of the 
mechanism of action is necessary for the identification of predictive biomarkers for 
positive therapeutic response and a more rational setting of stimulation parameters. Over 
the last 20 years, there has been an increasing amount of evidence indicating that 
activation of the locus coeruleus (LC) norepinephrine (NE) system is critical for the 
antiepileptic effect of VNS [Fornai et al., 2011]. In addition, a recent preclinical study 
carried out in our laboratory has demonstrated a strong positive correlation between the 
VNS-induced increase in NE levels in the brain and the seizure-suppressing effect of VNS 
[Raedt et al., 2011]. These results suggest that the degree of NE release in the brain can 
be a useful biomarker for the therapeutic efficacy of VNS in epileptic patients. 
Currently, there are no techniques available for direct measurement of NE levels in the 
human brain. Fortunately, changes in NE levels can be indirectly inferred from 
parameters that are modulated by the amount of noradrenergic signaling in the brain. 
One of these parameters is the P3 component of the event-related potential (ERP). The 
P3 is a broad positive component with an onset latency of 300–900 ms that can be 
measured using the auditory oddball paradigm. In this cognitive paradigm, low-
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probability target stimuli (“oddballs”, e.g., low frequency tones) are embedded in a train 
of high-probability nontarget stimuli (“standards”, e.g., high-frequency tones). After the 
presentation of the infrequent target stimuli a large P3 can be measured at parietal 
midline electrodes [Polich, 2007; Duncan et al., 2009]. 
Converging evidence from animal, genetic, and pharmacological studies suggests that 
the P3 component of the scalp-recorded ERP reflects the phasic activity of the 
neuromodulatory LC–NE system [Nieuwenhuis et al., 2005; Murphy et al., 2011]. The 
hypothesis that the LC–NE system contributes to P3 generation during a target detection 
task is consistent with the allocation of attentional resources and arousal effects in 
humans [Berridge and Waterhouse, 2003; Polich, 2007; Sara, 2009; Nieuwenhuis et al., 
2011]. Monkey studies with the oddball paradigm have shown that the conditions for 
generating the P3 are highly similar to those for the LC phasic response: both are 
preferentially elicited by attended, task-relevant, arousing, and salient stimuli that are 
important for goal-directed behavior [Nieuwenhuis et al., 2005; Aston-Jones and Cohen, 
2005]. Furthermore, the timing and topographic distribution of intracranial and scalp-
recorded P3 activity are consistent with the anatomical and physiological activation of 
temporo-parietal areas by the LC–NE system [Nieuwenhuis et al., 2005; Polich, 2007]. 
Finally, lesions of the LC cell bodies reduce the auditory P3 amplitude in monkeys, 
indicating that the LC nucleus and its ascending fibers are important in the generation 
and modulation of the P3 [Pineda et al., 1989]. 
In this study, we assessed the effect of VNS on the NE signaling in patients with epilepsy 
by investigating VNS-induced modulation of the P3 ERP component recorded during a 
standard auditory oddball paradigm. In light of the important role of the noradrenergic 
system in the therapeutic effect of VNS, and given the association between the P3 
component and this specific neurotransmitter system, we hypothesized that we would 
find a different modulation of the P3 component in VNS responders versus VNS non-
responders. The goal of this study was to investigate whether VNS-induced modulation of 
the P3 ERP component could be used as a non-invasive biomarker for the treatment 
response to VNS. 
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METHODS 
Patients 
Twenty patients with epilepsy were included (8 men and 12 women, mean age 44 years). 
The study took place during a video-electroencephalogram (EEG) monitoring session in 
the Reference Center for Refractory Epilepsy, Ghent University Hospital, Ghent, Belgium. 
Patients were included in the study if they met the following criteria: 1) at least 
18 months of treatment with VNS for refractory epilepsy; 2) older than 18 years; 3) full-
scale IQ score ≥ 70 on the Wechsler Adult Intelligence Scale, Third Edition. Only patients 
who were treated with VNS for at least 18 months were included because current reports 
suggest that VNS efficacy has a tendency to improve up to 18 months after surgery, 
after which a plateau is usually reached [Boon et al., 2007; Shahwan et al., 2009]. 
Patients were divided into 2 groups depending on their reduction in mean monthly 
seizure frequency: 10 responders (>50 % reduction) and 10 non-responders (≤50 % 
reduction). Mean monthly seizure frequency was defined as the mean seizure frequency 
during the 3 consecutive months before implantation and before testing. The mean 
monthly seizure frequency before VNS was not significantly different between both 
groups [non-responders: 53.2 ± 54.4 seizures/month; responders: 39.3 ± 48.4 
seizures/month; t(18) = 0.61, p  = 0.55]. Conversely, the mean monthly seizure 
frequency reduction post-VNS was significantly higher in the group of responders 
(86.7 %) than in the group of non-responders (14.2 %) [t(18) = 8.53, p < 0.001]. The 
main clinical characteristics of patients and habitual VNS parameters are summarized in 
Table 1. The study was approved by the ethics committee of Ghent University Hospital. 
After a full description of the procedure was provided and explained, all patients gave 
written informed consent. 
VNS Parameters and Procedure 
All patients had a chronically implanted VNS device (Cyberonics, Houston, TX, USA), 
comprising a programmable pulse generator placed subcutaneously under the left clavicle 
and 2 helical electrodes wound around the left vagus nerve in the neck. Time since start 
of VNS treatment varied between 1.5 and 16.2 years. During this period, the stimulation 
parameters were individually adjusted by a previously described standard ramping-up 
scheme [Vonck et al., 1999; De Herdt et al., 2007]. Stimulation parameters were 
gradually changed in order to achieve maximal therapeutic effect with minimal side 
effects. At the start of the study VNS parameters, battery voltage and lead impedance 
were checked with a handheld computer and programmable wand. 
Patients performed the task during 2 stimulation conditions—VNS OFF and VNS ON—in a 
randomized, counterbalanced order. During the VNS ON condition the duty cycle was 7 s 
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ON/18 s OFF. Other stimulation parameters during the VNS ON condition were patient-
specific (see Table 1), with output current ranging between 0.75 and 3.00 mA, a 
frequency of 20 or 30 Hz, and a pulse width of 250 or 500 μs. These values were the 
habitual therapeutic parameters of each patient that had optimal clinical efficacy. There 
were no significant differences in stimulation parameters between the group of 
responders and non-responders. After switching the VNS device ON or OFF, there was a 
pause of 20 min in order to allow habituation and achieve a stable baseline condition 
before the oddball task was initiated. 
Auditory Oddball Paradigm 
Patients performed a standard auditory oddball task [Duncan et al., 2009]. This task 
requires participants to press a predefined button with the index finder of the dominant 
hand in response to “target” tones (low frequency), but not to respond to “nontarget” 
tones (high frequency). Participants were given a practice session in order to become 
familiar with the target and nontarget tones. The target tones were presented with a 
probability of 10 %. During 4 blocks of 140 trials (total = 560 trials), participants listened 
to a series of tones consisting of 504 nontarget and 56 target tones that were presented 
in a random order with an inter stimulus interval of 1 s. Both speed and accuracy of the 
response to the infrequent target tone were emphasized. To reduce ocular artifacts, 
participants were instructed to fixate their gaze on a cross on the monitor while listening 
to the stimuli. Stimulus presentation and response time recording were controlled using 
E-Prime software 2.0 (Psychology Software Tools, Pittsburgh, PA, USA) on a Dell (Round 
Rock, TX, USA) desktop computer. 
 Table 1 Patient characteristics 
Patient Sex Age Seizure VNS VNS Parameters HEZ AED P3 absolute P3 relative 
ID  (years) reduction Impl Output Frequency Pulsewidth Lobe Side  amplitude (μV) amplitude (%) 
   (%) Year (mA) (Hz) (μs)    OFF ON ON-OFF (ON-OFF)/OFF 
Responders             
R_1 M 52 100.0 1995 2.00 30 500 TL Bilateral VPA, VGB, CBZ 7.41 11.77 4.36 58.81 
R_2 F 57 100.0 1997 1.50 30 500 FL+TL+PL Right LTG 3.94 5.58 1.64 41.78 
R_3 F 52 100.0 2003 2.50 30 500 TL right LEV, CBZ 3.77 3.63 -0.14 -3.61 
R_4 M 22 100.0 2007 0.75 20 500 General bilateral VPA, LTG 3.96 6.21 2.26 57.09 
R_5 M 36 95.6 2010 2.25 20 250 FL right LEV, PGB, CZP 2.37 2.04 -0.34 -14.15 
R_6 F 66 95.0 2003 2.50 20 500 General bilateral LEV, LTG, CZP 3.15 4.48 1.32 41.92 
R_7 F 55 85.0 2002 3.00 20 500 TL right LEV, LTG, CBZ 7.30 8.88 1.58 21.65 
R_8 F 45 73.3 1997 2.75 20 250 TL right LEV, LTG, CZP 4.34 7.44 3.10 71.48 
R_9 F 30 63.3 2005 2.50 25 500 General bilateral VPA, LEV, PGB, CZP 4.99 7.06 2.07 41.45 
R_10 F 21 54.5 2009 3.00 30 500 General bilateral VPA, LTG, PGB, LCZ 2.45 2.68 0.23 9.55 
Mean  44 86.7 2003 2.28 25 450    4.37 5.98 1.61 32.60 
Non-responders             
NR_1 F 62 50.0 2008 3 30 130 General bilateral PHT, LEV, LTG, CZP, RG 5.30 5.94 0.64 11.98 
NR_2 M 55 46.9 2003 2.75 30 500 FL+TL bilateral PHT, LCZ 16.45 16.29 -0.16 -0.98 
NR_3 M 61 33.3 1999 2.5 20 500 FL bilateral CBZ, PB, LEV, PGB, CZP 6.50 5.56 -0.93 -14.38 
NR_4 M 53 9.1 2007 2.75 30 500 FL+PL bilateral VPA, LTG 2.32 1.77 -0.55 -23.75 
NR_5 M 23 3.1 2007 2.75 30 500 FL+PL bilateral LTG, CZP, OXC, LCZ 3.35 3.82 0.46 13.83 
NR_6 M 25 0.0 2008 2 30 500 OL left LEV, CZP, CBZ 5.90 7.80 1.89 32.08 
NR_7 F 32 0.0 2007 2 20 250 FL+OL right LEV, CZP, CBZ 10.06 5.95 -4.11 -40.89 
NR_8 F 30 0.0 2011 0.75 20 250 FL+TL+PL left CLB, CZP, OXC 6.61 6.09 -0.52 -7.94 
NR_9 F 54 0.0 2010 2.75 20 500 FL left CZP, CBZ, RG, LCZ 5.74 6.71 0.98 17.06 
NR_10 F 48 0.0 2010 1.75 30 500 FL left VPA, LEV, PB, LCZ 4.14 4.46 0.32 7.82 
Mean  44 14.2 2007 2.30 26 413    6.64 6.44 -0.20 -0.52 
VNS vagus nerve stimulation; HEZ hypothesized epileptogenic zone; AEDs antiepileptic drugs; R responder; NR non-responder; M male; F female; TL temporal lobe; FL 
frontal lobe; PL parietal lobe; OL occipital lobe; VPA valproic acid; VGB vigabatrin; CBZ carbamazepine; LTG lamotrigine; LEV levetiracetam; PGB pregabalin; CZP 
clonazepam; PHT phenytoin; RG retigabine; LCZ lacosamide; PB phenobarbital; OXC oxcarbazepine; CLB clobazam 
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Electrophysiological Recordings 
The EEG was recorded with a Micromed System Plus (Micromed, Mogliano, Italy) using 
Ag/AgCl electrodes placed at 59 standard locations according to the extended 
International 10-20 System using a precabled electrode cap (WaveGuard EEG cap 
system; Eemagine, Berlin, Germany). The online reference electrode was placed on CPz 
and the ground electrode on AFz. The vertical electro-oculogram was monitored using 2 
facial electrodes placed on inferior and superior areas of the left orbit. The 
electrocardiogram (ECG) was recorded with 2 ECG electrodes placed above the heart. 
Two additional electrodes were placed in the neck cranial and caudal to the vagus nerve 
electrode to monitor the VNS artifact. The EEG, electro-oculogram, ECG, and VNS signals 
were digitized online with a sampling frequency rate of 1024 Hz, antialiasing filter of 
250 Hz, gain of 50 dB, and a resolution of 16 bits. Electrode impedance was maintained 
below 10 kΩ. ERPs of interest were computed offline following a standard sequence of 
data transformations [Picton et al., 2000]. Using an independent component analysis that 
subtracts artifact components from each electrode, the EEG was corrected for vertical 
and horizontal eye movements, blinks, heartbeat, and VNS artifacts. The EEG signal was 
then re-referenced to the average of all 59 recorded channels. The continuous EEG was 
first digitally filtered with a 50-Hz notch filter and a half-power band-pass filter between 
0.1 and 30 Hz, and a roll-off of 12 dB/octave and then down-sampled to 256 Hz. The 
EEG was segmented into epochs from −200 ms to +1000 ms relative to the onset of the 
target and standard stimuli. Baseline correction was performed on the 200-ms 
prestimulus interval, and epochs with a voltage exceeding ±75 μV were excluded from 
averaging. Artifact-free epochs were averaged separately for standard and target stimuli, 
for each condition and each individual. To isolate the P3 component, we created a 
classical target-standard difference waveform; P3 amplitude and latency were measured 
from the resulting difference waves. For each patient, the P3 peak was determined using 
automatic local peak detection in the 300–900 ms interval poststimulus onset at the 
parietal midline electrode Pz. The latency of the P3 was measured as the time point at 
which the voltage reached 50 % of the peak amplitude. This is because in averaged 
waveforms the absolute onset latency will reflect the trials with the earliest onsets rather 
than the average of the single trial onset latencies. Therefore, the 50 % peak latency 
measure is a much more accurate and sensitive measure of the relative onset time of an 
ERP component [Luck, 2005; Kappenman et al., 2012]. The P3 amplitude was calculated 
as the mean amplitude during the 100-ms interval round the peak detected by the 
automatic peak detection relative to baseline. Mean amplitude measurements capture 
more of a component than just the extreme value, and are less sensitive to noise than 
peak amplitude measurements [Luck, 2005]. ERP amplitude measurements can be 
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influenced by individual differences in nuisance variables [Luck, 2011], such as skull 
thickness [Frodl et al., 2001] and cortical folding patterns [Ahlfors et al., 2010]. To 
minimize the impact of these nuisance factors, we calculated the percentage difference in 
P3 amplitude of the ON condition relative to the OFF condition with following formula: P3 
amplitude (ON–OFF)/OFF. 
Statistical Analysis 
All statistical analyses were conducted with SPSS version 20.0 (SPSS, Chicago, IL, USA). 
The level of statistical significance was set at 0.05. The behavioral and 
electrophysiological data were analyzed using a mixed model analysis of variance 
(ANOVA) with between-subject factor group (responders vs.non-responders) and within-
subject factor condition (ON vs.OFF). Two-tailed paired t tests were also computed as 
post hoc analyses. Logistic regression analysis was used to test whether VNS-induced 
modulation of the P3 amplitude is a good indicator to differentiate between responders 
and non-responders. Odds ratios (OR) were calculated with 95 % confidence intervals 
(CI). Receiver operating characteristic (ROC) curve analysis was used to assess the 
optimal cut-off value with maximal sensitivity and specificity. Correlation between the 
relative P3 amplitude and behavioral responses (reaction time and accuracy) were tested 
using Pearson’s correlation coefficient. 
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RESULTS 
Behavioral Results 
The behavioral results are summarized in Table 2: mean accuracy (percentage correct 
responses) and reaction times are shown, along with F- and p-values of the statistical 
analyses. During the auditory oddball task patients detected the target stimuli with a 
very high accuracy: mean performance was 97 % correct. The high accuracy confirms 
that patients were paying attention to the stimuli and could easily discriminate between 
target and nontarget stimuli. Patients had significantly greater accuracy and faster 
reaction times during VNS ON than during VNS OFF condition. The accuracy and reaction 
time measures indicate that both groups of patients were generally better in detecting 
the targets during VNS ON condition, leading to a significant main effect of condition, but 
no group with condition interaction. 
 
Table 2  Behavioral results and P3 measures (mean ± SD), with F- and p-values for 
the statistical analyses 
  Responders Non-responders Statistics 
Dependent 
variable 
OFF ON OFF ON 
Group 
df=1,18 
Condition 
df=1,18 
Group × 
Condition 
df=1,18 
Accuracy 
(%) 
95.71 
(±2.82) 
98.21 
(±2.06) 
96.61 
(±5.29) 
98.21 
(±2.66) 
F=0.12 
p=0.729 
F=5.58 
p=0.030 
F=0.26 
p=0.615 
Reaction  
time (ms) 
417.52 
(±59.85) 
408.98 
(±78.40) 
419.34 
(±68.17) 
394.54 
(±62.24) 
F=0.05 
p=0.831 
F=4.53 
p=0.047 
F=1.07 
p=0.313 
Amplitude  
(μV) 
4.37 
(±1.77) 
5.98 
(±2.97) 
6.64 
(±4.04) 
6.44 
(±3.84) 
F=0.92 
p=0.351 
F=4.22 
p=0.055 
F=5.39 
p=0.017 
Latency 
(ms) 
439.84 
(±107.14) 
437.11 
(±149.59) 
420.32 
(±82.99) 
400.39 
(±80.08) 
F=0.35 
p=0.561 
F=1.26 
p=0.276 
F=0.73 
p=0.405 
df degrees of freedom 
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Electrophysiological Results 
Consistent with many previous ERP studies [16, 30–36], the P3 component of the 
auditory ERP was recorded at the parietal midline electrode Pz. During the auditory 
oddball task, the processing of deviant auditory stimuli was associated with the 
generation of this well-characterized P3 component. Table 1 summarizes the P3 
amplitudes of each individual patient in the responder and non-responder groups. Owing 
to the large interindividual variability in P3 latency and amplitude in the heterogeneous 
patient population, visualization of the effect of VNS on the P3 was optimized by plotting 
the separate difference waves of each individual patient (Figure 1). 
 
Figure 1. Target-standard event-related potential difference waveforms at the parietal 
midline electrode Pz displayed separately for each patient: R_1–10 responders and 
NR_1–10 non-responders. P3 amplitude was measured as the mean of the 100-ms 
marked interval round the peak in the OFF condition (red) and ON condition (green). 
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Table 2 summarizes the means of the P3 latency and amplitude and F and p-values of 
the statistical analysis. Mixed-model ANOVA of the latency of the P3 component revealed 
no significant effects of condition, group or the group × condition interaction. Post hoc 
tests confirmed that there were no significant differences in the latency of the P3 
component between the ON and OFF conditions in both groups: responders [t(9) = 0.16, 
p = 0.875] and non-responders [t(9) = 1.81, p = 0.105]. However, the mixed-model 
ANOVA of the amplitude of the P3 component revealed a significant interaction between 
group and condition [F(1,18) = 5.39, p  = 0.017]. The main effects of group and condition 
were not significant. Post hoc analysis comparing the VNS ON and OFF conditions 
revealed that the amplitude of the P3 was significantly increased in responders: 
amplitude OFF 4.4 ± 1.8 μV and ON 6.0 ± 3.0 μV [t(9) = 3.48, p = 0.007], while in non-
responders this increase was not observed: amplitude OFF 6.6 ± 4.0 μV and ON 
6.4 ± 3.8 μV [t(9) = 0.39, p = 0.706] (Figure 2). VNS induced an average P3 amplitude 
increase of 32.6 % in responders, while in non-responders there was an average 
decrease of 0.5 % when the ON condition was compared with the OFF condition (see 
Table 1). In conclusion, VNS induces a significant increase of the oddball P3 amplitude at 
the parietal midline electrode in VNS responders only. 
 
Figure 2. Bar plots showing the average and standard error of the P3 peak amplitude, 
displayed separately for each group: (a) responders and (b) non-responders. Only in the 
responder group was the amplitude of the P3 significantly larger for the vagus nerve 
stimulation (VNS) ON condition compared with the VNS OFF condition. **p < 0.01. 
Logistic regression analysis with VNS responder as the dependent variable showed that a 
1 % VNS-induced increase of the P3 amplitude has an OR of 1.056 (95 % CI 1.005–
1.109; p =  0.030). This OR means that with each percentage of increase of the P3 
amplitude the odds of being a VNS responder will be 5.6 % higher. The ROC analysis 
revealed an area under the curve of 0.82 (95 % CI 0.63–1.00; p = 0.016) (Table 3, 
Figure 3). This indicates that the measured variable has a very good predictability for 
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VNS responders vs.non-responders. ROC analysis of the VNS-induced P3 amplitude 
increase shows that a cut-off score of  > 20 % has the optimal trade-off between 
sensitivity and specificity, and the highest predictive values. Sensitivity and specificity for 
a P3 amplitude cut-off score of >1.0 μV were 70 % and 90 %, respectively. The positive 
predictive value for this cut-off score was 88 %; the negative predictive value was 75 %. 
Table 3. Receiver operating characteristic and predictive values of P3 amplitude 
for vagus nerve stimulation responders 
Cut-off 
score 
NPV PPV Specificity Sensitivity AUC SE 95 % CI p-value 
> 15 % 0.73 0.78 0.80 0.70     
> 20 % 0.75 0.88 0.90 0.70 0.82 
0.0
97 
0.63 - 1 0.016 
> 25 % 0.69 0.86 0.90 0.60     
> 35 % 0.71 1.00 1.00 0.60      
NPV negative predictive value; PPV positive predictive value; AUC area under curve; SE 
standard error; CI confidence interval 
 
 
Figure 3. (a) Receiver operating characteristic (ROC) curve of the relative P3 amplitude 
for vagus nerve stimulation (VNS) responders/non-responders. (b) Scatter plot of the 
group of responders and non-responders. Logistic regression analysis with VNS 
responder as the dependent variable and cut-off score of >20 % (horizontal line) has a 
sensitivity of 70 % and specificity of 90 %.  
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DISCUSSION 
This study provides novel evidence that supports the hypothesis that VNS-induced 
activation of the LC–NE system is associated with the therapeutic response to VNS in 
patients with epilepsy. Our ERP results show that VNS induces a significant increase of 
the oddball P3 amplitude at the parietal midline electrode in VNS responders only. In 
addition, logistic regression analysis revealed that the increase of the P3 amplitude can 
be used as a non-invasive indicator for VNS responders and non-responders with high 
sensitivity and specificity when a cut-off value of >20 % amplitude increase is used. 
Our new ERP results are consistent with the research of Neuhaus et al., who examined 
the effect of VNS on the P3 component of the auditory ERP in patients with major 
depressive disorder [Neuhaus et al., 2007]. Their study reported that after 10 weeks of 
VNS the amplitude of the P3 was significantly increased, but only in VNS responders, that 
is in patients with a significant reduction of the depressive symptoms, as measured using 
the Hamilton Depression Rating Scale. So far, only 2 ERP studies focusing on the effect of 
VNS on the P3 have been conducted in patients with refractory epilepsy [Hammond et 
al., 1992; Brázdil et al., 2001]. Hammond et al. found no effect of either acute or chronic 
VNS on the latency and amplitude of the auditory P3 component [Hammond et al., 
1992]. Brázdil et al. showed that VNS had no effect on auditory ERP components [Brázdil 
et al., 2001]. In contrast, VNS induced higher visual N2/P3 peak-to-peak amplitude on 
visual ERPs [Brázdil et al., 2001]. However, both studies had rather small sample sizes (9 
and 10 patients, respectively) and did not distinguish between VNS responders and non-
responders, which might explain these discrepant results. The results of the previous ERP 
studies of VNS in epilepsy patients are not inconsistent with our study or the study by 
Neuhaus et al. [Neuhaus et al., 2007], as in both the latter studies clear effects at the 
level of the P3 were evidenced only when separating responders and non-responders to 
VNS. 
Early observations in patients with epilepsy have shown that VNS has mood-enhancing 
effects [Handforth et al., 1998]. Prospective studies using standard depression rating 
scales confirmed that VNS is associated with statistically significant mood improvements 
[Elger et al., 2000; Harden et al., 2000]. Today, VNS is used as a safe and effective 
therapy for treatment-resistant depression [Nahas et al., 2005; Daban et al., 2008]. 
Depression is the most frequent psychiatric comorbidity in epilepsy [Kanner and 
Schachter, 2010]. Converging evidence indicates that mood disorders and epilepsy have 
a complex bidirectional relationship with the existence of common pathogenic 
mechanisms that are operant in both conditions [Kanner, 2011]. At the neurotransmitter 
level, reduced noradrenergic signaling has been proposed as one of the underlying 
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mechanisms giving rise to epilepsy and depression [Jobe, 2003]. In line with this 
assumption several antidepressive medications, such as selective noradrenaline reuptake 
inhibitors, work by increasing the NE levels in the brain. Therefore, the antidepressive 
effects of VNS can also be caused by activation of the neuromodulatory LC–NE system 
[Jobe, 2003]. This hypothesis is supported by the study of Neuhaus et al. [Neuhaus et 
al., 2007], which demonstrated that the P3 is enhanced in responders to VNS for 
treatment of major depressive disorder. This suggests that the P3 can be used as an 
indirect measure for VNS-induced activation of the LC–NE system to detect VNS 
responders in both refractory epilepsy and depression. As such, our new results confirm 
that ERPs may provide a valuable tool as potential biomarkers for several psychiatric and 
neurologic disorders (for a review, see [Luck et al., 2011]). 
In this study, we found that in VNS responders, the ON condition led to an increase of 
the P3 amplitude compared with the OFF condition, which suggests, though indirectly, a 
mediation of this antiepileptic effect by the LC–NE system. Our new ERP results add to 
the existing literature showing that electrical stimulation of the vagus nerve activates the 
LC–NE system and that this activation is critical for the antiepileptic effect of VNS [Fornai 
et al., 2011]. This hypothesis is supported by several lines of converging evidence in the 
literature. First, the vagus nerve afferent fibers project to the nucleus of the solitary 
tract; in turn, the nucleus of the solitary tract projects both directly and indirectly to the 
LC [Van Bockstaele et al., 1999]. Acute electrical stimulation of the vagus nerve induces 
an increase in the discharge rate of LC noradrenergic neurons [Groves et al., 2005]. In 
addition, the basal firing rate in the LC is significantly increased after long-term 
treatment with VNS [Dorr and Debonnel, 2006]. In rats, VNS induces an increase of NE 
concentration in the hippocampus [Roosevelt et al., 2006], the amygdala [Hassert et al., 
2004], and the cerebral cortex [Roosevelt et al., 2006; Follesa et al., 2007]. Moreover, 
lesions of the LC block the anticonvulsant effect of VNS [Krahl et al., 1998]. Furthermore, 
a strong positive correlation was found between the VNS-induced increase in NE levels 
and the seizure-suppressing effects of VNS [Raedt et al., 2011]. Intrahippocampal 
application of an alpha-2 adrenoreceptor antagonist in a hippocampal seizure model 
blocked the anticonvulsant effect of VNS [Raedt et al., 2011]. Together, these results 
bolster the assumption that the degree of NE release in the brain can be a useful 
biomarker for the therapeutic efficacy of VNS in epileptic patients. 
To our surprise, we found a general improvement in behavioral response (i.e., faster 
reaction times and greater accuracy) during VNS in all patients, regardless of the 
therapeutic efficacy of VNS. These results are consistent with previous evidence 
demonstrating VNS-induced cognitive and behavioral improvements that were not related 
to the changes in seizure frequency [Clark et al., 1999; Sackeim et al., 2001; Aldenkamp 
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et al., 2002; Sjogren et al., 2002]. It seems contradictory that VNS improves the 
behavioral performance in all patients, while it increases the P3 amplitude only in 
responders. However, it is possible that the threshold for “functional” activation of the 
LC–NE system (reflected by the behavioral improvement) is much lower than the 
threshold for the antiepileptic effect of the LC–NE system (reflected by the P3). The P3 
component is thought to originate from neuronal inhibitory signals that inhibit unrelated 
neural activity to promote processing efficiency of task-relevant stimuli, thereby yielding 
large P3 amplitudes [Polich, 2007]. Correspondingly, activation of the LC–NE system in 
response to an important stimulus sends a “network reset” signal to the brain that 
interrupts the activity of the ongoing functional networks and facilitates their 
reorganization to promote rapid behavioral adaptation [Sara, 2009; Sara et al., 2012]. It 
is probable that only in the group of responders, because of differences in network 
connectivity and interactions with other neuromodulators, the VNS-induced activation of 
the LC–NE system results in a stronger inhibition and network reorganization that causes 
the antiepileptic effect. The P3 amplitude is proposed to reflect the LC–NE inhibition 
[Polich, 2007] and this could explain why the amplitude is increased only in responders. 
Nonetheless, this remains a hypothetical explanation and further research is necessary to 
clarify the different effects of VNS on cognition and seizure control. 
The current results should be interpreted with caution because epilepsy is a complex, 
heterogeneous, and variable neurological condition, and various potential confounding 
factors need to be taken into account, such as type of epilepsy, type and frequency of 
seizures, age of onset and duration of epilepsy, brain lesions, side and localization of the 
hypothesized epileptogenic zone, and antiepileptic drugs (AEDs) [Kubota et al., 1998; 
Caravaglios et al., 2001]. The strength of our approach was to compare responder and 
non-responder patients with epilepsy while controlling as much as possible for potential 
confounding factors stemming from the heterogeneous clinical parameters and the AEDs. 
It is conceivable that the differential P3 modulation in responders versus non-responders 
could be a consequence of different AEDs. However, this seems unlikely given the 
extensive evidence that AED can increase the latency of P3 components, but are not 
responsible for P3 amplitude modulation in both healthy adults [Meador et al., 1995] and 
epilepsy patients [Enoki et al., 1995; Kubota et al., 1998; Caravaglios et al., 2001]. In 
our study, both groups took a comparable range of AEDs, and no reliable modulation of 
the latency of the P3 component was found depending on the experimental condition. 
Only the P3 amplitude varied systematically with the protocol in the responder group 
exclusively. None of the patients’ AEDs were tapered after they became VNS responders, 
which excludes that the VNS-induced effects on P3 amplitude are caused by reduced 
AED-related side effects after drug tapering. 
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Our analysis has several other limitations. First, there is considerable overlap between 
the P3 amplitude values of the responder and non-responder groups. Although a cut-off 
of P3 amplitude increase of >20 % has reasonably good sensitivity (70 %) and specificity 
(90 %), this biomarker is definitely not perfect, because 30 % of responders and 10 % of 
non-responders are misclassified with this cut-off. The patients in our study had very 
heterogeneous ERP waveshapes and clinical characteristics. It is highly probable that 
because of these interindividual differences VNS will not have the same effect on the P3 
in all patients. The P3 component of the ERP is only an indirect measure of LC–NE 
activity, and other confounding factors could influence the amplitude of the P3. We have 
tried to control for these factors by comparing the P3 amplitude between the ON and OFF 
condition within the same subject and by calculating the relative amplitude differences. 
Second, the vagus nerve has widespread projections to nuclei in the brainstem and to all 
cortical regions, as well as to the thalamus, hippocampus, and amygdala, where they 
modulate the activity of target cells and networks [Boon et al., 2001; Ben-Menachem, 
2002]. In addition, there are strong reciprocal connections between the different 
neuromodulatory systems (noradrenaline, dopamine, serotonin, and acetylcholine), 
which makes it very hard to delineate the role of one single system [Sara, 2009]. 
Consequently, the LC–NE system does not act alone, but interacts with other modulatory 
neurotransmitter pathways that also play an important contributive role in the 
antiepileptic effect of VNS. A third limitation is that we were unable to determine 
causality in our study. We found a significant increase of the P3 in the group of 
responders, but we cannot be certain what caused the seizure reduction. The P3 is 
probably an epiphenomenon of the LC–NE activation and subsequent inhibition. These 
limitations notwithstanding, we believe that the significant difference that was found in 
our analysis indicates that the P3 has potential as a non-invasive biomarker for VNS 
responders. 
In the present study, we have recruited patients who received VNS therapy for at least 
18 months. Presumably, this chronic stimulation has led to long-term changes in the 
neuronal networks and neurotransmitter systems [Boon et al., 2001]. Therefore, it 
remains unclear whether these P3-effects will also be observed in epilepsy patients prior 
to initiation of VNS therapy. Future longitudinal prospective studies are needed to resolve 
this issue. Patients with epilepsy should be tested prior to implantation of the VNS device 
as well as 12–18 months afterwards in order to compare the acute versus chronic effects 
of VNS. These longitudinal studies are required to assess whether we can predict, based 
on the baseline measurement (phasic effects), which patients will eventually become 
responders to the VNS therapy (chronic effects) and whether modulation of P3 amplitude 
can be used as a prospective measure to predict the therapeutic efficacy of VNS. 
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In conclusion, our novel ERP results support the hypothesis that VNS-induced activation 
of the LC noradrenergic signaling is associated with the antiepileptic effect of VNS. 
Amplitude modulations of the P3 should be further investigated as a non-invasive 
biomarker to predict the treatment response to VNS in patients with refractory epilepsy. 
A biomarker for the efficacy of VNS could help neurologists to choose the optimal 
stimulation parameters in a more objective way. In combination with a non-invasive 
technique to deliver VNS, such as transcutaneous VNS (tVNS) [Stefan et al., 2012], 
responders could be identified prior to surgery. Hence, the biomarker could avoid 
unnecessary implantations of a VNS device in non-responders and consequently improve 
the clinical efficacy of VNS. 
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CHAPTER 2  
Event-related potentials reveal preserved attention 
allocation but impaired emotion regulation in patients 
with epilepsy and comorbid negative affect 
Leen De Taeye, Gilles Pourtois, Alfred Meurs, Paul Boon, Kristl Vonck, Evelien Carrette, 
Robrecht Raedt 
 
ABSTRACT 
Patients with epilepsy have a high prevalence of comorbid mood disorders. This study 
aims to evaluate whether negative affect in epilepsy is associated with dysfunction of 
emotion regulation. Event-related potentials (ERPs) are used in order to unravel the 
exact electrophysiological time course and investigate whether a possible dysfunction 
arises during early (attention) and/or late (regulation) stages of emotion control. Fifty 
epileptic patients with (n=25) versus without (n=25) comorbid negative affect plus 
twenty-five matched controls were recruited. ERPs were recorded while subjects 
performed a face- or house-matching task in which fearful, sad or neutral faces were 
presented either at attended or unattended spatial locations. Two ERP components were 
analyzed: the early vertex positive potential (VPP) which is normally enhanced for faces, 
and the late positive potential (LPP) that is typically larger for emotional stimuli. All 
participants had larger amplitude of the early face-sensitive VPP for attended faces 
compared to houses, regardless of their emotional content. By contrast, in patients with 
negative affect only, the amplitude of the LPP was significantly increased for unattended 
negative emotional expressions. These VPP results indicate that epilepsy with or without 
negative affect does not interfere with the early structural encoding and attention 
selection of faces. However, the LPP results suggest abnormal regulation processes 
during the processing of unattended emotional faces in patients with epilepsy and 
comorbid negative affect. In conclusion, this ERP study reveals that early object-based 
attention processes are not compromised by epilepsy, but instead, when combined with 
negative affect, this neurological disease is associated with dysfunction during the later 
stages of emotion regulation. As such, these new neurophysiological findings shed light 
on the complex interplay of epilepsy with negative affect during the processing of 
emotional visual stimuli and in turn might help to better understand the etiology and 
maintenance of mood disorders in epilepsy. 
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INTRODUCTION 
Patients with epilepsy have a very high prevalence of comorbid psychiatric disorders 
[Kanner and Schachter, 2010]. Negative affect occurs in up to 80 % of patients with 
epilepsy [Miller et al., 2008] and may manifest as major depressive disorder (MDD) 
meeting the diagnostic and statistical manual IV (DSM-IV) criteria, or atypical mood 
disorders with waxing and waning affective symptoms called “interictal dysphoric 
disorder” [Blumer et al., 2004] or “dysthymic-like disorder of epilepsy” [Kanner and 
Schachter, 2010]. In patients with epilepsy, depressive symptoms have a major negative 
impact on the quality of life [Boylan et al., 2004; Johnson et al., 2004] and increase the 
risk of suicide up to 10-fold [Jones et al., 2003]. Given the high impact on the quality of 
life and the associated elevated mortality due to suicide a better understanding of the 
pathogenic mechanisms of negative affect in epilepsy is important [Jones et al., 2005]. 
Negative affect in epilepsy has been attributed to several causes, including the 
psychological reaction to the chronic seizure disorder, endocrine or metabolic effects of 
seizures, adverse effects of antiepileptic drugs (AEDs) and common pathophysiological 
mechanisms between depression and epilepsy, such as neurotransmitter disturbances 
and abnormal frontotemporal networks [Kondziella et al., 2007; Miller et al., 2008; 
Kanner and Schachter, 2010; Hoppe and Elger, 2011; Kanner, 2011]. The common 
pathological changes can compromise the integrity of a functional neuronal network that 
is implicated in emotion control [Ochsner and Gross, 2005; Price and Drevets, 2010; 
Disner et al., 2011]. Emotion control refers to both early automatic forms of regulation, 
like controlling attention to emotional arousing stimuli, as well as higher forms of 
cognitive control, such as the conscious reappraisal of the emotional valence of stimuli 
[Ochsner and Gross, 2005]. Recently, Holtzheimer and Mayberg proposed a model for 
negative affect that is hallmarked by dysfunction of both forms of emotion control 
[Holtzheimer and Mayberg, 2011]. This model emphasizes that it is not the negative 
affect state that is abnormal. Instead, it is the tendency to enter the negative affect state 
and the inability to disengage from this state because of the impaired emotion regulation 
that defines mood disorders. Therefore, this study focuses on emotion control and more 
specifically investigates whether negative affect in patients with epilepsy is associated 
with dysfunction during early attention processes and/or later stages of emotion 
regulation. 
To address this question, we used a variant of the face- or house-matching task 
[Wojciulik et al., 1998], a standard task for measurement of attention and emotion 
regulation [Vuilleumier et al., 2001; Holmes et al., 2003; Bentley et al., 2003; 
Vuilleumier et al., 2004; Bishop et al., 2004a; Bishop et al., 2004b; Fales et al., 2008]. 
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In this procedure, participants are shown a display with two houses and two faces 
presented in vertical and horizontal pairs. They have to attend only one pair and have to 
make a demanding same/different judgment on the attended pair of stimuli. The faces 
have either a neutral or emotional expression and are positioned either in attended or 
unattended spatial locations. This paradigm provides an ideal situation in which both 
attention and emotion can be manipulated independently [Vuilleumier et al., 2001]. 
Event-related potentials (ERP) are recorded during this paradigm in order to disentangle 
effect of attention and emotion during early (attention) and late (regulation) stages of 
emotion processing. One previous ERP study has investigated spatial attention during the 
face- or house matching task in healthy participants [Holmes et al., 2003]. This study 
has demonstrated that the early face-sensitive N170 component amplitudes were 
significantly enhanced when faces were at attended spatial locations. The N170 is a 
negative component with latency around 170 ms that has a larger amplitude for faces 
than houses or other objects at occipitotemporal electrodes. The N170 has remarkable 
temporal and functional similarity with the vertex positive potential (VPP) that is recorded 
at the central midline electrode and is also typically enhanced in response to face stimuli 
[Botzel and Grusser, 1989; Botzel et al., 1995; Jeffreys, 1989; George et al., 1996]. 
Hence, it has been suggested that both N170 and VPP components are part of the same 
neural dipole located in or near the fusiform gyrus [Rossion et al., 2003; Luo et al., 
2010]. The temporally coincident N170 and VPP are the earliest markers of a reliable 
processing difference between faces and objects and are linked with the structural 
encoding of faces [Rossion et al., 2003; Holmes et al., 2003]. Therefore, we measured 
the early face-sensitive N170/VPP components to examine whether epilepsy and negative 
affect have an influence on object-based attention. 
Many ERP studies that study emotion have focused on a broad parietal positive 
component that occurs roughly 300 ms after emotional stimuli, called the late positive 
potential (LPP). The LPP is a robust visual ERP component that is known to have an 
enhanced amplitude for both positive and negative arousing emotional stimuli compared 
to neutral stimuli [Schupp et al., 2000; Schupp et al., 2006; Sabatinelli et al., 2007; 
Olofsson et al., 2008; Hajcak et al., 2010]. The magnitude of the LPP is sensitive to 
emotion regulation strategies and can be reduced by reappraisal of the emotional 
significance of stimuli, e.g., reappraising unpleasant stimuli as less negative decreases 
the LPP amplitude [Moser et al., 2006; Foti and Hajcak, 2008; Hajcak et al., 2010]. 
Hence, the LPP can be used indirectly as an electrophysiological marker of the covert 
processing of the emotional intensity of the visual stimuli.  
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In the present study, attention and emotion effects during the face- or house-matching 
task were compared between epileptic patients with vs.without comorbid negative affect 
and matched healthy controls. ERPs were used in order to explore the exact 
electrophysiological time course and investigate whether a possible dysfunction arises 
during early (attention, VPP/N170) and/or late (regulation, LPP) stages of emotion 
control.  
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METHODS 
Ethics statement 
The study was approved by the ethics committee of Ghent University Hospital and 
conducted in accordance with the declaration of Helsinki. After a full description of the 
procedure was provided and explained, all participants gave written informed consent 
prior to participation. 
Participants 
A total of fifty patients with refractory epilepsy were included (M/F: 26/24, mean age 
34.7 years). The study took place during presurgical video-EEG monitoring in the 
Reference Center for Refractory Epilepsy (Ghent University Hospital, Belgium). Patients 
were included in the study if they met the following inclusion criteria: (i) confirmed 
epilepsy based on continuous video/EEG monitoring, (ii) age 18–65, (iii) no arguments 
for mental retardation. Twenty-five healthy volunteers free from neurological or 
psychiatric symptoms were matched as closely as possible to the patients with respect to 
age, sex, and education (M/F: 14/11, mean age 37.0 years). The main clinical 
characteristics of participants are summarized in Table 1. 
Presence of negative affect was assessed by using the validated Dutch version of the 
Beck Depression Inventory II (BDI-II) [Beck et al., 1996; Van der Does, 2002]. The BDI-
II is a 21-item self-report questionnaire that assesses the severity of depressive 
symptomatology, including affective, cognitive, behavioral, somatic and motivational 
symptoms of depression. Individuals rate each symptom on a scale ranging from 0 to 3. 
Higher scores on the BDI reflect more negative affect with scores ranging from 0 to 63. 
Using the criteria proposed by Beck et al. (0–13 minimal, 14–19 mild, 20–28 moderate, 
29–63 severe depressive symptoms) [Beck et al., 1996], a cut-off score of >14 was used 
to subdivide the patients in two groups: 25 patients with negative affect (mean BDI: 
23.6 ± 9.4), 25 patients without negative affect (mean BDI: 5.0 ± 3.5) and 25 control 
participants (mean BDI: 3.6 ± 3.0). In addition, state and trait anxiety levels of all 
participants were measured, following standard practice, using the State-Trait Anxiety 
Inventory (STAI) [Spielberger et al., 1983], translated in Dutch [Van der Ploeg et al., 
2000].
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Table 1. Demographic data for each group of participants 
 Patients 
with  
negative 
affect 
Patients 
without 
negative 
affect 
Controls Statistics 
 (n=25) (n=25) (n=25)  
BDI 23.6 (±9.4) 5.0 (±3.5) 3.6 (±3.0) p<0.001 
Age (years) 33.7 (±10.0) 35.7 (±10.9) 37.0 (±11.9) p=0.502 
Sex (M/F) 16 / 9  10 / 15  14 / 11 p=0.156 
Education (years) 13.1 (±1.5) 13.6 (±1.7) 14.6 (±1.5) p=0.292 
HEZ: side   NA p=0.683 
Right 9 12   
Left 15 12   
Bilateral 1 1   
HEZ: lobe    NA p=0.232 
Frontal 10 5   
Temporal 11 17   
Fronto-temporal 1 2   
Parietal/Occipital 3 1   
3T MRI    NA p=0.733 
Normal 6 5   
Abnormalities 19 20   
• Frontal 7 8   
 Temporal 10 12   
o Medial temporal 9 10   
• Parietal/Occipital 3 2   
Epilepsy duration 
(years) 
11.7 (±9.5) 18.9 (±10.8) 0 p=0.016 
Seizure frequency 
(/month) 
11.9 (±12.2) 11.1 (±13.0) 0 p=0.825 
Number of AEDs (/day) 2.4 (±0.8) 2.9 (±0.9) 0 p=0.074 
AEDs total dose 
(mg/day) 
2474.8 
(±1416.1) 
2631.6 
(±1773.7) 
0 p=0.731 
ADDs total dose 
(mg/day) 
27.7 (±67.2) 0 0 p=0.045 
STAI State 46.3 (±10.4) 34.8 (±8.1) 28.0 (±4.9) p<0.001 
STAI Trait 52.3 (±8.3) 35.8 (±7.9) 34.6 (±7.5) p<0.001 
Values represent means (± 1 standard deviation) or numbers. 
Abbreviations: BDI Beck Depression Inventory, M male, F female, HEZ hypothesized 
epileptogenic zone; 3T MRI 3 tesla magnetic resonance imaging, AEDs antiepileptic 
drugs; ADDs antidepressant drugs, STAI state-trait anxiety inventory 
 CHAPTER 2 | Emotional ERPs in epilepsy with negative affect  69 
Stimuli 
All stimuli comprised displays of four pictures, with two faces and two houses arranged in 
vertical and horizontal pairs around a central black fixation cross (Figure 1). All pictures 
were black and white photographs presented on a gray background and had the same 
size across all experiments (108 [width] × 154 [height] pixels on a 1024 * 768 resolution 
screen) subtending 4.0 × 5.7° of visual angle at a 50 cm viewing distance. The stimuli 
included 10 fearful faces, 10 neutral faces, 10 sad faces and 20 houses, with pictures 
from each category repeated equally across all trials. The neutral, fearful and sad facial 
expression photographs were drawn from the set of Ekman and Friesen [Ekman and 
Friesen, 1976]. 
 
Figure 1. Sample visual stimuli of the face- or house-matching task. 
Each trial comprised a display of four pictures, with two houses and two faces arranged 
in vertical and horizontal pairs around a central black fixation cross. Before each block, a 
visual cue (i.e., thickening of two frames) instructed participants to attend either to the 
vertical pair or the horizontal pair of stimuli, while ignoring the other pair. Subjects had 
to indicate quickly and accurately whether the two stimuli at the task-relevant locations 
were the same or different (i.e., matching task). On any given trial, both faces had either 
a fearful, sad or neutral expression and were shown at task-relevant or task-irrelevant 
locations. The neutral, fearful and sad facial expression photographs were drawn from 
the set of Ekman and Friesen [Ekman and Friesen, 1976]. 
Procedure 
The face- or house-matching task was adapted from previous studies [Vuilleumier et al., 
2004]. Stimulus presentation and response time recording were controlled using E-Prime 
software 2.0 (Psychology Software Tools Inc., Pittsburgh, USA). Before each block, a 3 s 
display instructed subjects to attend to horizontal or vertical stimulus pairs, while 
ignoring the other stimulus pairs. The instruction display consisted of four empty frames 
placed at the location of the stimuli, with either the two horizontal or the two vertical 
frames being thickened. Trials began with a central fixation cross for 1 s, followed by the 
four-picture display for 300 ms. Subjects were asked to maintain fixation centrally 
throughout the trials and attend covertly to the stimulus pair at the relevant locations, in 
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order to judge whether these two stimuli were the same or different by pressing one out 
of two keys. The inter-trial interval (ITI) varied randomly between 1 and 3 s. All 
participants completed 10 practice trials and 4 blocks of 48 trials, with two blocks where 
the attention was directed to horizontal positions and two blocks where the attention was 
directed to vertical positions. In each block, all possible combinations of two object 
categories (faces vs.houses), their locations, same/different identity, and facial 
expression were fully randomized and counterbalanced across trials, resulting in a total of 
32 neutral, 32 sad and 32 fearful faces at task-relevant locations, and the same number 
for each expression at task-irrelevant locations (total 192 trials). Instructions emphasized 
both accuracy and speed. Response times were recorded from stimulus onset. Trials were 
excluded when there was no response within 2 seconds. 
EEG recording 
The electroencephalogram (EEG) was recorded with Micromed System Plus (Micromed, 
Mogliano Veneto, Italy) using gold electrodes placed at 27 standard locations from the 
extended international 10–20 system (Fp1, Fpz, Fp2, F7, F3, Fz, F4, F8, T3, C3, Cz, C4, 
T4, T5, P3, Pz, P4, T6, O1, Oz, O2, T9, TP9, FT9, T10, TP10 and FT10). The online 
reference electrode was placed on the right mastoid and ground electrode on the left 
mastoid. The electrocardiogram (ECG) was recorded with two ECG electrodes placed 
above the heart. The EEG and ECG signals were digitized online with a sampling 
frequency rate of 1024 Hz, anti-aliasing filter of 250 Hz, gain of 50 dB and 16 bits 
resolution. Electrode impedance was maintained below 10 kΩ. 
ERP analysis 
ERPs of interest were computed offline following a standard sequence of data 
transformations [Picton et al., 2000]. All offline ERP analyses were performed using 
BrainVision Analyzer 2 software (Brain Products GmbH, Gilching, Germany). The EEG was 
corrected for vertical and horizontal eye movements, blinks and ECG artifacts with an 
independent component analysis (ICA) that subtracts these artifact components from 
each electrode. The raw EEG was first decomposed into ICA components using the 
restricted infomax algorithm. Then the three components related to eye-movements, 
blinks and ECG artifacts were selected by visual inspection, relying on both the time 
course and the spatial maps of the components herewith generated. These components 
were removed and the remaining ICA components were projected back using an inverse 
ICA to reconstruct the artifact-free EEG. The EEG signal was then re-referenced to the 
average of all 27 recorded channels. The continuous EEG was first digitally filtered with a 
50 Hz notch filter and a half-power band-pass filter between 0.1–30 Hz with a roll-off of 
12 dB/octave. The EEG was segmented into epochs from −200 ms to +1000 ms relative 
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to the onset of the stimuli. Baseline correction was performed on the 200 ms pre-
stimulus interval and epochs with voltage exceeding ±75 µV were excluded from 
averaging. The average fraction of rejected epochs was 4.7 % in the group of patients 
with negative affect, 4.1 % in the group of patients without negative affect and 5.4 % in 
the control group (one-way ANOVA F=0.2, p=0.8). Artifact free epochs were averaged 
separately for each condition and each individual. The grand average ERPs were 
generated by computing mean ERPs across subjects, for each condition separately. The 
effects of attention and emotion on sensory processing were analyzed by focusing on two 
well-documented ERP components: the vertex positive potential (VPP) and the late 
positive potential (LPP). The VPP was detected automatically as the maximum positive 
amplitude in the 140–210 ms interval post-stimulus onset at the central midline Cz 
[Rossion et al., 2003]. The VPP amplitude was calculated as the mean amplitude of the 
20 ms interval around this peak. The N170 measurements were made on lateral 
temporal-occipital electrode sites T5 and T6 using the same time window [Rossion et al., 
2003; Holmes et al., 2003]. The LPP amplitude was measured as the average amplitude 
of the 350–600 ms interval post-stimulus onset at parietal midline electrode Pz [Schupp 
et al., 2000; Moser et al., 2006]. Repeated measures analysis of variance (ANOVA) was 
used with a 2-tailed alpha level of 0.05 for all statistical tests. When assumptions of 
sphericity were violated (Mauchly’s sphericity test, p<0.05), Greenhouse—Geisser epsilon 
correction was applied. The analyses of the ERP measures included a between-subjects 
factor of group (with negative affect vs.without negative affect vs.control) and a within-
subjects factor of attention (task-relevant vs.task-irrelevant) and emotion (neutral vs. 
sad vs. fear). Post-hoc tests of simple effects were adjusted with the Bonferroni 
correction for multiple comparisons. In order to control for possible confounding factors 
of damage to the medial temporal lobe, frontal lobe and antidepressant dose, separate 
ANOVA’s were performed with these factors entered as covariates. Correlation between 
the LPP amplitude differences and antidepressant dosing were tested using 2-tailed 
Pearson’s correlation coefficient.  
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RESULTS 
Clinical data 
Differences in clinical parameters between epileptic patients with negative affect and 
without negative affect were assessed with unpaired t-test for continuous variables and 
Pearson chi-square test for categorical variables. There were no significant differences in 
age [t(48)=0.7, p=0.5], sex [Χ2=2.9, p=0.1], years of education [t(48)=1.1, p=0.3], 
side of the hypothesized epileptogenic zone (HEZ) [Χ2=1.1, p=0.3], lobe of the HEZ 
[Χ2=4.3, p=0.2], 3T MRI abnormalities [Χ2=0.1, p=0.7], damage to medial temporal 
lobe [Χ2=0.1, p=0.8], seizure frequency [t(48)=0.2, p=0.8], number AEDs [t(48)=1.8, 
p=0.1] and AEDs dose [t(48)=0.3, p=0.7]. Duration of epilepsy was significantly higher 
in the group of patients without than with negative affect [t(48)=2.5, p=0.02]. 
Accordingly, longer duration of epilepsy was not associated with increased negative 
affect. As expected, the mean BDI score was significantly higher in the group with 
negative affect (23.6 ±9.4) than the group without negative affect (5.0 ±3.5) 
[t(48)=9.2, p<0.001]. The STAI-S and STAI-T scores were also significantly higher in the 
group with than without negative affect [STAI-S: t(48)=4.3, p<0.001, STAI-T: 
t(48)=7.2, p<0.001]. Correlation analysis using a 2-tailed Pearson coefficient showed 
significant positive correlations of the BDI scores with the STAI-S (r=0.73, p<0.001) and 
the STAI-T (r=0.81, p<0.001) scores. 
Behavioral results 
Mean response times and accuracy in same/different judgments, performed during 
continuous video-EEG monitoring, were computed for each subject in each of the six 
conditions. Behavioral results are summarized in Figure 2. To examine data, mixed model 
ANOVA was performed with group as between-subject factor (control vs. patients with 
negative affect vs. patients without negative affect) and two within-subject factors: 
attention (faces vs. houses) and emotional expression (fearful vs. neutral vs. sad). 
Mean error rate was 25 % indicating that the matching task was relatively demanding. A 
significant group-related effect was found for accuracy: epileptic patients with negative 
affect made most errors (35 %), epileptic patients without negative affect made 25 % 
errors, while control subject had an error-rate of 18 % [main effect of group 
F(2,72)=10.4, p<0.001]. Subjects made more errors overall when judging faces (30 %) 
than houses (19 %) [main effect of attention F(1,72)=103.2, p<0.001]. Participants had 
lower accuracy when the faces carried a fearful or sad emotional expression [main effect 
of emotion F(2,72)=4.2, p=0.017]. Subjects made significantly more errors when the 
negative emotional faces were task-relevant [interaction attention*emotion F(2,72)=7.2, 
p=0.001]. Post-hoc analysis with Bonferroni correction revealed higher error rates for 
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relevant sad [p<0.001] and fearful faces [p=0.031] relative to neutral faces. All other 
comparisons were not significant. There was no significant interaction of attention or 
emotion with group [interaction attention*group F(2,72)=0.3, p=0.8, interaction 
emotion*group F(2,72)=1.3, p=0.3, interaction emotion*attention*group F(4,72)=0.3, 
p=0.9]. 
Analysis of reaction times (RTs) showed a mean RT of 639 ms, that was not significantly 
different between groups [main effect of group F(2,72)=0.8, p=0.4]. Participants were 
significantly slower to make same/different judgments with faces (672 ms) compared to 
houses (606 ms) [main effect of attention F(1,72)=44.2, p<0.001]. In addition, we found 
a significant interaction of group with attention [F(2,72)=4.1, p=0.02]. In the control 
group there was a larger difference in RT when comparing houses (mean 554 ms) than 
faces (mean 659 ms) [p<0.001] than in the other two groups. RTs were significantly 
slower for emotional compared to neutral faces [main effect of emotion F(2,72)=4.3, 
p=0.019]. RT analysis revealed a significant interaction of attention and emotion: all 
subjects showed significantly slower reaction times in displays in which task-relevant 
faces had a fearful (681 ms) or sad (683 ms) compared to neutral (651 ms) expression 
[interaction attention*emotion F(2,72)=6.7, p=0.002]. Post-hoc analysis with Bonferroni 
correction revealed slower reaction times for task-relevant sad [p=0.002] and fearful 
faces [p=0.004] relative to neutral faces. All other comparisons were not significant. 
However, there was no significant interaction of group with emotion [interaction 
emotion*group F(2,72)=0.6, p=0.6; interaction emotion*attention*group F(4,72)=0.6, 
p=0.7].  
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Figure 2. Behavioral results. 
Percentage errors (upper panels) and reaction time in ms (lower panels) in response to 
faces (red bars) and houses (grey bars), displayed separately for each group: control 
(left panels), patients with epilepsy without negative affect (middle) and with comorbid 
negative affect (right). All three groups made more errors and had slower reaction times 
when attended faces carried a fearful or sad emotional expression, relative to a neutral 
expression. 
Electrophysiological results 
VPP/N170. All groups had a large face-sensitive VPP component at central midline 
electrode Cz (Figure 3). The amplitude of the VPP was significantly larger on trials in 
which attention was focused on the face pairs relative to trials during which faces were 
presented outside the attention focus [main effect of attention F(1,72)=13.0, p<0.001]. 
Noteworthy, there was no significant effect of group or interaction group*attention on the 
amplitude of the face-sensitive VPP component, indicating that the processing of the face 
stimuli was normal and preserved in all groups [main effect of group F(2,72)=2.2, p=0.1, 
interaction group*attention F(2,72)=0.8, p=0.4]. The effect of emotion or any interaction 
with this factor did not reach significance [F(2,72)≤1.6, p≥0.2]. 
The N170 is suggested to be the negative counterpart of the positive VPP, because both 
components are temporally coincident and have a high functional sensitivity for faces 
[Rossion et al., 2003]. This is confirmed by our ERP results showing very similar effects 
of attention for the VPP and N170 components. The amplitude of the N170 at the T5 and 
T6 electrodes was significantly larger when faces were attended compared to when 
houses were attended [main effect of attention F(1,72)=5.4, p=0.023 at T5 electrode 
and F(1,72)=22.1, p<0.001 at T6 electrode]. However, not all subjects showed a clear 
N170 component, because there were more artifacts and noise at the lateral T5 and T6 
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electrodes than at the central midline electrode Cz. Therefore, we focus on the VPP 
component in this study. 
 
Figure 3. Stimulus-locked grand average ERP waveforms. 
Grand average ERP waveforms recorded from central midline electrode Cz (upper panels) 
and parietal midline electrode Pz (lower panels) in response to faces (red lines) and 
houses (blue lines), displayed separately for each group: control (left panel), patients 
with epilepsy without negative affect (middle) and with comorbid negative affect (right). 
In the three groups alike, the amplitude of the VPP and LPP components was significantly 
larger for face-cued relative to house-cued trials. 
LPP. The emotion-sensitive LPP component was analyzed at the parietal midline 
electrode Pz from 350 to 600 ms post stimulus (Figure 4). There were no significant 
differences between groups on the mean amplitude of the LPP [main effect of group 
F(2,72)=1.7, p=0.2]. In all subjects the amplitude of the LPP component was enhanced 
for displays in which faces were task-relevant compared to displays in which houses were 
task-relevant [main effect of attention F(1,72)=49.7, p<0.001] (Figure 3). In addition, 
we found a significant three-way interaction of group with attention and emotion 
[F(4,72)=3.0, p=0.021]. For post-hoc analyses we made pairwise comparisons with 
Bonferroni correction between the 3 emotional conditions (fear vs. neutral vs. sad) within 
each attention condition (house vs. face) and within each group. In total 18 comparisons 
were made (3 emotion * 2 attention conditions * 3 groups). These analyses revealed 
that only in patients with negative affect the LPP component was significantly increased 
in response to task-irrelevant sad [p=0.026] and fearful faces [p=0.003] relative to task-
irrelevant neutral faces. All other comparisons were not significant. 
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Figure 4. LPP results. 
Grand average ERP waveforms recorded from parietal midline electrode Pz in responses 
to task-relevant faces (upper panels) and houses (lower panels), displayed separately for 
each group: control (left), patients with epilepsy without negative affect (middle) and 
with comorbid negative affect (right). Note that only in the group of epileptic patients 
with negative affect, when the emotion was task-irrelevant, the amplitude of the LPP was 
significantly larger for sad and fearful expressions compared to neutral faces. 
Correlation between the differences of the LPP amplitudes between unattended emotional 
and neutral faces and BDI and STAI scores were tested using 2-tailed Pearson’s 
correlation coefficients. There were significant positive correlations found between the 
LPP amplitude differences between unattended fearful and neutral faces and the BDI 
(r=0.34, p=0.014) as well as the STAI (r=0.29, p=0.038). No such significant 
correlations were found between the LPP amplitude differences between unattended sad 
and neutral faces and either the BDI (r=0.20, p=0.155) or the STAI (r=0.14, p=0.335). 
The type and location of the lesions in each group turned out to be very heterogeneous 
(Supplementary Table 1). Most common lesions were hippocampal sclerosis, focal cortical 
dysplasia, cysts and cavernomas. Only one patient had a brain tumor, which was located 
in the left posterior hippocampus and suspected to be a low-grade glioma. This patient 
was part of the group of patients with epilepsy without negative affect. In order to 
examine whether damage to the medial temporal lobe has an influence on the emotion 
modulation of the LPP, all patients with epilepsy, regardless of negative affect, were 
subdivided into two groups: one group where the 3T MRI showed clear damage to the 
medial temporal lobe (n=19) and one group without damage to the medial temporal lobe 
(n=31). Noteworthy, repeated-measures ANOVA showed no significant main effect of 
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medial temporal lobe damage on the LPP amplitude [F(1,48)=1.3, p=0.3] and there were 
no significant interactions with other factors. In addition, a separate analysis that 
examined the effect of damage to the frontal lobe showed neither significant main effect 
of frontal lobe damage on LPP amplitude [F(1,48)=0.4, p=0.5] nor significant 
interactions with other factors. These results suggest that damage to the medial 
temporal lobe or frontal lobe did not account for the amplitude modulation of the LPP. 
Another possible confounding factor is that some patients of the group with negative 
affect took antidepressant drugs (ADDs) while none of the participants in the other two 
groups took ADDs. However, there was no significant main effect of ADD dose on the LPP 
[F(1,23)=0.02, p=0.9] and no significant interactions of the ADD dose with the other 
experimental factors [attention*ADD dose F(1,23)=3.1, p=0.1; emotion*ADD dose 
F(2,23)=1.8, p=0.2; attention*emotion*ADD dose F(2,23)=0.4, p=0.7]. Moreover, a 
correlation analysis using a 2-tailed Pearson coefficient failed to show a significant 
association between the ADD dose and the amplitude difference between unattended fear 
faces compared to unattended neutral faces [r=0.10, p=0.62] or unattended sad faces 
compared to unattended neutral faces [r=0.14, p=0.50].  
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DISCUSSION 
This study provides novel neurophysiological findings on the processing of emotional 
stimuli in patients with epilepsy with and without comorbid negative affect, when 
compared to a group of matched healthy controls. At the behavioral level, all subjects 
made more errors and had slower reaction times when attended faces carried a fearful or 
sad emotional expression, relative to a neutral expression. These results suggest that 
negative emotional face expressions, when attended, interfered with the matching task 
requiring the processing of the identity (as opposed to emotional content) of the face 
stimuli. At the electrophysiological level, the face-sensitive VPP had enhanced amplitude 
for attended faces compared to houses, equally so in all three groups and regardless of 
the emotional content of the face stimulus. These ERP results indicate that attention was 
directed to the correct stimulus category independently of the emotional content of the 
face, and that this early structural encoding of faces was normal and preserved in 
patients with epilepsy, regardless of negative affect. By contrast, the amplitude of the 
LPP was significantly enhanced for negative emotional expressions when faces were 
unattended, but only in patients with comorbid negative affect. The modulation of the 
LPP component by unattended emotional stimuli during the late stages of stimulus 
processing suggests that emotion regulation is disturbed in patients with epilepsy and 
comorbid negative affect. 
Our behavioral results show that in all groups the attended negative emotional face 
expressions decreased task performance, which resulted in lower accuracy and slower 
reaction times, compared to attended neutral faces. These findings are in line with 
previous studies that have reported interference effects created by negative emotional 
stimuli [Vuilleumier et al., 2001; Bishop et al., 2004a; Pessoa, 2009]. From an 
evolutionary perspective, priority processing of emotional information facilitates adaptive 
behavior, promoting survival and reproductive success [Lang, 1995; Lang and Bradley, 
2010]. The enhanced processing demands associated with emotional stimuli leave limited 
resource capacities for performance during the task, that requires to match the identity 
of the two attended visual stimuli [Vuilleumier, 2005; Pessoa, 2009; Pourtois et al., 
2013]. Accordingly, these behavioral findings confirm that in all three groups, emotion 
interfered with task performance when it was attended, although not explicitly task-
relevant. 
The results obtained for the VPP/N170 component reveal a clear gating effect, in the 
expected direction, of object-based attention mechanisms. All subjects showed enhanced 
amplitudes of the VPP/N170 components for attended faces (regardless of their 
emotional content) compared to attended houses. Our findings are in agreement with a 
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previous ERP study using the same task in healthy adult participants that reported similar 
increased amplitudes of the N170 in response to attended faces [Holmes et al., 2003]. 
Importantly, in our study, this object-based attention effect was evidenced in all three 
groups alike; suggesting that neither epilepsy alone, nor epilepsy combined with negative 
affect actually impaired the normal and early structural encoding of faces. According to 
previous ERP studies, [Botzel et al., 1995; Jeffreys, 1989; George et al., 1996; Rossion 
et al., 2003], the VPP is the counterpart at the vertex of the occipito-temporal N170 
component and this dipolar activity reflects the earliest markers of a reliable processing 
difference between faces and objects. Therefore, our new ERP findings clearly show that 
this early categorization process is spared in epilepsy with or without negative affect. 
By contrast, at a later time point following stimulus onset than the VPP, we found 
evidence for a modulatory effect of epilepsy with comorbid negative affect on the 
processing of these complex stimuli. We found that in patients with epilepsy and 
comorbid negative affect the amplitude of the LPP was significantly modulated when the 
emotional faces were unattended. It seems contradictory that emotional stimuli 
presented outside the focus of attention have a stronger influence on the LPP than when 
the same stimuli are attended. This is in contrast with many ERP studies that have shown 
that the LPP component has enhanced amplitudes for attended negative emotional 
stimuli compared to neutral stimuli in healthy participants [Schupp et al., 2000; Moser et 
al., 2006; Schupp et al., 2006; Sabatinelli et al., 2007; Foti and Hajcak, 2008; Olofsson 
et al., 2008; Hajcak et al., 2010]. However, these studies had longer picture 
presentation time (≥1 second) and the emotional expression of the face was task 
relevant because participants had to rate pictures for arousal and valence. Therefore, the 
task-relevant emotional content was probably much more strongly processed, reflected 
by increased LPP amplitudes. In our study, the stimuli were presented very briefly (300 
ms) and the emotional expression was not explicitly relevant for the matching task. This 
might explain why in healthy control group and the group of patients without negative 
affect there was no significant modulation of the LPP by the emotional expression of the 
faces. By contrast, the LPP was enhanced in patients with epilepsy and comorbid 
negative affect when the emotional faces were unattended. It is probable that the 
negative affect triggers an automatic emotional processing or vigilance effect (reflected 
by increased amplitude of the LPP) when negative stimuli are distracters. This could point 
to a deficit to inhibit distracting negative emotional information, or conversely, to a 
better sensitivity to process them “covertly” outside the focus of attention. Accordingly, 
our LPP results show that negative emotional distracters have an influence on the late 
stages of stimulus processing in epilepsy patients with negative affect. Hence, the deficit 
in these patients is a deficit during the late stages of emotion control, during which they 
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fail to ignore distracting emotional information, unlike the two other groups where the 
late processing of visual stimuli is not influenced by emotional distracters at unattended 
locations. 
A few limitations have to be pointed out. Firstly, we have not included an additional 
control group of patients with negative affect but without epilepsy. More than 70 % of 
mood disorders in epilepsy are atypical and fail to meet any of the diagnostic criteria of 
the DSM-IV [Blumer et al., 2004; Kanner and Schachter, 2010]. Therefore, a group of 
patients with mood disorders would not fully control for the type of negative affect in 
epilepsy. Patients with major depressive disorder, for example, would have more severe 
depression than the patients included in this study. As expected, epileptic patients with 
negative affect were not only showing higher levels of depressive symptoms (BDI) than 
patients without negative affect, but also higher levels of anxiety (STAI). This 
multicollinearity is not surprising, but instead in line with previous studies that have 
identified comorbid anxiety symptoms in 73 % of patients with epilepsy and depression 
[Jones et al., 2005]. There is a substantial symptom overlap and comorbidity between 
depression and anxiety and both disorders are characterized by high levels of negative 
affect [Clark and Watson, 1991]. Accordingly, future ERP studies are needed in order to 
establish whether depression or rather anxiety lies at the root of the emotion regulation 
disorder observed in our study at the level of the LPP. To the best of our knowledge, until 
now no ERP studies have been published on the face- or house-matching task in patients 
with negative affect. Studies on the VPP and LPP in mood and anxiety disorders during 
other tasks have yielded mixed results, depending on the used paradigm, type of stimuli, 
stimulus presentation time and study population. There is evidence for increased 
processing of negative emotional stimuli soon after stimulus presentation, reflected by 
enhanced early ERPs like the VPP, followed by avoidance of unpleasant stimuli at later 
processing stages, reflected by a reduced LPP for aversive stimuli, both in patients with 
general anxiety disorder [Weinberg and Hajcak, 2011] and patients with major 
depressive disorder [Foti et al., 2010]. In contrast, other studies have reported increased 
LPP for aversive compared to neutral pictures among subjects with high negative affect 
[Dennis and Hajcak, 2009; MacNamara and Hajcak, 2009]. Therefore, it would be very 
interesting in future studies to compare ERP results during the face-or house-matching 
task in different control groups of patients without epilepsy but with other types of 
negative affect disorders, such as major depressive disorder, dysthymic disorder, bipolar 
disorder, general anxiety disorder, in order to evaluate whether this is a general effect 
found across these negative affect disorders, or instead, whether it is specific for 
negative affect in epilepsy. 
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Secondly, the administration of antidepressant drugs (ADDs) in one group selectively but 
not in the two others may have obscured our new ERP findings. However, if ADDs would 
influence the amplitude of the LPP, then we would expect to see a main effect, and not a 
complex three-way interaction effect, as we report here. Moreover, when the ADD dose 
was added as a covariate in the statistical analysis for the LPP, no significant contribution 
of this factor was found. Furthermore, there was no significant correlation between the 
ADD dose on the one hand and the LPP amplitude differences between unattended sad or 
fearful compared to unattended neutral faces on the other hand. Taken together, it 
therefore appears very unlikely that the condition-specific modulation of the LPP might be 
explained by exposure to antidepressant medication. 
Thirdly, we did not use eye tracking during the face- or house-matching task. However, 
participants were asked to maintain central fixation and eye movements were 
discouraged and unlikely with this specific demanding matching task, given the brief 
stimulus duration and task requirements used. This was formally confirmed by previous 
studies with eye tracking during the same task that demonstrated that saccades were 
very rare, with no major differences in eye position associated with the experimental 
factors [Wojciulik et al., 1998; Vuilleumier et al., 2001; Bentley et al., 2003; Vuilleumier 
et al., 2004]. In addition, an ICA was used to correct for horizontal and vertical eye 
movements. 
Fourthly, it is important to consider the type of lesions because specific lesions can cause 
widespread reorganization of neural networks. For example, patients with left sided 
tumors show signs of functional reorganization and employ a much broader bilateral 
network during language processing than healthy controls [Rosler et al., 2014]. However, 
in our study, only one patient had a brain tumor in the group of patients without negative 
affect. The type, size and location of lesions of the patients were very heterogeneous and 
therefore the groups for each lesion were too small in size to compare at the statistical 
level the possible differential effect of each specific type of underlying lesion on negative 
affect and ERP results. Notwithstanding this limitation, we note that it may be possible 
that some of these lesions could have had a greater influence on our ERP results than 
other ones, especially lesions located in regions that are presumably important for 
emotion control processes, like the frontal and medial temporal regions. Therefore, we 
performed additional data analyses and grouped the patients based on the presence of 
either frontal or medial temporal lobe structures lesions, but these analyses failed to 
show any significant effect on the LPP amplitude. Hence, the abnormalities arising during 
the later stages of emotion stimulus processing in patients with epilepsy and comorbid 
negative affect could not be linked to damage in one specific lobe but are more likely the 
result from dysfunction in a broad network for emotion control in which both cortical and 
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subcortical structures interact with each other [Ochsner and Gross, 2005; Price and 
Drevets, 2010]. 
Comorbid negative affect in patients with epilepsy has often been considered to be a 
consequence or complication of the chronic seizure disorder. However, a fascinating 
bidirectional relationship between epilepsy and depression has recently been 
demonstrated [Kanner, 2011; Hesdorffer et al., 2012]: not only are patients with 
epilepsy at greater risk of developing a depressive disorder, but patients with primary 
depressive disorders are at greater risk of developing epilepsy [Hesdorffer et al., 2000; 
Hesdorffer et al., 2012]. This suggests that the pathogenic mechanisms may be strongly 
intertwined and the structural and functional alterations from one disease are likely to 
trigger the other [Kondziella et al., 2007; Kanner et al., 2012]. Identification of these 
common underlying pathogenic mechanisms may shed new light on the neurobiological 
bases of mood disorders and epilepsy. Our findings suggest comorbid negative affect in 
patients with epilepsy may be due to impaired emotion regulation. 
In conclusion, the face-sensitive VPP results indicate that early attention was allocated to 
the correct stimulus category and that early stimulus processing was preserved in all 
patients with epilepsy, regardless of negative affect. Conversely, the LPP results suggest 
that during later stages of stimulus processing the emotion regulation is disturbed, but 
only in patients with epilepsy and comorbid negative affect. These new 
neurophysiological findings shed light on the complex interplay of epilepsy with negative 
affect during the processing of emotional visual stimuli and in turn might help to better 
understand the etiology and maintenance of mood disorders in epilepsy.  
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CHAPTER 3  
Abnormal reappraisal during emotion regulation in 
refractory epilepsy: an ERP study 
Leen De Taeye, Gilles Pourtois, Alfred Meurs, Paul Boon, Kristl Vonck, Evelien Carrette, 
Robrecht Raedt 
 
ABSTRACT 
Patients with refractory epilepsy have a very high comorbidity of negative affect 
disorders. Reappraisal is a cognitive emotion regulation strategy that is successful in 
decreasing negative affect. Cognitive reappraisal involves reinterpreting the meaning of 
emotional situations in a way that alters its emotional impact. The late positive potential 
(LPP) component of the visual event-related potential is larger following the presentation 
of emotional compared to neutral stimuli. The amplitude of the LPP can be reduced by 
cognitive reappraisal of emotional stimuli. Therefore, the LPP is a sensitive 
neurophysiological marker for cognitive emotion regulation. The aim of this study was to 
investigate whether the electrophysiological response to negatively valenced stimuli in 
patients with refractory epilepsy is sensitive to reappraisal.  
Fifty-two patients with refractory epilepsy participated in the study, of whom 25 with 
negative affect (BDI-score >14) and 27 without negative affect (BDI-score ≤14). Event-
related potentials were recorded while subjects viewed negatively valenced and neutral 
pictures that were preceded by either more neutral or more negative descriptions.  
In all patients, the valence-ratings, arousal-ratings and LPP amplitude were significantly 
increased in response to unpleasant compared to neutral pictures. In addition, 
unpleasant pictures following the more neutral description (reappraisal condition) had 
significantly reduced ratings for negative valence and arousal. However, there was no 
significant modulation of the LPP amplitude of unpleasant pictures during the reappraisal 
condition. Deficient reappraisal of the LPP activity in response to unpleasant stimuli was 
independent of negative affect and not linked to localization of the epileptogenic zone in 
frontal or medial temporal lobe.  
This study shows that modulation of LPP amplitude as electrophysiological correlate of 
cognitive emotion regulation is absent in patients with epilepsy. This suggests abnormal 
functioning of the brain during cognitive emotion regulation in patients with epilepsy. 
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INTRODUCTION 
The ability to cognitively regulate our emotional responses to negative emotional events 
is a critical component for good mental health [Ochsner and Gross, 2005]. Disturbance of 
our emotion control capacity may lead to an increased vulnerability to negative affect 
[Mathews et al., 2005; Disner et al., 2011]. Patients with epilepsy have a very high 
comorbidity of negative affect disorders [Kanner and Schachter, 2010]. Negative affect 
occurs in up to 80 % of patients with refractory epilepsy [Miller et al., 2008], with a 
major negative impact on the quality of life [Boylan et al., 2004] and an elevated 
mortality due to suicide [Jones et al., 2003]. Negative affect comorbidity has been 
attributed to several causes, including the psycholocial burden of having a chronic seizure 
disorder, adverse effects of antiepileptic drugs (AEDs), endocrine or metabolic effects of 
seizures, neurotransmitter disturbances and network reorganization associated with 
chronic epilepsy [Miller et al., 2008; Kanner and Schachter, 2010; Hoppe and Elger, 
2011; Kanner, 2011]. These pathological changes can compromise the integrity of a 
functional neuronal network that is implicated in emotion control [Ochsner and Gross, 
2005; Price and Drevets, 2010; Disner et al., 2011]. 
Reappraisal is a commonly used cognitive emotion regulation strategy that is successful 
in decreasing negative affect [McRae et al., 2010]. Cognitive reappraisal involves 
reinterpreting the meaning of emotional situations in a way that alters its emotional 
impact [Ochsner and Gross, 2005; Todd et al., 2012]. Functional neuroimaging studies 
have shown that successful reappraisal depends upon interactions between prefrontal 
cortex that implements cognitive control, and amygdala that mediates the emotional 
responses [Ochsner and Gross, 2005; McRae et al., 2010].  
Event-related potentials (ERPs) have been used to investigate the time course of 
cognitive emotion regulation processes. These studies have focused on the late positive 
potential (LPP) component of ERP that has proven to be a sensitive and effective 
neurophysiological marker for investigating the time course of emotional processing in 
both healthy individuals and patients [Hajcak et al., 2010; Moran et al., 2013]. The LPP 
is a robust visual ERP component known to have an enhanced amplitude for both positive 
and negative arousing emotional stimuli compared to neutral stimuli [Schupp et al., 
2000; Sabatinelli et al., 2007; Hajcak et al., 2010]. Moreover, the magnitude of the LPP 
is sensitive to emotion regulation strategies and can be reduced by reappraisal of the 
emotional significance of stimuli [Hajcak  and Nieuwenhuis, 2006; Moser et al., 2006; 
Foti and Hajcak, 2008; Dennis and Hajcak, 2009; MacNamara and Hajcak, 2009]. Hence, 
the LPP is a usefull tool for studying emotion regulation during a reappraisal task [Foti 
and Hajcak, 2008; Dennis and Hajcak, 2009; Hajcak et al., 2010]. 
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Our previous study in patients with refractory epilepsy [De Taeye et al., 2015] provided 
neurophysiological evidence that early attention processes were not compromised by 
epilepsy. By contrast, patients with epilepsy and comorbid negative affect showed an 
abnormal enhanced LPP in response to unattended negative stimuli, suggesting 
dysfunction during the later stage of emotion regulation [De Taeye et al., 2015]. 
Whether the LPP response in patients with epilepsy and comorbid negative affect can be 
reduced by cognitive reappraisal remains an intriguing question. 
The aim of the present study was quadruple: (i) to confirm that negative emotional 
stimuli induce a stronger LPP response compared to neutral stimuli in patients with 
refractory epilepsy, (ii) to examine whether this emotional LPP response is sensitive to 
reappraisal, a cognitive emotion regulation strategy, (iii) to investigate the hypothesis 
that epilepsy with comorbid negative affect is associated with insufficient reappraisal, and 
(iv) to determine whether efficacy of reappraisal is affected by localization of the 
epileptogenic zone or brain lesions in crucial regions within the network for emotion 
control such as the medial temporal lobe and the frontal lobe.  
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METHODS 
1 Ethics statement 
The study was approved by the ethics committee of Ghent University Hospital and 
conducted in accordance with the declaration of Helsinki. After a full description of the 
procedure was provided and explained, all patients gave written informed consent prior 
to participation. 
2 Participants 
A total of 52 patients with refractory epilepsy were included (M/F: 24/28, mean age 36.3 
years). The study took place during presurgical video-EEG monitoring at the Reference 
Center for Refractory Epilepsy (Ghent University Hospital, Belgium). Patients were 
included in the study when they met following inclusion criteria: (i) confirmed epilepsy 
based on continuous video-EEG monitoring, (ii) age 18-65, (iii) no arguments for mental 
retardation. The main clinical patient characteristics are summarized in Table 1. 
Presence of negative affect was assessed using the validated Dutch version of the Beck 
Depression Inventory II (BDI-II) [Beck et al., 1996; Van der Does, 2002]. The BDI-II is a 
21-item self-report questionnaire that assesses the severity of depressive 
symptomatology, including affective, cognitive, behavioral, somatic and motivational 
symptoms of depression. Higher scores on the BDI reflect more negative affect with 
scores ranging from 0 to 63. Using the criteria proposed by Beck et al. (0-13 minimal, 
14-19 mild, 20-28 moderate, 29-63 severe depressive symptoms) [Beck et al., 1996], a 
cut-off score of >14 was used to subdivide the patients in two groups: 25 patients with 
negative affect (mean BDI: 26.1 ± 10.9) and 27 patients without negative affect (mean 
BDI: 7.4 ± 4.4). In addition, state and trait anxiety levels of all participants were 
measured, following standard practice, using a validated Dutch version of the State-Trait 
Anxiety Inventory (STAI) [Spielberger et al., 1983; Van der Ploeg et al., 2000].  
Ten healthy volunteers (M/F: 3/7, mean age 26.5 years) were recruited to validate our 
Dutch version of the reappraisal paradigm [Foti and Hajcak, 2008].  
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Table 1. Clinical characteristics of patients 
 Patients with  
negative affect 
Patients without 
negative affect 
Statistics 
 (n=25) (n=27)  
BDI 26.1 (±10.9) 7.4 (±4.4) p<0.001 
Age (years) 38.6 (±10.9) 34.1 (±12.5) p=0.174 
Sex (M/F) 9/16 15/12 p=0.177 
Education (years) 12.4 (±2.0) 13.3 (±2.0) p=0.127 
HEZ: side   p=0.712 
Right 13 17  
Left 10 8  
Bilateral 2 2  
HEZ: lobe    p=0.343 
Frontal 7 6  
Temporal 11 18  
Fronto-temporal 1 0  
Parietal/Occipital 4 1  
General 2 2  
3T MRI    p=0.687 
Normal 7 6  
Abnormalities 18 20  
• Frontal 5 4  
 Temporal 10 13  
o Medial temporal 9 8  
• Parietal/Occipital 5 8  
Epilepsy duration (years) 17.9 (±11.8) 17.2 (±13.3) p=0.852 
Seizure frequency (/month) 7.8 (±9.4) 11.2 (±15.4) p=0.350 
Number of AEDs (/day) 2.6 (±1.1) 2.6 (±1.2) p=0.925 
AEDs total dose (mg/day) 2612.2 (±1604.1) 2605.4 (±1383.5) p=0.987 
ADDs total dose (mg/day) 36.5 (±149.24) 0  
STAI State 50.2 (±10.1) 39.3 (±10.7) p<0.001 
STAI Trait 53.0 (±8.4) 39.9 (±9.7) p<0.001 
Values represent means (± 1 standard deviation) or numbers. BDI Beck Depression 
Inventory, M male, F female, HEZ hypothesized epileptogenic zone; 3T MRI 3 tesla 
magnetic resonance imaging, AEDs antiepileptic drugs; ADDs antidepressant drugs, STAI 
state-trait anxiety inventory 
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3  Stimuli 
The stimuli consisted of 75 color photographs taken from the International Affective 
Picture System (IAPS) [Lang et al., 2008]: 25 neutral pictures (mean normative 
valence=5.05 ± 1.21; mean normative arousal=2.91 ± 1.93) and 50 negative pictures 
(mean normative valence=2.82 ± 1.64; mean normative arousal=5.71 ± 2.16). Each 
neutral picture was preceded by a corresponding neutral description and each negative 
picture was preceded by either a negative description that highlighted the negative 
aspects of the upcoming image, or a more neutral description that described the image in 
more neutral terms. The paradigm was adapted from a previous study conducted in 
healthy participants [Foti and Hajcak, 2008]. Exactly the same pictures were used and 
the corresponding descriptions were translated to Dutch. A complete list of the used IAPS 
picture numbers and corresponding neutral and negative descriptions can be found in 
[Foti and Hajcak, 2008]. 
4 Procedure 
Each trial started with a white fixation cross presented on a black screen for 6 s during 
which participants heard a short (3–5 s) description through headphones. Following the 
description, the unpleasant or neutral IAPS picture was presented against a homogenous 
dark background for 3 s. After the offset of each picture, participants rated the picture on 
the dimensions of valence and arousal. After a delay that varied randomly between 1 and 
2 s, the next trial began (Figure 1).  
 
Figure 1. Sequence of events in the reappraisal task.  
Prior to each picture, a white fixation cross was presented on a black screen for 6 s. 
During this period, a brief (3–5 s) description of the upcoming picture was played 
through headphones. The description was neutral for neutral pictures. For negative 
pictures, this description could either be negative or neutral (reappraisal condition). 
Following the description, the negatively valenced or neutral IAPS picture was presented 
for 3 s. After the picture the patients had to give separate ratings for valence and arousal 
on two visual analog scales. The inter-trial interval varied randomly between 1 to 2 s. 
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Participants were told that they would be viewing emotional pictures and that they would 
hear a short description before each picture about the content of the upcoming picture. 
After presentation of each picture, subjects were instructed to rate the picture for 
valence and arousal on two separate scales, i.e., the Self Assessment Manikin (SAM) 
arousal and valence scales [Bradley and Lang, 1994]. The SAM valence scale shows five 
cartoon figures ranging from unhappy to happy; below this scale were the numbers ‘‘1’’ 
through ‘‘9’’. Participants were told to use this scale to indicate how unpleasant or 
pleasant they felt about the preceding picture. The SAM arousal scale shows five cartoon 
figures with expressions ranging from calm and relaxed to excited and wide-eyed; again, 
the numbers ‘‘1’’ through ‘‘9’’ were presented below this scale, and participants were told 
to rate the picture, but this time based on the strength of their emotional activation by 
the picture. On both the valence and arousal dimension, a score of 5 represented the 
midpoint between the two extreme ratings. Valence and arousal ratings were reverse-
scored so that a score of 9 represented pleasant valence and high arousal.  
All participants completed one practice block with three trials to ensure that the sequence 
of events was clear (Figure 1), and that they understood the rating scales. After the 
practice block, each participant performed 75 trials subdivided in 5 blocks of 15 trials 
with short (self-paced) breaks in between. In each block, the three conditions were 
randomized, resulting in a total of 25 neutral trials, 25 negative trials with a preceding 
negative description and 25 negative trials with a preceding more neutral description 
(reappraisal condition). Each picture was presented only once and the order of trials and 
the description that preceded each negative picture were chosen randomly for each 
subject [Foti and Hajcak, 2008]. Stimulus presentation and response recording were 
controlled using E-Prime software 2.0 (Psychology Software Tools Inc., Pittsburgh, USA) 
on a Dell laptop computer. 
5 EEG recording  
The electroencephalogram (EEG) was recorded with Micromed System Plus (Micromed, 
Mogliano Veneto, Italy) using gold electrodes placed at 27 standard locations from the 
extended international 10–20 system (Fp1, Fpz, Fp2, F7, F3, Fz, F4, F8, T3, C3 ,Cz, C4, 
T4, T5, P3, Pz, P4, T6, O1, Oz, O2, T9, TP9, FT9, T10, TP10 and FT10). The online 
reference electrode was placed on the right mastoid and ground electrode on the left 
mastoid. The electrocardiogram (ECG) was recorded with two ECG electrodes placed 
above the heart. The EEG and ECG signals were filtered using an anti-aliasing filter of 
250 Hz and digitized at a sampling frequency of 1024 Hz, gain of 50 dB and 16 bits 
resolution. Electrode impedance was maintained below 10 kΩ.  
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6 ERP analysis 
ERPs of interest were computed offline following a standard sequence of data 
transformations [Picton et al., 2000]. All offline ERP analyses were performed using 
BrainVision Analyzer 2 software (Brain Products GmbH, Gilching, Germany). The EEG was 
corrected for vertical and horizontal eye movements, blinks and ECG artifacts with an 
independent component analysis (ICA). The raw EEG was first decomposed into ICA 
components using the restricted infomax algorithm. Then the three components related 
to eye-movements, blinks and ECG artifacts were selected by visual inspection, relying 
on both the time course and the spatial maps of the components herewith generated. 
These artifact components were removed and the remaining ICA components were 
projected back using an inverse ICA to reconstruct the artifact-free EEG. The EEG signal 
was then re-referenced to the average of all 27 recorded channels. The continuous EEG 
was first digitally filtered with a 50 Hz notch filter and a half-power band-pass filter 
between 0.1–30 Hz with a roll-off of 12 dB/octave. The EEG was segmented into epochs 
from −200 ms to +1000 ms relative to the onset of the stimuli. Baseline correction was 
performed on the 200 ms pre-stimulus interval and epochs with voltage exceeding ±75 
µV were excluded from averaging. The average fraction of rejected epochs was balanced 
across conditions and groups: 23.7 % in the group of patients with negative affect and 
23.6 % in the group of patients without negative affect (unpaired t-test t(50)=0.2, 
p=0.9); and 23.5 % in the neutral condition, 23.7 % in the negative condition and 23.8 
% in the reappraisal condition (one-way ANOVA F=0.3, p=0.8). Artifact free epochs were 
averaged separately for each condition and each individual. The grand average ERPs 
were generated by computing mean ERPs across subjects, for each condition separately. 
The LPP amplitude was measured as the average potential of the 300 to 1000 ms interval 
post-stimulus onset at the parietal midline electrode Pz [Schupp, 2000; Moser, 2006; 
Foti, 2008; Dennis, 2009]. 
Repeated measures analysis of variance (ANOVA) was used with a 2-tailed alpha level of 
0.05 for all statistical tests. When assumptions of sphericity were violated (Mauchly’s 
sphericity test, p<0.05), Greenhouse-Geisser epsilon correction was applied. The 
analyses of the valence and arousal ratings and LPP measures included the between-
subjects factor group (with negative affect vs. without negative affect) and the within-
subjects factor condition (neutral vs. negative vs. reappraisal). Post-hoc tests of simple 
effects were adjusted with the Bonferroni correction for multiple comparisons. 
Correlations of the LPP emotion effect (LPP amplitude difference between neutral pictures 
and unpleasant pictures with preceding negative description) and LPP reappraisal effect 
(LPP amplitude difference between unpleasant pictures with preceding negative and 
neutral description) with BDI and STAI were tested using 2-tailed Pearson’s correlation 
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test. To examine the influence of hypothesized epileptogenic zone (HEZ) lobe and side, 
and damage to the medial temporal lobe and frontal lobe, separate ANOVA’s were 
performed with these factors entered as covariates.   
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RESULTS 
1 Clinical data 
Differences in clinical parameters between epilepsy patients with negative affect and 
without negative affect were assessed with unpaired t-test for continuous variables and 
Pearson chi-square test for categorical variables (Table 1). There were no significant 
differences in age [t(50)=1.38, p=0.174], sex [Χ2=2.00, p=0.177], years of education 
[t(50)=1.55, p=0.127], side of the hypothesized epileptogenic zone (HEZ) [Χ2=0.68, 
p=0.712], lobe of the HEZ [Χ2=4.50, p=0.343], 3T MRI abnormalities [Χ2=0.17, 
p=0.687], damage to medial temporal lobe [Χ2=0.24, p=0.63], epilepsy duration 
[t(50)=0.19, p=0.852], seizure frequency [t(50)=0.94, p=0.350], number of AEDs 
[t(50)=0.09, p=0.925] and AEDs dose [t(50)=0.02, p=0.987]. As expected, the mean 
BDI score was significantly higher in the group with negative affect (26.1 ± 10.9) 
compared to the group without negative affect (7.4 ± 4.4) [t(50)=8.25, p<0.001]. The 
STAI-S and STAI-T scores were also significantly higher in the group with than without 
negative affect [STAI-S: t(50)=3.79, p<0.001, STAI-T: t(50)=5.18, p<0.001]. 
Correlation analysis using a 2-tailed Pearson coefficient showed significant positive 
correlations of the BDI scores with the STAI-S (r=0.56, p<0.001) and the STAI-T 
(r=0.72, p<0.001) scores.  
2 Behavioral results 
Mean rating scores for valence and arousal are summarized in Figure 2. Unpleasant 
pictures were rated as more negative and more arousing compared to neutral pictures. 
In addition, the description that preceded the unpleasant picture significantly influenced 
both valence and arousal ratings: during the reappraisal condition, the neutral 
descriptions increased valence (towards the pleasant extreme) and decreased arousal 
ratings compared to the negative descriptions. Condition (neutral vs. negative vs. 
reappraisal) had a significant effect on both valence [main effect of condition 
F(2,49)=179.59, p<0.001] and arousal [main effect of condition F(2,49)=120.63, 
p<0.001]. Post-hoc comparisons with Bonferroni correction revealed that relative to 
neutral pictures (5.62 ± 0.87) patients gave more negative valence-ratings for 
unpleasant pictures following both negative (2.58 ± 0.86) [p<0.001] and neutral 
descriptions (4.22 ± 0.95) [p<0.001]. In addition, unpleasant images that followed 
negative descriptions were rated as less pleasant than unpleasant images that followed 
neutral descriptions [p<0.001]. Post-hoc comparisons with Bonferroni correction of 
arousal ratings revealed that unpleasant images following both negative (6.48 ± 1.69) 
and neutral (5.40 ± 1.58) descriptions were rated as more emotionally arousing than 
neutral pictures (2.84 ± 1.76) [both comparisons p<0.001]. Unpleasant pictures 
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following negative descriptions were rated as more arousing compared to unpleasant 
pictures that followed neutral descriptions [p<0.001]. There was no group (patients with 
negative affect vs. patients without negative affect) difference for valence [main effect of 
group F(1,50)=0.08, p=0.778]. Arousal ratings were significantly higher in patients with 
comorbid negative affect (5.36 ± 2.23) compared to patients without negative affect 
(4.49 ± 2.22) [main effect of group F(1,50)=5.91, p=0.019]. However, there was no 
significant interaction of condition with group for valence or arousal ratings [interaction 
group*condition F(2,49)=2.98, p=0.063 and F(2,49)=0.12, p=0.939, respectively].  
 
Figure 2. Behavioral results.  
Valence and arousal ratings on the SAM-rating scales, displayed separately for each 
group: patients with epilepsy without negative affect (left panel) and with comorbid 
negative affect (right panel). Higher scores reflect more positive and higher arousal 
ratings. Both groups rated unpleasant pictures as more negative and higher arousing 
compared to neutral pictures. In addition, the description that preceded the unpleasant 
picture also significantly influenced both valence and arousal ratings: during the 
reappraisal condition the neutral descriptions increased valence and decreased arousal 
ratings compared to the negative descriptions. 
 
3 Electrophysiological results 
A pilot study was performed in 10 healthy participants to validate the paradigm [Foti and 
Hajcak, 2008] translated to Dutch with our EEG-recording set-up. The LPP component 
was analyzed at the parietal midline electrode Pz from 300 to 1000 ms post stimulus 
(Figure 3). There was a significant effect of condition on the LPP amplitude [main effect 
of condition F(2,8)=3.64, p=0.047], with larger amplitudes for unpleasant pictures 
compared to neutral pictures [p=0.029]. In addition, the description that preceded the 
unpleasant picture also modulated the LPP amplitude: during the reappraisal condition 
the neutral descriptions induced trend significant smaller LPP amplitudes compared to 
negative descriptions [p=0.078].  
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Figure 3. LPP results of pilot study performed in 10 healthy participants.  
Grand average ERP waveforms recorded from parietal midline electrode Pz in responses 
to neutral pictures (black line), unpleasant pictures with preceding negative descriptions 
(red line) and unpleasant pictures with preceding neutral descriptions, i.e., reappraisal 
condition (blue line). Note that the amplitude of the LPP was significantly larger for 
unpleasant pictures compared to neutral pictures. In addition, the description that 
preceded the unpleasant picture also modulated the LPP amplitude: during the 
reappraisal condition the neutral descriptions induced smaller LPP amplitudes compared 
to negative descriptions. 
After validation of the reappraisal paradigm, the LPP was measured in 52 patients with 
refractory epilepsy, of whom 25 with negative affect and 27 without negative affect 
(Figure 4). There were no significant differences between groups on the mean amplitude 
of the LPP [main effect of group F(1,50)=0.75, p=0.389]. In all patients, the amplitude 
of the LPP component was enhanced for negative stimuli/scenes with preceding negative 
or neutral descriptions compared to neutral ones [main effect of condition 
F(2,49)=30.06, p<0.001]. There was no interaction of group with condition [interaction 
group*condition F(2,49)=0.08, p=0.922]. For post-hoc analyses, we made pairwise 
comparisons with Bonferroni correction between the three conditions (neutral vs. 
negative vs. reappraisal) within each group. In total six comparisons were made (3 
conditions * 2 groups). These analyses revealed that in all patients, neutral pictures 
induced smaller LPP amplitudes compared to unpleasant pictures with a preceding more 
negative description [p<0.001 in both groups] and unpleasant pictures with a preceding 
more neutral description [p=0.002 in the group with negative affect; p<0.001 in the 
group without negative affect]. However, in both groups, the amplitude of the LPP did not 
significantly differ between unpleasant pictures described neutrally and negatively 
[p=1.000, in both groups]. A possible confounding factor is that some patients of the 
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group with negative affect took antidepressant drugs (ADDs) while none of the patients 
in the group without negative affect took ADDs. However, there was no significant effect 
of ADD dose on the LPP [F(1,23)=1.41, p=0.248]. 
 
Figure 4. LPP results of patients with epilepsy.  
Grand average ERP waveforms recorded from parietal midline electrode Pz in responses 
to neutral pictures (black line), unpleasant pictures with preceding negative descriptions 
(red line) and unpleasant pictures with preceding neutral descriptions, i.e., reappraisal 
condition (blue line), displayed separately for each group: patients with epilepsy without 
negative affect (left) and with comorbid negative affect (right). Note that the amplitude 
of the LPP was significantly larger for unpleasant pictures compared to neutral pictures. 
However, the amplitude of the LPP did not significantly differ between unpleasant 
pictures described neutrally and negatively. 
Correlation of the LPP emotion effect (LPP amplitude difference between neutral pictures 
and unpleasant pictures with preceding negative description) and LPP reappraisal effect 
(LPP amplitude difference between unpleasant pictures with preceding negative and 
neutral description) with BDI and STAI scores were tested using 2-tailed Pearson’s 
correlation coefficients. No significant correlations were found between the LPP emotion 
effect with either the BDI (r=0.15, p=0.302,) the STAI-S (r=0.11, p=0.430) and the 
STAI-T (r=0.15, p=0.278). In addition, no significant correlations were found between 
the LPP reappraisal effect with either the BDI (r=0.16, p=0.246,) the STAI-S (r=0.22, 
p=0.111) or the STAI-T (r=0.02, p=0.881).  
To evaluate whether modulation of LPP was influenced by the localization of the HEZ, 
repeated-measures ANOVAs with HEZ side (left vs. right vs. bilateral) and HEZ lobe 
(frontal vs. temporal vs. frontotemporal vs. parietal/occipital vs. general) as between-
subject factors were performed. There were no significant main effects of HEZ lobe 
[F(4,47)=0.22, p=0.927] and HEZ side [F(2,49)=0.04, p=0.962] on the LPP and there 
were no significant interactions of both factors with condition. To reduce the number of 
comparisons, a separate ANOVA compared only the patients with HEZ in the frontal lobe 
(n=13) with patients with HEZ in the temporal lobe (n=29), but again this analysis 
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showed no significant effect of HEZ in frontal or temporal lobe [F(1,40)=0.64, p=0.427], 
nor significant interaction with condition [F(2,39)=1.42, p=0.247]. These results suggest 
that localization of the HEZ in a specific lobe or side could not explain the modulation of 
the LPP.  
In order to examine whether structural damage to the medial temporal lobe has an 
influence on the emotion modulation of the LPP, all patients with epilepsy, regardless of 
negative affect, were subdivided into two groups: one group where the 3T MRI showed 
damage to the medial temporal lobe (n=17) and one group without damage to the 
medial temporal lobe (n=35). Repeated-measures ANOVA showed no significant main 
effect of medial temporal lobe damage on the LPP amplitude [F(1,50)=1.92, p=0.173] 
and there was no significant interaction with condition [F(2,49)=0.71, p=0.496]. In 
addition, a separate analysis that examined the effect of damage to the frontal lobe 
showed neither significant main effect of frontal lobe damage on LPP amplitude 
[F(1,50)=1.34, p=0.252] nor significant interaction with condition [F(2,49)=0.31, 
p=0.737]. These results suggest that damage to the medial temporal lobe or frontal lobe 
did not account for the modulation of the LPP.   
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DISCUSSION 
In the present study, emotional (self-reports) and reappraisal effects during a cognitive 
emotion regulation task were examined in patients with refractory epilepsy. The main 
findings are that: (i) negative emotional stimuli induce a stronger LPP response than 
neutral stimuli, (ii) this emotional LPP response is not modulated by reappraisal, a 
cognitive emotion regulation strategy, (iii) deficient reappraisal of the LPP does not 
correlate with comorbid negative affect, and (iv) there is no relation between the efficacy 
of reappraisal and location of the epileptogenic zone or brain lesions in medial temporal 
and frontal lobe. Taken together, our results provide novel electrophysiological evidence 
for deficient reappraisal of unpleasant pictures in patients with refractory epilepsy at the 
level of the LPP component.  
Reappraisal tasks often test the capacity to generate a personal alternative interpretation 
of emotional stimuli in a less negative way in order to reduce their emotional impact. The 
advantage of these tasks is that the cognitive reinterpretation is individualized and the 
alternate context is optimal for each subject. The downside is that it remains unclear 
whether reduction in LPP amplitude associated with reappraisal reflects reduced 
emotional response or increased cognitive demands [Foti and Hajcak, 2008]. By 
reframing the pictures in a more neutral or negative context with a description preceding 
their presentation, as is done in the reappraisal paradigm used in this study, the 
cognitive demands during processing of the picture are balanced across conditions. 
Moreover, this reappraisal paradigm is particularly effective because it changes the 
emotional meaning of a picture ‘proactively’, that is prior to the emotional response being 
elicited [Foti and Hajcak, 2008; MacNamara and Hajcak, 2009; Dennis and Hajcak, 
2009]. 
The valence and arousal ratings are consistent with previous studies using the same 
paradigm in healthy controls [Foti and Hajcak, 2008], with unpleasant IAPS pictures 
rated as more negative and higher arousing compared to neutral IAPS pictures. In 
addition, the description that preceded the unpleasant picture also significantly influenced 
both valence and arousal ratings: during the reappraisal condition, the neutral 
descriptions increased valence and decreased arousal ratings compared to the negative 
descriptions [Foti and Hajcak, 2008]. In our population of patients with refractory 
epilepsy reappraisal did not modulate the amplitude of the LPP while it did influence 
subjective ratings. This dissociation is not odd as similar evidence was found in patients 
with bipolar disorder [Kanske et al., 2015], which suggests that neurophysiological 
correlates of reappraisal (such as the LPP) may capture alterations that are not visible in 
self-reports.  
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Negative emotional stimuli induced a stronger LPP response relative to neutral stimuli, 
across all patients with refractory epilepsy. The observed enhanced LPP amplitude in 
response to emotional arousing pictures is similar to the LPP findings obtained in healthy 
subjects [Schupp et al., 2000; Moser et al., 2006; Hajcak and Nieuwenhuis, 2006; 
Sabatinelli et al., 2007; Foti and Hajcak, 2008; MacNamara and Hajcak, 2009; Moran et 
al., 2013]. The significant LPP enhancement by unpleasant pictures indicates that the 
observed reappraisal deficiency was not caused by a reduced processing of emotional 
arousing stimuli. The emotional pictures modulate the LPP in a normal way but this 
response seems insensitive to the emotion regulation strategy. 
Our previous study [De Taeye et al., 2015] provided electrophysiological evidence that 
early attention processes were not compromised by epilepsy. By contrast, the amplitude 
of the LPP was significantly enhanced for unattended negative pictures, but only in 
patients with comorbid negative affect. The modulation of the LPP component by 
unattended emotional stimuli during the late stages of stimulus processing suggested 
that emotion regulation is disturbed in patients with epilepsy and comorbid negative 
affect [De Taeye et al., 2015]. However, in the present study, we were unable to find a 
relation between reappraisal of the electrocortical response and negative affect. BDI and 
STAI scores are subjective, self-reported ratings for depressive and anxiety symptoms, 
respectively. Subdividing patients with refractory epilepsy in two groups based on these 
simple measures is likely an oversimplification, because refractory epilepsy is a complex, 
heterogeneous and variable neurological condition and various potential confounding 
factors need to be taken into account, such as type of epilepsy, type and frequency of 
seizures, age of onset and duration of epilepsy, brain lesions, side and localization of the 
HEZ and antiepileptic drugs. Our approach was to compare patients with epilepsy with 
and without negative affect while controlling as much as possible for potential 
confounding factors stemming from the heterogeneous clinical parameters and the AEDs.  
It is important to consider the localization of epileptogenic zone and brain lesions 
because it is possible that some of these lesions could have influenced our ERP results, 
especially lesions located in regions that are presumably important for emotion control 
processes, like the frontal and medial temporal regions. Neuroimaging studies found that 
reappraisal of unpleasant stimuli was associated with increased activation of the 
prefrontal cortex and decreased activation of the amygdala [Ochsner and Gross, 2005; 
McRae et al., 2010]. Therefore, we performed additional data analyses and grouped the 
patients based on location of the HEZ and the presence of either frontal or medial 
temporal lobe structures lesions, but these analyses failed to show any significant effect 
on the LPP amplitude. Hence, the deficient reappraisal in patients with refractory epilepsy 
could not be easily linked to damage in one specific lobe but is more likely the result from 
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dysfunction in a broad network underlying emotion control in which both cortical and 
subcortical structures presumably interact with each other [Ochsner and Gross, 2005; 
Price and Drevets, 2010]. Recurrent seizures in refractory epilepsy can cause widespread 
reorganization of overlapping neuronal networks [Spencer, 2002; Richardson, 2010]. 
Emerging neuropsychological and neuroimaging evidence indicates that temporal lobe 
epilepsy is associated with frontal lobe dysfunction, in which both executive function and 
working memory are compromised [Bell et al., 2011; Stretton and Thompson, 2012]. It 
has been speculated that surround inhibition in the frontal lobe is a dynamic defense 
mechanism against seizure propagation and could be responsible for functional deficits 
observed in temporal lobe epilepsy [Nelissen et al., 2006]. Resection of the epileptogenic 
zone often results in a gain in frontal lobe functions, with cognitive improvement and 
normalization of the neuroimaging abnormalities [Stretton and Thompson, 2012]. These 
findings highlight the importance of looking at broader network function instead of 
specific lesions or lobes when examining psychophysiological measures of emotional 
regulation in epilepsy.  
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CHAPTER 4  
Systematic gating of attention but versatile influence of 
emotion in the human amygdala revealed by intracranial 
event-related potential recordings in patients with 
refractory epilepsy 
Leen De Taeye, Gilles Pourtois, Alfred Meurs, Dirk Van Roost, Rik Achten, Paul Boon, 
Kristl Vonck, Evelien Carrette, Robrecht Raedt  
Aim: Whether unattended negative emotional stimuli activate the amygdala or not 
remains a matter of controversy in the literature. This study investigated whether the 
sensory processing of negative emotional visual stimuli can be evidenced in the 
amygdala when these stimuli are shown either inside or outside the focus of attention, 
using a time-resolved neurophysiological technique with enhanced spatial resolution.  
Methods: Ten patients with refractory epilepsy, implanted with depth electrodes in 
mesial temporal lobe regions for presurgical evaluation, were included in this study. Local 
field potentials were unilaterally or bilaterally recorded in the amygdala while the patients 
performed a face- or house-matching task in which fearful, sad or neutral faces were 
presented either at attended or unattended spatial locations. This paradigm enables to 
tease apart effects of attention versus emotion on stimulus processing in the amygdala. 
Results: Event-related potentials (ERPs) in the amygdala showed a very reproducible 
wave morphology. Attending houses led to significantly higher negative amplitudes (300-
600 ms post stimulus onset) compared to attending faces across the entire sample. 
However, at the group level, amygdala ERPs were not systematically modulated by either 
emotional valence (fear and sad vs. neutral) or arousal (fear vs. sad and neutral) of the 
face stimuli. Analysis of single trial amygdala ERPs from individual subjects did show 
significant effects of arousal or valence in six out of ten patients, occurring at different 
latencies from 110 to 920 ms following stimulus onset. 
Conclusions: This study provides direct evidence for asymmetric effects of attention and 
emotion in the human amygdala during visual face stimulus processing. While object-
based attention exerts a systematic effect on amygdala ERPs at group-level, only a 
subset of the patients shows amplitude modulations of amygdala ERPs by emotion at 
variable delays after stimulus presentation. These results suggest that attention and 
emotion can differentially influence sensory processing in the amygdala, likely via 
different pathways, with stable gating by attention but versatile modulation by emotion.  
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INTRODUCTION 
Emotional facial expressions form an essential part of social communication and are 
processed by a broad neuronal network in which the amygdala plays a central role [Davis 
and Whalen, 2001; Adolphs, 2002]. Functional imaging studies have shown that the 
amygdala responds preferentially to both positive and negative emotionally valenced 
faces [Breiter et al., 1996]. Moreover, converging evidence indicates that the amygdala 
is not only responsible for recognition of emotional expressions but has a much broader 
role in visual processing and serves to coordinate the function of cortical networks to 
allocate processing resources to (salient) stimuli that have biological significance [Pessoa 
and Adolphs, 2010]. This explains why the amygdala is activated not only during 
processing of emotional stimuli, but also shows robust selectivity for faces in the absence 
of emotional expressions [Mende-Siedlecki et al., 2013], and is implicated in stimulus 
evaluation during attention tasks where no emotional stimuli are involved [Halgren et al., 
1995; Pourtois et al., 2010a; Davis and Whalen, 2001].  
How emotion and attention interact in the amygdala remains a matter of intense debate 
in the literature. Although some studies have found evidence that unattended emotional 
facial expressions “automatically” activate the amygdala [Vuilleumier et al., 2001; 
Vuilleumier et al., 2004; Pourtois et al., 2010b], other studies indicate that the activity in 
the amygdala can be regulated by top-down attention control and specific task demands 
[Pessoa et al., 2002; Krolak-Salmon et al., 2004]. We hypothesized that attention and 
emotional factors operate independently and in parallel on the sensory processing in the 
amygdala in order to increase the saliency and selection of behaviorally relevant 
information. 
To address this question, we used a variant of the face- or house-matching task 
[Wojciulik et al., 1998], a standard task for measurement of attention and emotion 
effects [Vuilleumier et al., 2001; Holmes et al., 2003; Bentley et al., 2003; Vuilleumier et 
al., 2004; Bishop et al., 2004a; Bishop et al., 2004b; Fales et al., 2008; Pourtois et al., 
2010b; De Taeye et al., 2015]. In this procedure, participants are shown a display with 
two houses and two faces presented in vertical and horizontal pairs. They have to attend 
only one pair and have to make a demanding same/different judgment on the attended 
pair of stimuli. The faces have either a neutral or emotional expression and are 
positioned either in attended or unattended spatial locations. This paradigm provides an 
ideal situation in which both attention and emotion can be manipulated independently 
[Vuilleumier et al., 2001]. Previous fMRI studies of the face- or house-matching task in 
healthy subjects reported that emotionally negative stimuli (fearful faces) induced a 
strong activation of the amygdala, even when the faces were unattended [Vuilleumier et 
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al., 2001]. Moreover, emotional visual stimuli also induced stronger activation in remote 
but interconnected visual areas such as the fusiform face area and occipital cortex 
[Vuilleumier et al., 2001; Vuilleumier et al., 2004]. Subsequent fMRI studies 
demonstrated that amygdala lesions abolished this enhanced neural response to 
emotional fearful faces in the distant visual areas, indicating that these visual areas are 
modulated by the amygdala [Vuilleumier et al., 2004].  
The small size and its location deep inside the brain, in combination with a relatively 
closed field electrical configuration, make that local field potentials from the amygdala 
cannot be measured with scalp electrodes [Hudry et al., 2001]. Therefore, patients with 
refractory epilepsy implanted with intracranial depth electrodes in the amygdala for 
diagnostic purposes offer a unique opportunity to directly record neural activity within the 
amygdala with a very high temporal resolution (ms). Intracranial event-related potentials 
(iERPs) in the amygdala of patients with refractory epilepsy were reproducibly recorded 
during varying tasks with different types of emotional and non-emotional stimuli (for a 
recent review see [Murray et al., 2014]).  
In the present study, local field potentials were recorded in the amygdala of ten patients 
with refractory epilepsy implanted with depth electrodes in mesial temporal lobe regions 
for presurgical evaluation. This study investigated whether sensory processing of both 
attended and unattended emotional visual stimuli can be inferred from local field 
potentials recorded in amygdala and whether amygdala iERPs are modulated by 
attentional control and emotional factors. Previous fMRI and iERP studies of the face- or 
house-matching task [Vuilleumier et al., 2001; Vuilleumier et al., 2004; Pourtois et al., 
2010b] only examined the effect of high arousing negative stimuli (fearful faces), while 
our study also included faces with sad emotional expressions in order to disentangle the 
effects of emotional valence versus arousal on the sensory processing in the amygdala. 
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METHODS 
1 Ethics statement 
The study was approved by the ethics committee of Ghent University Hospital and 
conducted in accordance with the declaration of Helsinki. After a full description of the 
procedure was provided and explained, all participants gave written informed consent 
prior to participation. 
2 Participants 
Local field potentials were recorded in ten patients with refractory partial epilepsy (M/F: 
5/5, mean age 38.7 years). The study took place during presurgical invasive video-EEG 
monitoring in the Reference Center for Refractory Epilepsy (Ghent University Hospital, 
Belgium). Patients were implanted with intracranial depth electrodes in mesial temporal 
lobe regions for diagnostic purposes in order to delineate the epileptogenic zone for 
potential surgical resection. Presence of negative affect (as a predisposition) was 
assessed by using the validated Dutch version of the Beck Depression Inventory II (BDI-
II) [Beck et al., 1996; Van der Does, 2002]. Patients’ main characteristics are 
summarized in Table 1. 
 
 Table 1. Patients’ characteristics and anatomical coordinates of the electrode contacts in the amygdala 
ID Age Sex BDI HEZ 
side 
Amygdala 
contacts 
MNI coordinates Talairach coordinates Artifact 
rejection 
AEDs 
x y z x y z  
1 
 
47 
 
male 
 
7 
 
left 
 
left 29 -4 -26 28 -7 -18 12 % 
 
LEV, OXC 
 right -24 -3 -31 -24 -6 -23 
2 
 
54 
 
male 
 
8 
 
right 
 
left 26 -4 -23 25 -7 -16 22 % 
 
LEV, LTG 
 right -27 -4 -26 -26 -7 -19 
3 
 
38 
 
female 
 
4 
 
right 
 
left 25 -5 -24 24 -7 -17 19 % 
 
LCZ, LEV, VPA 
 right -27 -5 -26 -26 -8 -17 
4 
 
47 
 
male 
 
11 
 
right 
 
left 
No post-implantation MRI available 
13 % 
 
CBZ, LEV, PB 
 right 
5 
 
29 
 
female 
 
21 
 
left 
 
left 25 -2 -28 24 -5 -20 10 % 
 
LEV, PGB 
 right -24 0 -27 -24 -3 -20 
6 53 female 5 left left -26 -4 -23 -25 -7 -16 10 % CZP, CBZ, PGB 
7 27 male 17 left left -23 -3 -28 -23 -6 -21 8 % CBZ, LEV, TPM 
8 29 female 1 right right 22 -5 -28 21 -8 -20 7 % CBZ, LCZ, LEV, TGB 
9 33 female 14 right right 31 -5 -26 30 -8 -18 2 % CBZ, LCZ, LEV 
10 30 male 36 right right 23 -3 -28 22 -6 -20 4 % CBZ, CLB, LCZ 
Abbreviations: ID identification number, BDI Beck Depression Inventory, HEZ hypothesized epileptogenic zone, MNI Montreal Neurological 
Institute, AED anti-epileptic drugs: CBZ carbamazepine, CLB clobazam, CZP clonazepam, OXC oxcarbazepine, LCZ lacosamide, LTG 
lamotrigine, LEV levetiracetam, PB phenobarbital, PGB pregabalin, TGB tiagabine, TPM topiramate, VPA valproic acid 
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3  Stimuli 
All stimuli comprised four pictures, two faces and two houses arranged in vertical and 
horizontal pairs around a central black fixation cross (Figure 1). All pictures were black 
and white photographs presented on a gray background and had the same size across all 
experiments (108 [width] x 154 [height] pixels on a 1024 * 768 pixel resolution screen) 
subtending 4.0 x 5.7 ° of visual angle at a 50 cm viewing distance. The stimuli included 
10 fearful faces, 10 neutral faces, 10 sad faces and 20 houses, with pictures from each 
category repeated equally across all trials. The neutral, fearful and sad facial expression 
photographs were drawn from the set of Ekman and Friesen [Ekman and Friesen, 1976].  
 
Figure 1. Sample visual stimuli of the face- or house-matching task.  
Each trial comprised a display of four pictures, with two houses and two faces arranged 
in vertical and horizontal pairs around a central black fixation cross. Before each block, a 
visual cue (i.e., thickening of two frames) instructed participants to attend either to the 
vertical pair or the horizontal pair of stimuli, while ignoring the other pair. Subsequently, 
subjects had to indicate quickly and accurately whether the two stimuli at the task-
relevant locations were the same or different (i.e., matching task). On any given trial, 
both faces had either a fearful, sad or neutral expression and were shown at task-
relevant or task-irrelevant locations. 
4 Procedure 
The face- or house-matching task was the same as in our previous study with scalp EEG 
in 50 patients with epilepsy and 25 healthy controls [De Taeye et al., 2015]. Stimulus 
presentation and response time recording were controlled using E-Prime software 2.0 
(Psychology Software Tools Inc., Pittsburgh, USA). Before each block, a 3 s display 
instructed subjects to attend to horizontal or vertical stimulus pairs, while ignoring the 
other stimulus pairs. The instruction display consisted of four empty frames placed at the 
location of the stimuli, with either the two horizontal or the two vertical frames being 
thickened. Trials began with a central fixation cross for 1 s, followed by the four-picture 
display for 300 ms. Subjects were asked to maintain gaze fixation centrally throughout 
the trials and attend covertly to the stimulus pair at the relevant locations, in order to 
judge whether these two stimuli were the same or different by pressing one out of two 
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keys. Hence, on each and every trial, a two-alternative forced choice task based in 
stimulus identity was required. The inter-trial interval (ITI) varied randomly between 1 
and 3 s. To ensure that patients understood the paradigm, they completed 2 practice 
blocks with 5 trials, with one block where the attention was directed to horizontal 
positions and one block where the attention was directed to vertical positions. After the 
practice block, patients 1 to 4 completed 4 blocks of 48 trials, with two blocks where 
attention was directed to horizontal positions and two blocks where attention was 
directed to vertical positions. In each block, all possible combinations of two object 
categories (pairs of faces vs. pairs of houses), their locations, same/different identity, 
and facial expression were fully randomized and counterbalanced across trials, resulting 
in a total of 32 neutral, 32 sad and 32 fearful faces at task-relevant (attended) locations, 
and the same number for each expression at task-irrelevant (unattended) locations (total 
192 trials). Patients 5 to 10 completed 6 blocks of 48 trials, with three blocks where the 
attention was directed to horizontal positions and three blocks where the attention was 
directed to vertical positions, resulting in a total of 288 trials. Task instructions 
emphasized both accuracy and speed. Response times were recorded from stimulus 
onset using a response box (RB-730, Cedrus).  
Patients with mesial temporal lobe epilepsy can experience difficulties in recognizing 
emotional expressions [Meletti et al., 2009]. Therefore, after the matching task, patient 5 
to 10 (n=6) were instructed to rate each picture for emotional valence and arousal on 
two separate scales, i.e., the Self Assessment Manikin (SAM) arousal and valence scales 
[Bradley et al., 1994]. The SAM valence scale shows five cartoon figures ranging from 
unhappy to happy ; below this scale were the numbers ‘‘1’’ through ‘‘5’’. Participants 
were told to use this scale to indicate how pleasant or unpleasant they felt about the 
preceding picture. The SAM arousal scale shows five cartoon figures with expressions 
ranging from calm and relaxed to excited and wide-eyed; again, the numbers ‘‘1’’ 
through ‘‘5’’ were presented below this scale, and participants were told to rate the 
picture, but this time based on the strength of their emotional activation by the picture. 
Valence ratings were reverse-scored to arousal ratings in such a manner that a score of 5 
represented pleasant valence and high arousal.  
5 Intracranial EEG recording  
Intracranial local field potentials were continuously recorded with Micromed System Plus 
(Micromed, Mogliano Veneto, Italy) with a sampling frequency rate of 1024 Hz, anti-
aliasing filter of 250 Hz, gain of 50 dB and 16 bits resolution, using depth electrodes 
containing four to ten evenly spaced platinum contacts. In patients 1, 2, 6 and 7 depth 
electrodes (model T08-08BM, DIXI) had 8 recording contacts with 5 mm contact length 
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and 2 mm inter-contact spacing. In patient 3, depth electrodes (model T08-10AM, DIXI) 
had 10 recording contacts with 3.5 mm contact length and 2 mm inter-contact spacing. 
In patient 4, depth electrodes (model 3387, Medtronic) had 4 recording contacts with 1.5 
mm contact length and 1.5 mm inter-contact spacing. In patients 5 and 10, depth 
electrodes (model SD08R-SP05X-000, Ad-Tech Medical Instruments) had 8 recording 
contacts with 2 mm contact length and 3.5 mm inter-contact spacing. The position of the 
electrode contacts in the amygdala was verified by a neuroradiologist (E.A.) based on 
post-implantation MRI. If more than one contact was in amygdala, the one with the 
clearest (neurophysiological) response and most consistent signal was chosen for 
subsequent analysis. The anatomical coordinates of each electrode contact in the 
amygdala (Table 1) were determined with spm12 [http://www.fil.ion.ucl.ac.uk/spm/] by 
coregistration of the individual pre- to post-implantation T1 MRI images and 
normalization of the pre-implantation MRI to the Montreal Neurological Institute (MNI) 
template. Additionally, MNI coordinates were translated to Talairach space according to 
the Nonlinear Yale MNI to Talairach Conversion Algorithm [Lacadie et al., 2008; 
http://sprout022.sprout.yale.edu/mni2tal/mni2tal.html]. The estimated Talairach 
coordinates of the electrodes (Table 1) overlapped with the basal and lateral amygdala, 
as according to the Talairach atlas, the amygdala occupies a region that runs from 17 to 
30 mm lateral to the midline, 1 mm anterior to 11 mm posterior to the anterior 
commissure and 7 to 21 mm below the intercommissural line [Zald, 2003]. Patient 4 had 
no post-implantation MRI and the exact coordinates could not be determined in this 
patient, however the electrodes were stereotactic implanted with the bilateral amygdala 
as targets. In all patients, the online reference electrode was placed on the right mastoid 
and ground electrode on the left mastoid.  
6 Data analysis 
Behavioral results were analyzed with mixed-model analysis of variance (ANOVA) with 
within-subjects factor of attention (house-cued vs. face-cued trials), valence [negative 
(fearful or sad) vs. neutral] and arousal [high (fearful) vs. low (sad or neutral)]. 
Offline ERP analyses were performed using BrainVision Analyzer 2 software (Brain 
Products GmbH, Gilching, Germany). The continuous EEG was first visually inspected to 
mark interictal epileptic discharges. Subsequently, it was digitally filtered with a 50 Hz 
notch filter and a half-power band-pass filter between 0.1–30 Hz with a roll-off of 12 
dB/octave, and then down-sampled to 512 Hz. The EEG was segmented into epochs from 
−200 ms to +1000 ms relative to the onset of the stimuli and submitted to automatic 
artifact rejection to exclude epochs with voltage exceeding ±200 µV from averaging. The 
average fraction of rejected epochs with artifacts and interictal epileptic discharges was 
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11 % (ranging from 2 to 22 %, see Table 1). The frequencies of artifact-contaminated 
epochs showed no significant systematic differences across experimental conditions with 
10.7 % fearful face-cued, 10.4 % neutral face-cued, 11.4 % sad face-cued, 11.7 % 
fearful house-cued, 10.5 % neutral house-cued and 9.2 % sad house-cued epochs (one-
way ANOVA F=0.1 , p=0.986). Baseline correction was applied on the 200 ms pre-
stimulus interval and potentials were averaged separately for each condition and each 
individual.  
Two different types of statistical analyses were performed on the amygdala iERPs. First, a 
group-level analysis compared the mean voltages of successive contiguous 100 ms time 
windows from -200 ms to 1000 ms latency around stimulus onset on the averaged 
potentials for each condition [Krolak-Salmon et al., 2004; Meletti et al., 2012]. The 100 
ms segments were analyzed with mixed-model ANOVA with within-subjects factor of side 
(left vs. right amygdala), attention (house-cued vs. face-cued trials), valence (negative 
vs. neutral), arousal (high vs. low) and BDI as covariate. Post-hoc tests were Bonferroni 
corrected. Second, individual analyses were performed on the single trial responses of 
each of the ten individual patients separately using Cartool software (developed by Denis 
Brunet, Functional Brain Mapping Laboratory, Geneva, Switzerland). Experimental 
conditions were compared using sample-by-sample unpaired t-tests with a significant 
alpha cutoff set to p<0.05 and with an additional criterion of temporal stability for at 
least five consecutive samples (=10 ms at 512 Hz sampling rate) [Naccache et al., 2005; 
Gaillard et al., 2009; Pourtois et al., 2010b].  
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RESULTS 
1 Behavioral results 
Mean response times and accuracy in same/different judgments were computed for each 
subject in each condition. Behavioral results during the face- or house-matching task are 
summarized in Figure 2A. Mean error rate was 25.5 ± 8.0 % indicating that the matching 
task was relatively demanding but could be performed well above chance level. Patients 
made significantly more errors when judging faces (31.3 %) than houses (20.0 %) [main 
effect of attention F(1,8)=20.5, p<0.001]. Judging faces carrying a negative emotional 
expression (26.4 %) was trend significant worse than judging neutral faces (22.1 %) 
[main effect of valence F(1,8)=2.8, p=0.099]. There was no significant effect of arousal 
[main effect of arousal F(1,8)=2.4, p=0.126], nor significant interaction of attention with 
either valence or arousal [interaction attention*valence F(2,8)=0.0, p=0.976, interaction 
attention*arousal F(2,8)=0.0, p=0.968].  
Analysis of reaction times (RTs) showed that participants were significantly slower to 
make same/different judgments with faces (630 ms) compared to houses (568 ms) 
[main effect of attention F(1,8)=9.8, p=0.003]. RTs were not significantly influenced by 
valence [main effect of valence F(1,8)=0.3, p=0.616], nor by arousal [main effect of 
arousal F(1,8)=1.0, p=0.326], nor was there a significant interaction of these factors 
with attention [interaction attention*valence F(2,8)=2.3, p=0.140, interaction 
attention*arousal F(2,8)=0.1, p=0.728]. This pattern of results was similar to the 
behavioral performance of a group of 25 healthy participants from our previous study 
using the same paradigm [De Taeye et al., 2015] with more errors and slower reaction 
times observed when faces had to be compared relative to houses (Figure 2). 
After the matching task, 6 patients were asked to rate the faces for valence and arousal 
using the SAM-rating scales (Figure 2B). Emotional expression (neutral vs. sad vs. 
fearful) had a significant effect on valence ratings [F(2,4)=13.4, p=0.003]. Post-hoc 
comparisons (Bonferroni corrected) revealed that relative to neutral faces (2.98), 
patients gave significantly more negative valence ratings for both sad faces (1.67) 
[p=0.023] and fearful faces (1.70) [p=0.004]. There was a trend of patients giving 
slightly higher arousal scores for fearful (3.38) compared to sad (3.00) and neutral 
(2.50) faces [F(2,4)=1.9, p=0.199].  
  CHAPTER 4 | Intracranial ERPs from the amygdala  117 
 
Figure 2. Behavioral results.  
(A) Reaction time in ms (upper panels) and percentage errors (lower panels) shown 
separately for the face-cued trials (red bars) and the house-cued trials (grey bars) of the 
ten patients (left panels), and in comparison with a group of 25 healthy controls (right 
panels) [De Taeye et al., 2015]. The ten patients showed a response pattern similar to 
these healthy participants with more errors and slower reaction times when they had to 
make same/different judgments for faces compared to houses. (B) Valence and arousal 
ratings on the SAM-rating scales. Higher scores reflect more positive and higher arousal 
ratings. Patients gave significantly more negative ratings for fearful and sad faces (red 
bars) compared to neutral faces (grey bars). In addition, patients rated fearful faces (red 
bars) as slightly more arousing than either sad or neutral faces (grey bars).  
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2 Electrophysiological results 
Clear stimulus-locked iERP in the amygdala were evident in each of the ten patients. The 
amygdala iERPs showed a reproducible wave morphology across them (Figure 3), sharing 
many similarities with previous and independent results obtained for this mesial temporal 
lobe structure [Krolak-Salmon et al., 2004; Meletti et al., 2012]. In all patients, a first 
negative component was found arising between 200 to 600 ms post stimulus onset, 
followed by a positive component between 600 to 1000 ms. The wave morphology of the 
local field potentials recorded in the contacts in the amygdala was clearly different from 
the morphology of the local field potentials recorded on the adjacent contacts in the 
anterior hippocampus (data not shown).  
 
Figure 3. Wave morphology of the amygdala iERPs.  
Averaged intracranial ERPs recorded from the amygdala displayed separately for each of 
the 10 patients. In all insets, blue lines represent iERPs to house-cued trials and red lines 
to face-cued trials. Results show that the stimulus-locked iERP wave morphology was 
very reproducible across patients with a negative component arising from 200 to 600 ms 
followed by a positive component between 600 to 1000 ms. 
 
2.1 Group-level analysis 
Statistical analyses were performed on grand average iERPs by comparing the mean 
voltages of successive contiguous 100 ms time windows from -200 ms to 1000 ms 
latency around stimulus onset for each condition. We found significant effects of attention 
with larger amplitudes of the negative component when judging houses compared to 
faces in three consecutive time windows: from 300 to 400 ms [F(1,74)=5.9, p=0.018], 
400 to 500 ms [F(1,74)=29.5, p<0.001] and 500 to 600 ms [F(1,74)=12.5, p<0.001]. 
The mean amplitude of the 300 to 600 ms time window was significantly higher in 
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amplitude for attending to houses compared to attending to faces in both left amygdala 
[p<0.001] and right amygdala [p<0.001] (Figure 4). By comparison, at group-level, 
there was no significant systematic modulation of the amygdala ERPs by either emotional 
arousal (high vs. low) or emotional valence (negative vs. neutral) of the face stimuli 
(Figure 5). In addition, there were no significant interactions of valence and arousal 
factors with attention or side (left vs. right amygdala). Modulation of the amygdala ERPs 
was also not associated with BDI-scores of self-reported depressive symptoms. 
 
Figure 4. Effect of attention at the group-level (n=10).  
Stimulus-locked grand average iERP waveforms recorded in the amygdala in response to 
house-cued trials (blue lines) and face-cued trials (red lines). Note the prolonged 
differential responses starting at 300 ms. At the group-level, the amplitude of the 
negative component was significantly larger for house-cued relative to face-cued trials 
from 300-600 ms post-stimulus in both left and right amygdala. *** p<0.001.  
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Figure 5. Effects of arousal and valence at the group-level (n=10). Stimulus-
locked grand average iERP waveforms recorded in the amygdala: upper panels show 
amygdala iERP separately for neutral faces (blue line) and negative faces (sad and fear, 
red line); lower panels for low arousal faces (neutral and sad faces, blue line) and high 
arousal faces (fear faces, red line). At the group-level, amygdala iERPs were not 
systematically modulated by either emotional arousal or emotional valence of the face 
stimuli, for both attended and unattended conditions. 
 
2.2 Individual analysis of single trial potentials 
Statistical analysis of the single trial potentials in the amygdala of the individual patients 
are summarized in Table 2. An effect of attention (face-cued vs. house-cued trials) was 
significant in nine out of ten patients (Table 2, Figure 3). The negative component 
between 300 and 600 ms post stimulus onset was significantly larger for making 
same/different judgment for houses compared to faces in seven patients (patients 1, 2, 
3, 4, 5, 9 and 10). Furthermore, the positive component between 600 and 1000 ms was 
significantly larger for face-cued relative to house-cued trials in five patients (patients 2, 
3, 5, 8 and 9). In addition, amygdala ERPs were significantly modulated by emotional 
valence and arousal in six out of ten patients (patients 1, 2, 3, 5, 7 and 10), however, 
occurring at different latencies from 110 to 920 ms following stimulus onset depending 
on the patient considered (Table 2, Figure 6-8). Valence (neutral vs. negative) had a 
significant effect in 4 different time windows varying between 150 and 920 ms after 
stimulus onset in patients 1, 3 and 7 (Table 2, Figure 6). Amygdala iERPs were 
systematically modulated by arousal in five out of ten patients (patients 1, 2, 3, 5 and 
10) in time windows varying between 110 and 900 ms post stimulus onset (Figure 6-8).   
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Table 2. Single trial potential analysis: attention, valence and arousal 
differences (p < 0.05 for > 10 ms) 
Patient Side Attention  Valence Arousal 
1 Left 348-424, 721-771,  
971-977 ms 
314-375 ms 615-658, 779-836,  
928-936 ms 
Right 236-252, 588-604,  
631-691, 703-723,  
740-876 ms 
393-734, 748-785 ms 365-387, 518-559,  
588-605, 625-637 ms 
2 Left 744-1000 ms n.s. 188-215, 229-246,  
555-563 ms 
Right 316-402 ms n.s. n.s. 
3 Left 453-674, 795-836 ms 154-248, 877-912 ms n.s. 
Right 469-828 ms n.s. 113-139, 148-158 ms 
4 Left 383-559 ms n.s. n.s. 
Right 943-957 ms n.s. n.s. 
5 Left 426-449, 748-766 ms n.s. 789-838 
Right 402-482, 645-734 ms n.s. 715-738, 748-895 ms 
6 Left 828-846 ms n.s. n.s. 
7 Left n.s. 582-596 ms 521-594 ms 
8 Right 797-807 ms n.s. n.s. 
9 Right 252-279, 453-680, 
713-791, 916-1000 ms 
n.s. n.s. 
10 Right 162-184, 398-518 ms n.s. 380-490 ms 
n.s. not significant 
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Figure 6. Effects of arousal and valence on single trial level in patient 1.  
(A) Averaged iERPs from the left and right amygdala of patient 1: left panel shows the 
average response to low arousing (blue) and high arousing faces (red); the right panel 
shows the average response to neutral (blue) and negatively valenced faces (red). 
Differential responses to high arousing stimuli compared to low arousing stimuli arose 
during 3 successive time windows in left amygdala spanning from 615 to 936 ms and 4 
successive time windows in right amygdala spanning from 365 to 637 ms post stimulus 
onset. Differential responses to negatively valenced stimuli compared to neutral stimuli 
arose during one time window spanning from 314-375 ms in the left amygdala and two 
successive time windows in the right amygdala spanning from 393 to 785 ms post 
stimulus onset. (B) ERP image (i.e., single trial decomposition) showing a two-
dimensional representation of amplitude x time data for all consecutive trials of patient 1 
for each condition. The amplitude of single-trial responses is plotted from −60 μV (blue) 
to +60 μV (red). Valence and arousal effects remained generally stable across the 
successive trials.  
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Figure 7. Effects of arousal and valence on single trial level in patient 5.  
(A) Averaged intracranial ERP from the left and right amygdala of patient 5: the left 
panel shows the average response to low arousing (blue) and high arousing faces (red); 
the right panel shows the average response to neutral (blue) and negatively valenced 
faces (red). (B) ERP image showing a two-dimensional representation of amplitude x 
time data for all consecutive trials of patient 5 for each condition. The amplitude of 
single-trial responses is plotted from −50 μV (blue) to +50 μV (red). Differential 
responses to high arousing faces compared to low arousing ones arose during the time 
window spanning from 789-838 ms in the left amygdala and two successive time 
windows in the right amygdala spanning from 715 to 895 ms post stimulus onset. The 
arousal effects remained generally stable across the successive trials. Single trial analysis 
showed no significant effect of valence.  
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Figure 8. Effects of arousal and valence on single trial level in patient 10.  
(A) Averaged intracranial ERP from the right amygdala of patient 10: the left panel shows 
the average response to low arousing (blue) and high arousing faces (red); the right 
panel shows the average response to neutral (blue) and negatively valenced faces (red). 
(B) ERP image showing a two-dimensional representation of amplitude x time data for all 
consecutive trials of patient 5 for each condition. The amplitude of single-trial responses 
is plotted from −50 μV (blue) to +50 μV (red). Differential responses to high arousing 
faces compared to low arousing faces arose during the time window spanning from 380-
490 ms in the right amygdala and remained generally stable across the successive trials. 
Single trial analysis showed no significant effect of valence. 
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DISCUSSION 
This study explored the effects of attention and emotion on the processing of visual face 
stimuli in ten patients implanted with intracranial electrodes that directly measured the 
neuronal activity in the amygdala. The results indicate that there is a systematic gating 
by object-based attention on the amygdala responses. Furthermore, our data suggest 
that neuronal processing in the amygdala can be modulated by both emotional valence 
and arousal, but these effects occur at variable latencies following stimulus onset in the 
different patients. Taken together, our findings therefore suggest that both attention and 
emotional factors can independently influence the sensory processing in the amygdala, 
but at distinct, sometimes overlapping, latencies following stimulus onset. This 
dissociation in time-course cannot be resolved with fMRI due to the slow temporal 
resolution of this technique and may explain previous discrepancies reported in the 
literature based on fMRI studies using the same task [Vuilleumier et al., 2001; 
Vuilleumier et al., 2004; Bishop et al., 2004; Fales et al., 2008]. The results of our study 
are in line with the notion that emotion processing may take place in parallel and 
independently from the strong and systematic gating effect exerted by voluntary 
attention and mediated by a large fronto-parietal network [Pourtois et al., 2013].  
Previous intracranial recordings from the left amygdala in one patient during the face- or 
house-matching task showed early (140 to 290 ms) modulation of the amygdala iERPs by 
fearful faces (arousal) that preceded the effects of attention at a much later latency (750 
to 950 ms) [Pourtois et al., 2010b]. The results of this study are very comparable with 
recordings in the left amygdala of patient 2 that showed a significant early effect of 
arousal in three time windows ranging from 188 to 563 ms, followed by a much later 
effect of attention ranging from 744-1000 ms. However, in other patients effects of 
emotion occurred at different latencies, suggesting that influence of emotion on visual 
processing in the amygdala varies among individuals, with some patients showing a 
significant early effect of emotional valence or arousal, while in other patients, early 
stimulus processing in amygdala seems rather insensitive to the (negative) emotional 
expression conveyed by the faces. These findings are in agreement with a previous study 
[Krolak-Salmon et al., 2004] which observed larger negative amplitudes of amygdala 
iERP specifically for fearful faces, but auxiliary analyzes of the single trial responses of 
the individual patients revealed that this fear-specific effect was actually significant only 
in half of the patients and in variable time windows ranging from 200 to 1000 ms post-
stimulus onset. In addition, the emotion effects in these patients were only observed 
during a task where patients had to recognize the emotional expression of the faces, but 
not when they had to discriminate their gender. In our paradigm, recognition of the 
emotional expression was not explicitly relevant for the matching task and stimuli were 
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presented very briefly (300 ms), which might potentially explain the lack of systematic 
modulation of the amygdala iERPs by emotional expressions during this task. 
The intracranial recordings in the amygdala carried out in this study showed a systematic 
difference between face-cued and house-cued trials. Single-unit activity recordings in the 
amygdala of monkeys reported that some neurons distinguish between faces and non-
face objects, while other neurons encode identity or expression of faces [Nakamura et 
al., 1992; Gothard et al., 2007]. Findings of category-specific neurons in monkey 
amygdala have been generalized to humans in single-unit recordings in patients with 
epilepsy [Fried et al., 1997; Kreiman et al., 2000; Quiroga et al., 2005; Mormann et al., 
2011]. These studies have demonstrated that single neurons in the human amygdala can 
discriminate objects from faces, with some neurons firing selectively to images of faces 
while others show category-specific response to objects [Fried et al., 1997; Kreiman et 
al., 2000]. There are even amygdala neurons with a visual categorical selectivity for 
animals and this selectivity appeared to be independent of emotional valence and arousal 
[Mormann et al., 2011]. Taken together, single-unit recordings suggest that during visual 
processing, amygdala neurons encode information about stimulus identity and category 
[Nakamura et al., 1992; Fried et al., 1997; Kreiman et al., 2000; Quiroga et al., 2005; 
Gothard et al., 2007; Mormann et al., 2011], which is necessary to coordinate the 
activation of cortical networks (interconnected with this amygdala) that are required to 
prioritize the processing of behaviorally relevant stimuli [Sander et al., 2003]. There are 
multiple parallel routes for visual information processing that may lead to substantial 
temporal dispersion of evoked responses. Notably, the amygdala may not be unique in 
the processing of affective visual stimuli as there are other largely parallel networks that 
enable comparable functions, such as the network operated by the connections between 
the pulvinar and the cortex [Pessoa and Adolphs, 2010]. 
It should be pointed out that the new neurophysiological results obtained here with 
intracranial recordings performed in patients with chronic refractory epilepsy are 
necessarily limited and cannot be generalized without caution. However, ERPs recorded 
in the amygdala during the face- or house-matching task showed a very reproducible 
wave morphology across patients. Moreover, the inclusion and systematic comparison of 
10 different patients in this study are rather exceptional, as most of the previous studies 
available in the literature were actually conducted with a much smaller sample size 
[Murray et al., 2014]. In all ten patients, a first negative component was found arising 
between 300 to 600 ms post stimulus onset, followed by a positive component between 
600 to 1000 ms. The observed amygdala ERP wave morphology is highly similar and 
consistent to previous studies that recorded amygdala ERPs in response to human face 
stimuli [Krolak-Salmon et al., 2004; Pourtois et al., 2010b; Meletti et al., 2012; Murray 
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et al., 2014]. Moreover, no clear laterally effects (left vs. right amygdala) were observed 
in our study; a result which is again in line with previous studies of amygdala ERPs 
[Krolak-Salmon et al., 2004; Meletti et al., 2012]. In general, lateralized activations by 
emotional stimuli are most supportive for the asymmetry framework in which the left 
hemisphere is dominant for approach and positive emotions and both hemispheres are 
involved in withdrawal and negative emotions [Davidson et al., 2000; Pizzagalli et al., 
2003; Wager et al., 2003]. Lanteaume and coworkers have shown that electrical 
stimulation of the right amygdala induced negative emotional states (fear and sadness), 
while stimulation of the left amygdala could induce either positive (happiness) or 
negative (fear, sadness) emotions [Lanteaume et al., 2007]. Although several 
neuroimaging studies have reported lateralization of amygdala responses as a function of 
valence, meta-analysis by Sergerie and colleagues found no evidence for functional 
asymmetry of the amygdala during emotional processing. The magnitude of activation in 
the left and right amygdala was similar in response to both positive and negative 
valenced stimuli, with a preference for faces depicting emotional expressions [Sergerie et 
al., 2008]. This is in agreement with our iERP results that showed no evidence of 
lateralized amygdala specialization. 
A second limitation of the present study is that some patients with temporal lobe epilepsy 
can have deficits in the processing and recognition of facial expressions [Meletti et al., 
2009], which might eventually explain why effects of emotion (either valence or arousal) 
in the amygdala were not systematic across patients, unlike attention. Nevertheless, in 
our study, patients rated the stimuli as being more negative when fearful and sad faces 
were presented, compared to neutral faces, and they also judged fearful faces more 
arousing for than either neutral or sad faces. Hence, these results agree with the 
assumption of preserved visual emotional processing abilities for the epileptic patients 
included in our study.  
In sum, this study provides direct evidence for asymmetric effects of attention and 
emotion in the human amygdala during visual stimulus processing. While object-based 
attention exerts a systematic effect on amygdala ERPs visible at the group-level, only a 
subset of the patients shows amplitude modulations of amygdala ERPs by emotion at 
variable latencies following stimulus onset. Therefore, these results suggest that 
attention and emotion can differentially influence sensory processing in the amygdala, 
likely via different pathways, with stable gating by attention but versatile modulation by 
emotion.  
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
This PhD project investigated three central research questions (see “Research aims” page 
7). The first section will discuss each of the research questions in light of the new insights 
revealed by our studies and mark out future research challenges and opportunities. In 
the second section, advantages and limitations of ERP recordings in patients with 
epilepsy will be discussed in turn and a general conclusion will be drawn. 
1 Current insights and future avenues 
1.1 The P3 is a potential biomarker for the response to VNS in epilepsy 
The first chapter provides new neurophysiological evidence which supports the 
hypothesis that VNS-induced activation of the locus coeruleus noradrenergic signaling is 
associated with the therapeutic response to VNS in patients with epilepsy. Our ERP 
results showed that VNS induces a significant increase of the oddball P3 amplitude at the 
parietal midline electrode, in VNS responders only. In addition, logistic regression 
analysis revealed that modulation of the P3 amplitude can be used as a non-invasive 
indicator for VNS responders and non-responders with relatively good sensitivity and 
specificity. Amplitude modulations of the P3 should be further investigated as a non-
invasive biomarker to predict the treatment response to VNS in patients with refractory 
epilepsy. A biomarker for the efficacy of VNS could help neurologists to identify the best 
patient candidates for VNS and fine-tune the patients’ individual stimulation parameters 
in a more objective way [Vonck and Boon, 2015].  
A biomarker is defined as a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention and that is quantifiable, precise and reproducible 
[Atkinson et al., 2001; Leiser et al., 2011]. The relative increase in P3 amplitude is an 
objective, quantifiable measure with a reasonably good precision: when a cutoff value of 
> 20 % amplitude increase is used, the sensitivity and specificity are 70 % and 90 % 
respectively. Nonetheless, the P3 is definitely not a perfect biomarker because 30 % of 
responders and 10 % of non-responders are misclassified with this cut-off. Previous work 
from our laboratory in a rat model for epilepsy has found that using a VNS-induced 
increase of hippocampal NE levels of at least 70 % as a classifier for the anticonvulsive 
effect of VNS had a sensitivity and specificity of 100 % [Raedt et al., 2013]. Several 
factors could underlie the lower sensitivity of the P3 in our patient study compared to the 
preclinical results. Patients included in our study had different types of epilepsy and 
heterogeneous clinical characteristics in comparison to the uniform and controlled rat 
model for epilepsy. In addition, the P3 component of the ERP is only an indirect measure 
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if LC-NE activity and other confounding factors (e.g., anti-epileptic drugs, brain lesions, 
type of epilepsy) could influence the amplitude of the P3. We have tried to control for this 
factors by calculating relative amplitude differences and comparing the P3 amplitude 
between the ON and OFF condition within each patient. Future research including more 
patients is needed to confirm the reproducibility of these P3 results. At this moment 
there are no biomarkers available for VNS treatment efficacy in patients with epilepsy. In 
this context, a further exploration of indexes of the LC-NE system as providing such 
biomarker appears valuable as it could potentially help to solve this problem. 
Novel techniques have been designed to deliver non-invasive VNS, including 
transcutaneous VNS (tVNS) that stimulates the auricular branch of the vagus nerve 
through the skin of cymba conchae of the ear [Ellrich, 2011; Frangos et al., 2015]. A 
proof of concept trial showed that tVNS is a safe and well-tolerated neurostimulation 
therapy for patients with epilepsy [Stefan et al., 2012]. Combination of non-invasive 
tVNS with a (neurophysiological) biomarker that predicts the therapeutic efficacy of VNS 
could help identifying responders prior to surgery.  
Besides the P3 component of the ERP, other non-invasive markers of the noradrenergic 
system could also be potential biomarkers for VNS. Recent studies have suggested that 
the pupil diameter is an indirect index for a LC-NE activity in the human brain [Gilzenrat 
et al., 2010; Murphy et al., 2011; Nassar et al., 2012; Jepma and Nieuwenhuis, 2011]. 
Simultaneous intracranial recordings of the locus coeruleus discharge frequency and pupil 
diameter in monkeys showed that these two are remarkably closely correlated 
[Rajkowski et al., 1993; Aston-Jones and Cohen, 2005]. In addition, there is strong 
pharmacological evidence that pupil dilation is controlled through alpha-2 
adrenoreceptors, by the release of noradrenaline from the LC [Phillips et al., 2000]. In 
healthy participants, administration of the alpha-2 adrenoceptor agonist clonidine (which 
inhibits LC activity and decreases NE release) significantly decreased the pupil diameter, 
whereas the alpha-2 adrenoceptor antagonist yohimbine (which increases LC activity and 
NE release) caused a significant pupil dilation compared to placebo. Therefore, pupil 
dilation should be a reliable measure of LC-NE activity, especially under moderate levels 
of illumination [Phillips, 2000; Sara, 2009]. Another frequently used non-invasive marker 
is the sympathetic skin conductance response (SCR), which is a momentary change of 
the electrical potential of the skin [Vetrugno et al., 2003; Nieuwenhuis et al., 2011]. 
Analogous to the pupil dilation response, pharmacological studies have shown that 
clonidine decreased the SCR, while yohimbine substantially increased the amplitude of 
the SCR [Yamamoto et al., 1994]. Hence, the SCR is an additional non-invasive approach 
to investigate the function of the LC-NE system [Nieuwenhuis et al., 2011]. The 
combination of various multimodal types of non-invasive biomarkers could substantially 
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increase the specificity and sensitivity of the prediction for therapeutic response to VNS 
in patients with refractory epilepsy. 
In our first study, we recruited patients who received VNS therapy for at least 18 
months. Presumably, this chronic stimulation had led to long-term changes in specific 
neuronal networks and neurotransmitter systems [Boon et al., 2001]. Therefore, it 
remains unclear whether these VNS-induced effects on P3 amplitude will also be 
observed in epilepsy patients prior to initiation of VNS-therapy. To resolve this issue, we 
are currently performing a longitudinal prospective study, in which there is a baseline 
measurement before the chronic VNS is initiated, and subsequently, a second 
measurement after one year of standard cycling VNS. This study is still ongoing, until 
now 15 patients have been tested a first time before initiation of VNS and 5 of these 
patients have been tested a second time after 1 year of VNS. In these patients different 
non-invasive markers of noradrenergic activity (i.e., P3 component, sympathetic skin 
response and pupil diameter) are compared between three conditions that are performed 
in random order: (i) no stimulation, (ii) invasive VNS and (iii) non-invasive tVNS. This 
longitudinal study is required to assess whether we can predict, based on the baseline 
measurement (acute effects), which patients will eventually become responders to the 
VNS therapy (chronic effects) and whether non-invasive markers of LC-NE activity can be 
used as a prospective measure to predict the therapeutic efficacy of VNS. If non-invasive 
tVNS affects the biomarkers of LC-NE activity similarly as invasive VNS, the use of these 
biomarkers in combination with tVNS could help to detect responders prior to surgery 
and hence avoid unnecessary implantations of a VNS device in non-responders and 
consequently improve the clinical efficacy of VNS. 
It should be noted that the mechanism of action of VNS not only involves activation of 
the LC-NE system, but more likely results from a complex cascade in which different 
networks and neuromodulatory systems are involved as well [Henry, 2002]. The vagus 
nerve has widespread projections to nuclei in the brainstem, the thalamus, hippocampus, 
amygdala, and to all cortical regions, where they modulate the activity of target cells and 
networks [Boon et al., 2001; Ben-Menachem, 2002; Vonck et al., 2009]. It has been 
demonstrated that VNS modulates the GABAergic, glutamatergic, dopaminergic, 
serotoninergic and cholinergic systems [Henry, 2002; Vonck et al., 2009; Manta et al., 
2013]. Given that these different neuromodulatory systems have strong reciprocal 
connections and influence each other, it is very hard to delineate the role of one single 
system [Sara, 2009]. Consequently, the noradrenergic system does not act alone, but 
interacts with other modulatory neurotransmitter pathways that may also contribute to 
the therapeutic effect of VNS. In addition, VNS is also being explored as a 
neuroimmunomodulatory treatment and has proven to change the activity of the 
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hypothalamic-pituitary-adrenal axis [Hosoi et al., 2000; de Herdt et al., 2009], with 
possible implications for disorders characterized by an abnormal stress reactivity, such as 
major depression [O'Keane et al., 2005; Pizzagalli, 2014]. Further exploration of the 
exact mechanism of action should improve the identification of functional biomarkers for 
VNS.  
1.2 Refractory epilepsy is associated with dysfunction of emotion regulation  
Patients with refractory epilepsy have a high prevalence of comorbid mood disorders. The 
second and third chapter gathered in this thesis aimed to evaluate whether negative 
affect in epilepsy was associated with dysfunction of emotion regulation. In the second 
chapter, ERPs were used in order to investigate whether a possible dysfunction arose 
during early (attention) and/or late (regulation) stages of emotional stimulus processing. 
Two ERP components were analyzed: the early vertex positive potential (VPP) which is 
normally enhanced when faces are presented as visual stimuli (compared to non-facial 
objects), and the late positive potential (LPP) that is typically larger for emotional stimuli. 
The face-sensitive VPP results revealed that early object-based attention processes were 
not compromised and that the early structural encoding of faces was normal and 
preserved in patients with refractory epilepsy, regardless of the amount of negative 
affect experienced by the patients and the actual emotional expression conveyed by the 
faces. By contrast, the amplitude of the LPP component, which is sensitive to emotion 
regulation, was significantly enhanced for unattented faces with negative emotional 
expressions, but only in patients with comorbid negative affect. The modulation of the 
LPP component by unattended emotional stimuli during the late stages of stimulus 
processing suggests that emotion regulation is disturbed in patients with epilepsy and 
comorbid negative affect.  
In this study, deficits of emotion regulation were only present in the group of patients 
with negative affect, which is in line with previous fMRI studies of the face- or house-
matching task performed in patients with negative affect disorders. For example, earlier 
fMRI results showed that patients with major depressive disorder had an enhanced 
amygdala response to unattended fearful faces compared to control subjects [Fales, 
2008]. In addition, during the processing of task-irrelevant fearful faces, the control 
subjects recruited the dorsolateral PFC, while patients with depression did not. 
Furthermore, comparison of participants with high and low state anxiety levels revealed 
that the “high-anxious” group showed increased amygdala response to unattended 
fearful versus neutral faces [Bishop et al., 2004a] and reduced recruitment of lateral PFC 
for unattended fearful faces [Bishop et al., 2004b]. These results support the proposal 
that negative affect is associated with both enhanced bottom-up input from the 
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amygdala, as well as reduced top-down control from the lateral PFC, resulting in 
dysregulation of the emotion regulation network [Bishop et al., 2004b; Ochsner and 
Gross, 2005; Fales et al., 2008].  
The aim of the third chapter was to investigate whether the ERP response to negatively 
valenced stimuli in patients with refractory epilepsy was sensitive to reappraisal, an 
antecedent-based cognitive emotion regulation strategy that can decrease negative 
affect. The main findings were that: (i) negative emotional stimuli induced a stronger LPP 
response than neutral stimuli, (ii) this emotional LPP response was not modulated by 
reappraisal, (iii) deficient reappraisal of the LPP did not correlate with comorbid negative 
affect, and (iv) there was no relation between the efficacy of reappraisal and location of 
the epileptogenic zone or brain lesions in medial temporal and frontal lobe. Taken 
together, our results provide novel evidence that the normal modulation of the LPP 
component as a function of cognitive emotion regulation is absent in patients with 
refractory epilepsy. This suggests abnormal cognitive emotion regulation brain processes 
in these patients, which could in turn underlie a higher vulnerability to negative affect. 
In the third study, abnormal reappraisal was found across the entire sample of patients 
with refractory epilepsy and no differences were found between group of patients with 
and without negative affect, a finding which contrasted with the results reported in the 
second study. This discrepancy could tentatively be explained by the use of different 
paradigms in these two studies, which required two different forms of emotion 
regulation. The matching task used in the second study was characterized by brief 
stimulus durations (only 300 ms) and the emotional content of the faces was not 
explicitly relevant for the matching task. Hence, emotions were processed in a more 
automatic manner, in a sense of being implicit and not directly task-relevant. By 
comparison, the reappraisal task used in the third study had a much longer stimulus 
presentation (3 s) and required cognitive the implementation of an effortful strategy 
meant to downplay the impact of negative emotions, a regulation process which relies 
primarily on regions involved in cognitive control, such as the prefrontal cortex [Ochsner 
and Gross, 2005; McRae et al., 2010]. Therefore, we hypothesize that defective 
reappraisal in patients with refractory epilepsy potentially reflects an increased 
vulnerability to develop negative affect disorders. Not all patients with refractory epilepsy 
had a current negative affect state (as reflected by the self-reported BDI and STAI 
scores), but our results suggest that they could have a higher risk of “getting stuck” in 
the negative affect state because of impaired cognitive emotion regulation [Holtzheimer 
and Mayberg, 2011]. 
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It is important to consider the localization of epileptogenic zone and brain lesions 
because it is possible that some of these lesions could have influenced our ERP results to 
a greater extent than other ones, especially lesions located in regions that are 
presumably important for emotion regulation processes, including frontal and medial 
temporal areas. Therefore, we performed additional data analyses and grouped the 
patients based on location of the HEZ and the presence of lesions in either frontal or 
medial temporal lobe structures, but these analyses failed to show any significant effect 
on the LPP amplitude, in both the second and the third study. Recent neuroimaging 
evidence have highlighted that recurrent seizures in refractory epilepsy can cause 
widespread reorganization of overlapping neuronal networks (for reviews, see [Spencer, 
2002; Richardson, 2010]). Hence, the deficient emotion regulation in patients with 
refractory epilepsy could not be easily linked to damage in one specific lobe but is more 
likely the result from dysfunction in a distributed network underlying emotion regulation 
in which both cortical and subcortical structures interact with each other [Ochsner and 
Gross, 2005; Price and Drevets, 2010].  
Quantitative volumetric MRI imaging studies in patients with epilepsy and depression 
found significant reduction in the volumes of the hippocampus, amygdala and prefrontal 
brain structures [Richardson et al., 2007; Kondziella et al., 2007; Kanner and Schachter, 
2010]. Comparable structural MRI abnormalities have been reported in patients with 
major depressive disorder alone [Arnone et al., 2012]. Examination of the cortical 
thickness in a group of patients with seizures originating from the left medial temporal 
lobe and with pathologically confirmed hippocampal sclerosis revealed that these patients 
showed up to 30 % decrease in cortical thickness, with noticeable thinning of frontal 
poles, frontal operculum, orbitofrontal, lateral temporal, and occipital regions. 
Interestingly, reductions in cortical thickness were evident in both cerebral hemispheres, 
despite unilateral seizure onset [Lin et al., 2007; Bell et al., 2011]. Furthermore, PET 
studies revealed that patients with unilateral mesial temporal lobe epilepsy show 
hypometabolism in bilateral frontal lobes, which correlates with frontal lobe deficits 
during neurophysiological testing [Arnold et al., 1996; Nelissen et al., 2006]. Ictal SPECT 
showed that during a seizure originating in the medial temporal lobe, there is 
hyperperfusion in the ipsilateral temporal lobe, but hypoperfusion in the bilateral frontal 
lobes [Van Paesschen et al., 2003]. The hypoactivity observed in the frontal regions in 
patients with temporal lobe epilepsy may be related to surround inhibition, which is a 
dynamic defense mechanism against seizure propagation [Nelissen et al., 2006]. These 
extratemporal abnormalities form a possible explanation for the observed broad cognitive 
dysfunction, with impaired executive function and working memory in mesial temporal 
lobe epilepsy that extends beyond memory function [Bell et al., 2011; Stretton and 
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Thompson, 2012]. Resection of the epileptogenic zone often results in a gain in frontal 
lobe functions, with cognitive improvement and normalization of the neuroimaging 
abnormalities [Stretton and Thompson, 2012]. These findings highlight the importance of 
looking at broader network functioning, rather than discrete regions, when examining 
psychophysiological measures of (cognitive) emotional regulation in epilepsy. These 
dynamic changes in the functional brain network could be investigated using advanced 
functional connectivity analyses [Van Mierlo et al., 2014]. 
An important limitation of the studies described in chapter 2 and 3 is that there was no 
psychiatric evaluation of the patients with epilepsy and therefore it remains unclear how 
many patients would meet the DSM-5 diagnostic criteria for mood or anxiety disorders. 
In our studies, presence of negative affect was only assessed with self-report inventories 
of the severity of depression (BDI) and anxiety (STAI). Negative affect is a general factor 
of subjective distress, and reflects a broad range of negative mood states, including 
anxiety and depression. Negative affect is considered a broad and pervasive 
predisposition to experience negative emotions that influences cognition, self-perception 
and world view [Watson, 1988]. In the highly influential tripartite model of Clark and 
Watson, negative affect is seen as a common underlying factor contributing to both 
anxiety and depression and this may explain the high rates of comorbidity and similarity 
between these disorders [Clark and Watson, 1991]. Future studies about emotion 
regulation in epilepsy should include a standard psychiatric interview of every patient. In 
addition, results should be compared with different control groups of patients without 
epilepsy but with other types of negative affect disorders, such as major depressive 
disorder, dysthymic disorder, bipolar disorder, general anxiety disorder, in order to 
evaluate whether this is a general effect found across these negative affect disorders, or 
instead, whether it is specific for negative affect in epilepsy. 
We have used the LPP to study emotion regulation in patients with refractory epilepsy. 
Previous ERP studies of emotion regulation have proved that the LPP is a sensitive, valid 
and effective neurophysiological marker for investigating emotion regulation processes in 
both healthy individuals and patients [Hajcak et al., 2010; Gross, 2013; Moran et al., 
2013]. However, LPP measures at centro-parietal scalp sites are only indirect measures 
of the underlying network for emotion regulation and therefore the contributions of the 
involved structures, including the amygdala and prefrontal cortex, remain to be 
elucidated. Source localization of high-density scalp EEG could help to further localize the 
active neuronal sources of the observed effects [Michel, 2004]. In addition, combination 
of EEG with functional neuroimaging techniques such as fMRI [Sabatinelli et al., 2007; 
Liu et al., 2013] in the same patients might help to gain additional insight into the 
disturbed activation patterns of the brain regions giving rise to the emotion regulation 
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dysfunction observed in our ERP studies and further support the hypothesis that negative 
affect in epilepsy is caused by dysfunction in the neurocircuitry underlying emotion 
regulation. 
1.3 Visual processing in the amygdala is modulated by attention and emotion 
In the fourth chapter we explored the effects of attention and emotion on the processing 
of visual face stimuli in ten patients with intracranial electrodes that directly measured 
the neuronal activity in the amygdala. The results indicated that there was a systematic 
gating by object-based attention on the amygdala responses. Further, our findings 
indicated that both attention and emotional valence or arousal factors could 
independently influence the sensory processing in the amygdala, but at distinct, non-
overlapping latencies following stimulus onset. As such, these results are in line with the 
notion that emotion processing may take place in parallel and independent from gating 
by voluntary attention control mediated by fronto-parietal attention networks [Pourtois et 
al., 2013]. 
With respect to intracranial EEG studies, there has been recently a growing interest in 
the analysis of frequency-specific oscillatory power changes that take place during 
cognitive tasks or the processing of emotional stimuli. These changes are termed event-
related desynchronization (ERD) or event-related synchronization (ERS), defined as a 
localized decrease or increase in oscillatory power in specific frequency bands 
[Pfurtscheller et al., 1999]. Two types of EEG oscillations should be considered: evoked 
and induced oscillations. An evoked response appears at the same latency and phase in 
each single trial and hence can be detected in the averaged ERP. An induced response 
appears with a jitter in latency from one trial to another, centered around a given latency 
and therefore this induced activity tends to partly or totally cancel out by the averaging 
process classically used in ERP studies. Specific detection methods, such as time-
frequency analysis with wavelet transformation, are therefore needed to detect them 
[Tallon-Baudry and Bertrand, 1999; Pfurtscheller et al., 1999]. The functional role of 
coherent oscillations remains speculative. One possibility is the temporal binding of 
information, particularly related to the coordination of neural networks [Singer, 1999; 
Varela et al., 2001]. The properties of neural networks indicate that low frequency 
oscillations (theta band) are likely associated with connectivity of larger scale neuronal 
networks, while higher frequency oscillations (gamma band) are constrained in smaller 
networks, and may be modulated by activity in the slower oscillating larger networks 
[Broyd et al., 2009]. Theta waves have also been described as “carrier waves,” in which 
gamma oscillations representing perceptual details are embedded. In particular, it has 
been proposed that theta band activity plays an important role in integrating and 
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synchronizing neural responses during emotional processing across sub-cortical 
(amygdala) and cortical structures, such as frontal and visual cortices [Lewis, 2005; 
Jensen and Colgin, 2007; Meletti et al., 2012]. 
In this line, time–frequency analyses of amygdala EEG revealed increases in the theta 
frequency band power during the processing of emotional faces. The increase in power of 
theta oscillations was sensitive to both the emotional valence of the stimulus and to the 
part of the face presented to subjects with a stronger increase in theta band power in 
response to isolated fearful eyes [Meletti et al., 2012; Murray et al., 2014]. In addition, 
analysis of induced oscillations in the amygdala in response to pleasant, unpleasant and 
neutral IAPS pictures revealed that oscillations in the gamma power band could 
discriminate between stimuli in different emotional categories, with significant increase in 
gamma band power only to aversive pictures [Oya et al., 2002]. The gamma band 
changes were of the induced type and not phased locked to stimulus onset, which 
indicates that gamma-band changes probably resulted from a temporally dispersed 
evaluation of the emotional meaning of the stimulus. Furthermore, time-frequency 
analysis of the human amygdala observed stronger gamma band activity for faces 
compared to non-face stimuli, especially when processing of faces was task-relevant 
[Musch et al., 2014]. The results showed strong attentional modulation over the 
frequency-specific changes in the gamma band and differences between fearful and 
neutral faces were rarely observed. The attention effects on the gamma band oscillations 
in the amygdala peaked between 350 and 450 ms after stimulus onset, which is 
consistent with the timing of the attentional gating effect observed in our iERP study. It 
would be very interesting to combine iERPs with time-frequency analysis of induced 
oscillations during the same paradigm, in order to compare the effects of attentional and 
emotional factors on both induced and evoked activity of the amygdala. 
In future studies using the face- or house-matching task, we plan to use an eye tracking 
device in order to have an objective measure of which stimuli were attended at the single 
trial level. Eye tracking technology allows direct and continuous measurement of overt 
visual attention which may provide an important supplement to the behavioral and ERP 
measures [Armstrong and Olatunji, 2012]. In addition, future research on the processing 
of emotional stimuli should combine (intracranial) ERP measurements with physiological 
markers of emotional response, such as electrodermal activity, facial muscle activity, 
cardiovascular responses, pupil dilation and changes in the neuroendocrine system 
[Collet et al., 1997; Bradley et al., 2001; Andreassi, 2013]. These objective peripheral 
physiological measures can provide complementary information about the emotional 
response of the participant. The physiological markers each have a specific response 
pattern that is sensitive to differentiate between specific aspects of emotional stimuli 
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[Collet et al., 1997]. It has been demonstrated that heart rate is a sensitive index for the 
valence of emotional stimuli. Heart rate accelerated during viewing of positive valenced 
IAPS pictures, whereas heart rate decelerated during viewing of negative valenced IAPS 
pictures [Bradley et al., 2001; Ohira et al., 2006]. By contrast, electrodermal activity 
(sympathetic skin conductance response) has been found to reflect emotional arousal 
regardless of the valence of the emotional stimuli [Bradley et al., 2001; Ohira et al., 
2006]. On the other hand, a considerable amount of data has indicated that emotional 
experiences are accompanied by changes in the neuroendocrine system [De Kloet, 
2004]. The most extensively studied endocrine system in the context of emotion and 
stress is the hypothalamic-pituitary-adrenocortical axis which is sensitive to emotional 
valence. Previous research has shown that levels of cortisol and adrenocorticotropic 
hormone increased after viewing affectively negative emotional stimuli but were 
unchanged after viewing neutral and positive stimuli [Codispoti et al., 2003].  
2 Advantages and limitations of ERP recordings in patients with epilepsy 
The main advantage of the ERP technique is its high temporal resolution in the order of 
milliseconds. In addition, ERPs provide a direct measure of electrical neuronal activity in 
response to specific stimuli or events. This makes it a powerful technique for 
investigating the electrophysiological time course of neuronal activity during specific 
cognitive tasks. ERPs allow continuous analysis of the ongoing neuronal processes from 
stimulus onset until response selection and decision making. Behavioral responses reflect 
the output of a large number of individual cognitive processes. Therefore, variations in 
reaction time and accuracy are difficult to attribute to changes to (or combination of) 
specific cognitive processes. In contrast, ERPs provide a continuous measure of the 
different processing stages, making it possible to determine which stage(s) of processing 
are likely to be affected by a specific experimental manipulation. ERPs can give 
information about the underlying neuronal process of behavioral responses and can 
frequently detect specific effects in the absence of clear differences at the behavioral 
level [Luck, 2014]. 
Our P3 results corroborate the notion that ERPs may provide a valuable tool as potential 
biomarkers in medical applications, by measuring aspects of brain function that are 
impaired in specific psychiatric and neurologic disorders, such as schizophrenia, mood 
disorders, attention deficit hyperactivity disorder, Alzheimer’s disease and aphasia 
[Jackson and Snyder, 2008; Duncan et al., 2009; Leiser et al., 2011; Luck, 2014]. First, 
ERPs may serve as brain function biomarkers that are more closely related to the 
underlying neurobiology of the disease than the traditional clinical symptoms and 
measures. Second, preclinical animal models are available for various ERP components 
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providing opportunities for translational research [Leiser et al., 2011; Luck et al., 2011]. 
Third, ERP markers could be used in clinical studies for evaluation of new treatments, to 
determine whether a given medication or neurostimulation therapy has an effect on the 
specific cognitive process, neural circuit, or neurotransmitter system of interest. 
Subsequently, ERP biomarkers could also be used in clinical practice to monitor therapy 
follow-up. Finally, ERP biomarkers could help to identify patients who are the best 
candidates for early interventions or for specific treatments and fine-tune the individual 
treatments [Leiser et al., 2011; Luck et al., 2011; Luck, 2014].  
However, several limitations of the ERP technique should be pointed out. ERP amplitude 
measurements can be influenced by individual differences in nuisance variables [Luck et 
al., 2011], such as skull thickness [Frodl et al., 2001] and cortical folding patterns 
[Ahlfors et al., 2010]. Scalp ERP recordings are mainly sensitive to activity from radial 
sources, in particular currents in the apical dendrites of the pyramidal cells in the cortical 
gyri near the surface of the head [Kropotov, 2009; Luck, 2014]. Scalp recorded EEG 
gives no information about activity in neurons that are not spatially aligned, because in 
this case dipoles will not summate but rather cancel each other out, resulting in “closed” 
electrical fields [Handy, 2005].  
It should be noted that the high temporal resolution of the ERPs is accompanied by a 
relatively low spatial resolution and it is difficult to determine the neuroanatomical origins 
of a given ERP effect purely on the basis of the observed scalp distribution [Luck, 2014]. 
This is because of the inverse problem: any given voltage distribution at the scalp can be 
explained by an infinite number of intracranial source configurations [Rugg and Coles, 
1996; Kropotov, 2009]. Therefore, intracranial recordings in patients with depth 
electrodes for diagnostic purposes offer a unique opportunity to merge temporal and 
spatial precision into one single recording and measure local field potentials or even 
single unit activity directly from neurons located deep inside the brain. When interpreting 
human intracranial ERP data it should be taken into consideration that participants of 
intracranial EEG studies generally belong to a clinical population suffering from refractory 
epilepsy and thus do not represent healthy participants [Murray et al., 2014]. 
Accordingly, generalization about neuronal functioning from recordings in patients with 
chronic refractory epilepsy to the healthy brain remains a potential limitation.  
Our scalp ERP results in patients with refractory epilepsy should be interpreted with 
caution as well because epilepsy is a complex, heterogeneous and variable neurological 
condition and various potential confounding factors need to be taken into account 
[Kubota et al., 1998; Caravaglios et al., 2001]. Epilepsy affects the whole age range 
from neonates to elderly people, and has variable causes and manifestations, with many 
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distinct seizure types and several identifiable electroclinical syndromes [Duncan et al., 
2006; Berg et al., 2010]. The type and location of the structural epileptogenic lesions can 
be very heterogeneous, including brain tumors, hippocampal sclerosis, focal cortical 
dysplasia, cysts and cavernomas. Even if lesions are limited to hippocampal sclerosis in 
the mesial temporal lobe, this can lead to frontal lobe dysfunction and broad cognitive 
deficits [Bell et al., 2011; Stretton and Thompson, 2012]. Moreover, recurrent seizures in 
refractory epilepsy can cause widespread reorganization of overlapping neuronal 
networks [Spencer, 2002; Richardson, 2010]. In addition, there are many comorbidities 
that may confound the results obtained, including learning disabilities, fixed neurological 
deficits, progressive conditions, psychological and psychiatric problems, and concomitant 
medical conditions [Duncan et al., 2006]. Finally, patients with refractory epilepsy take a 
wide range of different AEDs with common adverse effects on mood, cognition and 
behavior [Aldenkamp et al., 2003; Reijs et al., 2004].  
In summary, the ERP technique provides a valuable neurophysiological tool for studying 
specific neuronal processes or neurotransmitter systems in patients with refractory 
epilepsy. In addition, ERPs could provide potential biomarkers that will help to predict 
response to treatment. However, our ERP results should be interpreted with caution, 
bearing in mind that epilepsy is a very heterogeneous disorder with many comorbidities 
and various confounding factors. Future research should combine ERPs with 
complementary methods and techniques, such as time-frequency analysis of induced 
oscillations, functional neuroimaging and measurements of physiological markers of 
emotional response, in order to bring complementing evidence and eventually strengthen 
the new insights gained from the ERP findings gathered in this thesis.  
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SUMMARY 
The event-related potential (ERP) technique is a sensitive neurophysiological method for 
investigating human brain functioning in both healthy individuals and patients. ERPs are 
electrical brain potentials, recorded from scalp or intracranial electrodes, that are time-
locked to specific sensory, motor or cognitive events. This doctoral project used the ERP 
technique to study specific neuronal processes in patients with refractory epilepsy. 
Epilepsy is a brain disease characterized by an enduring predisposition to generate 
epileptic seizures, and by the neurobiological, cognitive, psychological, and social 
consequences of this condition. Worldwide, there are about 65 million patients with 
epilepsy, of whom about a third remain refractory to treatment with antiepileptic drugs. 
For those patients resective surgery is the first treatment of choice. When epilepsy 
surgery is not an option or patients in whom resection fails to control seizures alternative 
treatment options are available including vagus nerve stimulation (VNS).  
VNS is a neurostimulation therapy known to be safe and effective for both refractory 
epilepsy and depression. The mechanism of action of VNS is currently not fully 
understood and it is unclear which factors determine the patient’s response to the 
treatment. Recent preclinical experiments have highlighted the pivotal role of the locus 
coeruleus noradrenergic system in the antiepileptic effect of VNS. The first study aimed 
to evaluate the effect of VNS on noradrenergic signaling in the human brain through a 
non-invasive marker of this neurotransmitter system, i.e., the oddball P3 component of 
the ERP. We investigated whether VNS differentially modulated the amplitude of the P3 
component in VNS responders versus VNS non-responders. Our results revealed that 
VNS induced a significant increase of the P3 amplitude at the parietal midline electrode, 
in VNS responders only. In addition, logistic regression analysis showed that the increase 
of P3 amplitude can be used as a non-invasive indicator for VNS responders. These 
results support the hypothesis that activation of the locus coeruleus noradrenergic 
system is associated with the antiepileptic effect of VNS. Modulation of the P3 amplitude 
should be further investigated as a non-invasive biomarker for the therapeutic efficacy of 
VNS in epilepsy.  
Patients with refractory epilepsy have a high prevalence of comorbid mood disorders. The 
second and third study aimed to evaluate whether refractory epilepsy is associated with 
dysfunction of emotion regulation. In the second study, ERPs were recorded in order to 
investigate whether a possible dysfunction arises during early (attention) and/or late 
(regulation) stages of emotional stimulus processing. This ERP study revealed that early 
object-based attention processes are not compromised by epilepsy, regardless of 
negative affect. By contrast, the amplitude of the late positive potential (LPP), a 
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component that is sensitive to emotion regulation, was significantly enhanced for 
negative emotional expressions when visual face stimuli were unattended, but only in 
patients with comorbid negative affect. The modulation of the LPP component by 
unattended emotional stimuli during the late stages of stimulus processing suggests that 
emotion regulation is disturbed in patients with refractory epilepsy and comorbid 
negative affect. 
The aim of the third study was to investigate whether the ERP response to negatively 
valenced stimuli in patients with refractory epilepsy is sensitive to reappraisal, a cognitive 
emotion regulation strategy that can decrease negative affect. This study showed that 
modulation of LPP amplitude, as electrophysiological correlate of cognitive emotion 
regulation, is absent in patients with epilepsy. This suggests abnormal functioning of the 
brain during cognitive emotion regulation in patients with epilepsy, which could explain 
the high susceptibility of these patients to negative affect and comorbid mood disorders. 
How emotion and attention influence visual processing in the amygdala remains a matter 
of controversy in the literature. In the fourth study, we hypothesized that attention and 
emotional factors operate independently and in parallel on the sensory processing in the 
amygdala in order to increase the saliency and selection of behaviorally relevant 
information. To test this hypothesis ERPs were recorded directly in the amygdala of ten 
patients with refractory epilepsy implanted with intracranial depth electrodes. This study 
provided direct evidence for asymmetric effects of attention and emotion in the human 
amygdala during visual face stimulus processing. While object-based attention exerts a 
systematic effect on amygdala ERPs at group-level, only a subset of the patients shows 
amplitude modulations of amygdala ERPs by emotion at variable delays after stimulus 
presentation. These results suggest that attention and emotion can differentially 
influence sensory processing in the amygdala, likely via different pathways, with stable 
gating by attention but versatile modulation by emotion. 
In conclusion, the ERP technique provides a valuable neurophysiological tool for studying 
specific neuronal processes or neurotransmitter systems in patients with refractory 
epilepsy. In addition, specific ERPs could provide potential biomarkers that will help to 
predict response to treatment. However, our ERP results should be interpreted with 
caution, because epilepsy is a very heterogeneous disorder with many comorbidities and 
several confounding factors should be taken into account. Future research should 
combine ERPs with complementary methods, such as time-frequency analysis of induced 
oscillations, functional neuroimaging and measurements of physiological markers of 
emotional response, in order to bring complementing evidence and eventually strengthen 
the new insights gained from the ERP findings gathered in this thesis. 
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SAMENVATTING 
Event-gerelateerde potentialen (ERPs) worden gebruikt in neurofysiologische onderzoek 
naar de werking van de menselijke hersenen in zowel gezonde individuen als patiënten. 
ERPs zijn elektrische hersenpotentialen die gemeten worden met elektrodes op de scalp 
of intracraniëel en die tijdsgebonden voorkomen na specifieke sensorische, motorische of 
cognitieve gebeurtenissen. In dit doctoraatsproject werd gebruik gemaakt van ERPs om 
specifieke neuronale processen te bestuderen in patiënten met refractaire epilepsie. 
Epilepsie is een chronische hersenaandoening die gekenmerkt wordt door het 
herhaaldelijk optreden van spontane epileptische aanvallen. Er lijden wereldwijd 65 
miljoen patiënten aan epilepsie, waarvan ongeveer een derde niet afdoende reageert op 
behandeling met anti-epileptica. Voor de refractaire patiënten waarbij een chirurgische 
ingreep geen optie is of waarbij de chirurgie geen aanvalscontrole bracht, zijn er 
alternatieve behandelingsopties beschikbaar, waaronder nervus vagus stimulatie (NVS). 
NVS is een veilige en effectieve neurostimulatie behandeling voor zowel refractaire 
epilepsie als depressie. Het werkingsmechanisme van NVS is momenteel nog niet volledig 
gekend en het is onduidelijk welke factoren bepalen of een patiënt op de behandeling zal 
reageren. Preklinisch onderzoek wijst erop dat het noradrenerg systeem van de locus 
coeruleus een kritische rol speelt in het anti-epileptisch effect van NVS. In de eerste 
studie werd getracht het effect te achterhalen van NVS op de noradrenerge signalisatie 
in de menselijke hersenen. Dit werd gedaan door analyse van een niet-invasieve merker 
van dit neurotransmitter systeem, namelijk de P3 component van de ERP. Onze 
resultaten toonden aan dat NVS enkel in NVS-responders een significante toename 
induceerde van de P3 amplitude. Logistische regressie analyse toonde bovendien aan dat 
de toename van de P3 amplitude een niet-invasieve merker is voor de NVS respons. 
Deze resultaten ondersteunen de hypothese dat activatie van het noradrenerg systeem 
geassocieerd is met het anti-epileptisch effect van NVS. Ze suggereren ook dat modulatie 
van de P3 amplitude een mogelijke niet-invasieve biomerker is voor de therapeutische 
respons op NVS in epilepsie, een bevinding die noopt tot verder onderzoek. 
Een hoog aantal patiënten met refractaire epilepsie hebben stemmingsstoornissen als 
comorbiditeit. Het doel van de tweede en derde studie was om te onderzoeken of 
refractaire epilepsie gepaard gaat met een verstoring van de emotie regulatie. In de 
tweede studie werden ERPs gebruikt om na te gaan of er een verstoring optreedt 
tijdens de vroege (aandacht) en/of late (regulatie) stadia van de verwerking van 
emotionele stimuli. Deze ERP studie toonde aan dat vroege aandachtsprocessen niet 
verstoord zijn door epilepsie, onafhankelijk van negatief affect. Daarentegen was de 
amplitude van de late positieve potentiaal (LPP), een component die gevoelig is voor 
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emotie regulatie, significant toegenomen door taak-irrelevante negatieve emotionele 
expressies. Dit was echter enkel het geval in patiënten met comorbiditeit van negatief 
affect. De modulatie van de LPP component door taak-irrelevante emotionele stimuli 
tijdens de late stadia van stimulus verwerking suggereert dat emotie regulatie verstoord 
is in patiënten met refractaire epilepsie en comorbiditeit van negatief affect. 
Het doel van de derde studie was om te onderzoeken of de ERP respons op stimuli met 
een negatieve valentie gevoelig is voor herwaardering, een cognitieve emotie regulatie 
strategie die negatief affect kan doen afnemen. Deze studie toonde aan dat modulering 
van de LPP amplitude door herwaardering, als elektrofysiologisch correlaat van cognitieve 
emotie regulatie, afwezig is in patiënten met refractaire epilepsie. Deze bevindingen 
wijzen op een verstoord functioneren van de hersenen tijdens cognitieve emotie regulatie 
in patiënten met refractaire epilepsie. Dit zou kunnen verklaren waarom deze patiënten 
een verhoogde predispositie vertonen voor negatief affect. 
Hoe emotie en aandacht een invloed uitoefenen op de visuele verwerking in de amygdala 
blijft een onderwerp van discussie in de literatuur. Onze hypothese was dat aandachts en 
emotionele factoren onafhankelijk van elkaar een effect uitoefenen op de sensorische 
verwerking in de amygdala om zo gedragsrelevante informatie te selecteren. Om deze 
hypothese te testen werd een vierde studie opgezet, waarin ERPs werden gemeten in 
de amygdala van tien patiënten met refractaire epilepsie bij wie intracraniële diepte 
elektrodes geïmplanteerd waren. Hoewel er op groepsniveau een systematisch effect was 
van objectgebaseerde aandacht op de ERPs in de amygdala, werd er slechts bij een deel 
van de patiënten effecten van emotie geobserveerd en dit op variabele tijdspunten na 
presentatie van de stimulus. Deze studie leverde zo direct bewijs voor asymmetrische 
effecten van aandacht en emotie op de sensorische verwerking in de humane amygdala, 
met stabiele invloed door aandacht maar een variabele modulatie door emotie. 
Deze studies tonen gezamenlijk aan dat de ERP-techniek een waardevolle methode is 
voor het bestuderen van specifieke neuronale processen of neurotransmitter systemen in 
patiënten met refractaire epilepsie. Bovendien zijn ERPs potentiële biomerkers die 
kunnen helpen bij het voorspellen van de respons op de behandeling. Desalniettemin 
moeten onze ERP resultaten voorzichtig geïnterpreteerd worden, daar epilepsie een 
uitermate heterogene aandoening is met veel comorbiditeit en er verschillende mogelijke 
verstorende factoren bestaan. In verder onderzoek moeten ERP metingen gecombineerd 
worden met complementaire methodes, zoals tijd-frequentie analyse van geïnduceerde 
oscillaties, functionele beeldvorming en metingen van fysiologische merkers van emoties. 
Op deze manier kan aanvullend bewijs geleverd worden voor de nieuwe inzichten 
bekomen in dit ERP onderzoek. 
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